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Summary 
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    Only two genes involved in high-risk breast/ovarian cancer hereditary syndrome (HBOC) have been identified, 
BRCA1 and BRCA2, that do not explain more than 20% of all the HBOC cases. In the last years, Whole Exome 
Sequencing (WES) has been used to find new high susceptibility genes. Although initial attempts were not as 
conclusive as expected; recently, novel susceptibility genes for HBOC have been reported using WES. Thus, the 
main objective of this study is the quest for new high susceptibility genes in BRCAX hereditary breast cancer 
families with an apparent recessive pattern of inheritance, which has remained largely unexplored. After 
reviewing about 2000 stories of familial breast cancer, we selected four families showing an apparent pattern of 
monogenic recessive inheritance with the following characteristics: presence of two or more affected siblings 
with breast cancer at young age, absence of familial antecedents of the disease, availability of the samples and no 
mutations in BRCA1 and BRCA2 genes.  
 
In our first approach, studying the recessive model of inheritance, we found 14 candidate variants in two 
families where the exomes from the parents and the affected siblings was accessible (family 1 and 2). After that, 
regardless of the inheritance model, we explored the genes related with DNA repairing and maintenance systems, 
where we found a novel mutation in ATM (c.5441delT; p.Leu1814Trpfs*14), an already recognized gene for 
hereditary breast cancer, as a causal variant in a BRCAX family. We found other family with variants affecting 
RECQL5 gene (1709C>T, p. T570I and c.2874C>G, p. S958R), an excellent candidate to be associated with the 
disease. As we had found at least one family where the dominant model explained the cause of the disease, we 
completed the panorama by studying the rest of the genes under this model in the three families. We ended up 
with a total of 43 candidate variants from which we finally selected 25 as putative susceptibility alleles for 
hereditary breast cancer after performing a case-control association study in 1,500 cases of BRCAX families and 
500 controls in Spanish population.  
 
We performed full coding sequencing and exon-boundaries analysis of RECQL5 and ATM, in order to 
establish the frequency and spectrum of mutations of both genes in Spanish population. Regarding RECQL5, 
Truseq platform from Illumina was used in a cohort of 700 BRCAX BC-only cases and 754 controls. From this 
study, we propose RECQL5 as a novel BC susceptibility gene, by the identification of clearly deleterious 
mutations in the BRCAX cohort studied. Other potentially deleterious mutations were identified and in silico 
studies predict them to affect preferentially helicase domain of this enzyme. Concerning ATM, Next Generation 
Sequencing panels were used for ATM mutational screening in a cohort of 392 HBOC Spanish BRCAX families 
and 350 controls. 1.78% prevalence of mutations in the ATM gene was associated to HBOC and 1.94% in breast 
cancer-only BRCAX families in Spanish population. In the fourth family, which is a family with various cases of 
male breast cancer (MBC), we explored the recessive model and the X-linked inheritance model. Seven candidate 
variants were identified as putative susceptibility alleles for MBC, which were studied in an initial cohort of 50 
Spanish hereditary MBC cases and in an enlarged cohort of 1200 MBC and 500 controls from UK. In the Spanish 
cohort, we found another MBC case that was homozygous for c.1208G>A p.R403Q affecting TXNDC5 gene 
which is involved in the Androgen Receptor pathway and therefore we propose as a novel putative susceptibility 
allele for MBC, that requires further study. In conclusion, these set of studies using WES for exploring HBOC 
missing hereditability has guided to the exploration of different models of inheritance and has been useful to find 
new BC susceptibility candidate genes, as well as variants not previously reported in well-established BC 
susceptibility genes, which contributes to the understating of the still uncovered BRCAX landscape.  
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Resumen 
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    Sólo dos genes que confieren alta susceptibilidad al síndrome de cáncer de mama y ovario hereditario 
(CMOH) han sido identificados, BRCA1 y BRCA2, que no explican más del 20% de todos los casos de CMOH. 
La secuenciación completa de exoma ha sido empleada para encontrar nuevos genes que confieran alta 
susceptibilidad a HBOC. Así, el objetivo principal de este estudio es la búsqueda de nuevos genes de alta 
susceptibilidad en familias de cáncer de mama hereditario BRCAX con un patrón aparente de herencia recesiva 
mediante el uso de secuenciación de exoma completo. Después de revisar 2000 historias clínicas de cáncer de 
mama familiar, hemos seleccionado cuatro familias que muestran un patrón aparente de herencia monogénica 
recesiva: presencia de dos o más hermanas afectadas con cáncer de mama en edad joven, ausencia de 
antecedentes familiares de la enfermedad y ninguna mutación en los genes BRCA1 y BRCA2 (BRCAX). 
 
Estudiando el modelo de herencia recesivo, encontramos 14 variantes candidatas en dos familias donde los 
exomas de los padres y las hijas afectas con cáncer de mama estaban disponibles (familia 1 y 2). Después, 
independientemente del modelo de herencia, exploramos genes relacionados con sistemas de reparación y 
mantenimiento del DNA, donde encontramos una mutación no reportada previamente en ATM (c.5441delT; 
p.Leu1814Trpfs*14), un gen previamente reconocido como un gen de susceptibilidad a cáncer de mama, como la 
variante causal en una familia BRCAX. También, encontramos otra familia con dos variantes en el gen RECQL5 
(1709C>T, p. T570I y c.2874C>G, p.S958R), que consideramos un excelente candidato posiblemente 
relacionado con la enfermedad. Dado que encontramos al menos una familia donde el modelo dominante 
explicaba la causa de la enfermedad, completamos el panorama estudiando el resto de genes bajo este modelo de 
herencia en las tres familias. De las 43 variantes candidatas iniciales, identificamos 25 como alelos putativos de 
susceptibilidad a cáncer de mama hereditario, seleccionadas a través de un estudio de asociación de casos y 
controles efectuado en 1500 casos de familias BRCAX y 500 controles de población española.  
 
Realizamos la secuenciación completa de regiones codificantes en RECQL5 y ATM, a fin de establecer la 
frecuencia y espectro de las mutaciones de ambos genes en población española. En cuanto a RECQL5, el gen fue 
analizado utilizando la plataforma Truseq de Illumina en una cohorte de 700 casos de mama de familias BRCAX 
y 754 controles. De este estudio, proponemos RECQL5 como un nuevo gen que confiere susceptibilidad a cáncer 
de mama por la identificación de mutaciones claramente deletéreas en la cohorte de casos BRCAX. Otras 
mutaciones potencialmente deletéreas fueron identificadas y los estudios in silico predicen que afectan 
preferencialmente al dominio helicasa de esta enzima. Con respecto a ATM, se usó un panel de secuenciación de 
nueva generación para su análisis mutacional en una cohorte de 392 CMOH de familias BRCAX y 350 controles. 
Se encontró una prevalencia de 1.78% de mutaciones el gen ATM asociada con CMOH y 1.94% asociada a 
cáncer de mama en familias BRCAX en población española. En la cuarta familia, caracterizada por la presencia 
de varios casos de cáncer de mama en varón (CMV), exploramos el modelo recesivo y de herencia ligado al X. 
Siete variantes candidatas fueron identificadas como alelos putativos de susceptibilidad a CMV, las cuales fueron 
estudiados en una cohorte inicial de 50 casos de CMV hereditarios de población española y en una cohorte de 
1200 CMV y 500 controles de población inglesa. En población española, encontramos otro caso de CMV que era 
homocigoto para c.1208G>A p.R403Q, afectando el gen TXNDC5, relacionado con la ruta del receptor de 
andrógenos, el cual proponemos como un gen candidato de susceptibilidad al CMV hereditario que requiere más 
estudios moleculares. En conclusión, este conjunto de estudios usando la secuenciación de exoma completo ha 
sido útil para encontrar nuevos genes candidatos que confieren susceptibilidad a cáncer de mama, así como  
variantes no reportadas previamente en genes de susceptibilidad a cáncer de mama ya establecidos como tales, lo 
cual contribuye a entender una parte del panorama aún irresuelto de los casos BRCAX.  
 19 
 
Table of contents 
 21 
 
 
Table of contents 
 
1. Abbreviations         23  
 
2. Introduction          27 
2.1. Breast cancer 
2.1.1 Mammary gland anatomy and breast cancer    29 
2.1.2 Epidemiology        34 
2.1.3 Risk factors        34 
 
2.2. Hereditary breast cancer        37 
2.2.1 High susceptibility genes        38 
2.2.2 Moderate susceptibility genes      39  
2.2.3. Low susceptibility genes       40 
 
2.3. Next generation sequencing        41 
2.3.1. Brief concept into NGS        41 
2.3.2. Whole Exome Sequencing in hereditary breast cancer   43 
2.3.3. Limitations of WES        47 
2.3.4. Clinical Relevance       48 
 
3. General Objective          51 
 
4. Patients and Methods        55 
4.1 Patients and Families of study       57 
4.2 Methods         61 
4.2.1 Whole Exome Sequencing      61 
4.2.2  Bioinformatic analysis and variant filtration    61 
4.2.3 Segregation analysis and Sanger validation    63 
4.2.4 Case-Control Association Study      63 
4.2.5  Splicing studies        63 
4.2.6 Loss of heterozigosity (LOH) analysis     64 
4.2.7 Full coding sequencing of RECQL5      64 
4.2.8. In silico inference of missense variants effect in RECQL5 domains  65 
4.2.9 Mutational analysis of ATM gene      66 
 22 
 
4.2.10 Immunohistochemistry       67 
4.11 Genotyping of 50 Spanish MBC cases     67 
4.12 (KASP) Genotyping technology       67 
 
5. Results          69 
5. 1. Exploration of the recessive model of inheritance     71 
5. 2.  Exploration of genes related with DNA repairing systems    73 
5. 3. Exploration of the dominant model of inheritance in BRCAX families  78 
5. 4. Putative susceptibility genes associated with HBOC (BRCAx) families 
 identified through WES in Spanish population     80 
5.5 Massive sequencing of RECQL5 gene in Spanish population  83 
5.6 Almost 2% of Spanish BC families are associated to germline pathogenic  
mutations in ATM gene        95 
5. 7. Search for novel susceptibility genes for hereditary male breast cancer 97 
 
6. Discussion           101 
6. 1. Exploration of different models of inheritance in BRCAX families   103 
             6. 2. Main findings in family BRCAX 1: Best candidates putatively  
associated with increased susceptibility to hereditary BC   105 
             6. 3. Main findings in family BRCAX 2:      
6.3.1. RECQL5, another DNA helicase potentially involved in  
increased BC susceptibility      107 
6.3.2. Other findings in family 2 exploring dominant and  
recessive model of inheritance      112 
             6. 4. Main findings in family BRCAX 3: Almost 2% of Spanish BC families  
are associated to germline pathogenic mutations in the ATM gene  114 
             6. 5. Main findings in family BRCAX 4: Novel susceptibility alleles  
potentially implicated with hereditary male breast cancer   115 
 
7. Conclusions          119 
 
8. Supplementary Data and Tables       127 
 
9. References          143 
 
10. Publications and poster presentations      161 
 
 23 
 
1. Abbreviations 
 25 
 
 
ATM Ataxia Telangiectasia Mutated 
BC Breast Cancer 
BRCA1 Breast Cancer Susceptibility Gene 1 
BRCA2 Breast Cancer Susceptibility Gene 2 
BRCAX Breast Cancer Susceptibility Gene X 
cDNA Complementary DNA 
CHEK2 Checkpoint kinase 2 
DNA  Deoxyribonucleic acid 
dNTP Deoxyribonucleic triphosphate 
DSB DNA double-strand break  
FDA Food and Drugs Administration from the United States 
FFPE Formalin Fixed Paraffin Embedded 
GMAF Global Minor Allele Frequency 
GWAS  Genome Wide Association Study  
FA Fanconi Anemia 
HBOC Hereditary Breast and Ovarian Cancer 
HR Homologous Recombination 
IHC Immunohistochemistry 
KASP  KBioscience Competitive Allele-Specific PCR  
KEGG Kyoto Encicopledia of Genes and Genomes 
LOH Loss of heterozigosity   
MBC Male Breast Cancer 
mRNA  Messenger Ribonucleic acid 
NCBI  National Center for Biotechnology Information 
NGS Next Generation Sequencing 
NHEJ Non-Homologous End Joining 
NMD Nonsense-mediated mRNA decay 
PALB2 Parter and localizer of BRCA2 
PARP Poly ADP (Adenosine Diphosphate) Ribose Polymerase 
PCR Polymerase Chein Reaction 
PTC Premature termination codon  
RAD51 Recombination protein A 51 
RNA  Ribonucleic acid 
RT-PCR Reverse transcriptase polymerase chain reaction  
SNP Single Nucleotide Polymorphism 
SSB DNA single-strand break  
STK11 Serie/threonine kinase 11 
TEB Terminal end bud 
TP53 Tumor Protein 53 
UTR Untranslated region 
VUS  Variants of unknown significance 
WES Whole Exome Sequencing 
WT Wild type 
 
 27 
 
 2. Introduction 
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   2.1. Breast cancer 
2.1.1 Mammary gland anatomy and breast cancer 
 
Macroscopically, the mammary gland in adult women has between 15-20 lactiferous ducts, 
which begin at the nipple, branch into smaller ducts (segmentary and subsegmentary ducts) and 
culminate in the terminal duct lobular unit (lobule), which is composed of a terminal duct and 
many small ductules (or acini), which are the responsible of the production of maternal milk upon 
lactation period for feeding a newborn (Netter, 2007). This structure also possesses intralobulillar 
stroma (which separates the acini from each other, has loose connective tissue, lymphocytic 
infiltrate, capillary red blood and lymphatic vessels). The interlobulillar stroma has dense 
connective tissue rich in collagen and elastic fibers whereas the interlobular stroma has dense 
connective tissue surrounding the ramifications of the galactophoretic duct. There are also Cooper 
ligaments that are connective tissue strands that extend from the deep fascia to attach to the 
underlying skin and adipose tissue which determines the shape and size of the breast (Townsend 
et al., 2013) [Figure 1A]. 
 
Histologically, the main unit of the lobuli is named terminal end bud (TEB), which is a 
bulbous structure that has two main compartments, an outer one that is constituted by cap cells 
which differentiate into myoepithelial cells to allow the elongation of the duct; also they are 
theorized to be a reservoir of regenerative mammary stem cells. The inner part of the TEB has a 
multicellular layer of 4-6 cells, known as the body cells, which also harbor luminal and alveolar 
progenitors that upon differentiation give rise to the more mature luminal (predominate toward 
the neck of the TEB and the joint with the ducts) and alveolar cells (simple cubic tissue that are 
secretory cells, responsible for production of the milk). TEB structure is delimited by a basal 
lamina constituted of epithelial cells. There is a plethora of cellular types surrounding the laminar 
basement, among which we can find adipocytes, fibroblasts, macrophages, eosinophils, 
neutrophils and endothelial cells. Predominating cellular types within the ducts are the ones 
belonging to the basal lamina, myoephitelial cells (muscle contracting cells that are important for 
secretion of the content of the TEB toward the ductules) and luminal cells which form the body of 
the ducts (Paine et al., 2017; Ross et al., 2013) [Figure 1B]. 
  
The mammary glands have mesodermal origin and are formed since the fifth week of 
embryonic development. During childhood, the mammary glands do not develop and remain in 
relative quiescence until the onset of puberty. At that time, the tissue underneath the areola as well 
as the body of the gland increases in response to hormones such as progesterone, prolactin, 
corticoids and the growth hormone. The glandular ducts are scarcely branched (Netter, 2007). 
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Due to the influence of ovarian hormones, the mammary gland is modified cyclically, all of which 
increases its vascularization. After puberty, the tissue develops and remains in this form, until the 
stage of pregnancy, where other changes in the mammary gland are appreciated (Macias et al., 
2012). Given the large amount of estrogen and progestogen during this stage, the mammary gland 
develops and branches considerably. Other modifications are appreciated such as: myoepithelial 
hypertrophy, hyperpigmentation and hypervascularization, as well as ductal and lobular 
development, at the ends of the ducts alveoli are formed where the milk accumulates.  After 
lactation, the hormonal influence decreases and produces a regression of the breast by apoptosis, 
cellular degeneration and decrease in the number of alveoli and number of breast ducts (Lippert, 
2005). 
 
 
 
 
C) 
 
 
Figure 1. (A) Normal structure of adult mammary gland. (B) Histology of the mammary gland, the 
morphology of a duct and its terminal lobule together with the main cellula r types that conform this 
structure are presented in the diagram. (C) Hypothetical model of breast cancer progression (Adapted from 
National Cancer Institute, 2016; Sternlich, 2006; Po lyak, 2007). 
 
B) A) 
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Breast cancer (BC) is a highly complex disease, which is composed of distinct subtypes 
associated with different clinical outcome. Multiple factors have been associated to its 
development but the causes and mechanisms related have not been completely understood and 
several research lines have been established to improve current diagnosis, prognosis, treatment 
and prevention guidelines (Polyak, 2007). 
 
There are different breast cancer types, which receive their name based in their location as well 
as grade of progression. After premalignant lesions occur and upon tumoral transformation, a 
carcinoma in situ develops, where cells have not surpassed the basal layer and remain inside of 
the ducts (so called ductal carcinoma) or the lobuli (lobular carcinoma). Then, in a more advanced 
stage, the carcinoma can acquire infiltrating properties by disrupting the basal layer and invading 
the lumen of the duct (so called infiltrating ductal carcinoma) or the lobuli (infiltrating lobular 
carcinoma). The infiltrating ductal carcinoma is the most common type and the infiltrating lobular 
carcinoma arises in 10-15% of all BC cases. The infiltrating carcinomas in advanced stages can 
become invasive and they can spread to other tissues via lymphatic and/or blood vessels, causing 
metastasis [Figure 1C].  
 
Table 1. TNM staging system for breast cancer  
Primary Tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ  
Tis  (LCIS) Lobular carcinoma in situ 
Tis (Paget) Paget disease of the nipple NOT associated with invasive carcinoma and/or carcinoma in 
situ (DCIS and/or LCIS) in the underlying breast parenchyma  
T1 Cancer measures 2 cm in d iameter 
T2 Cancer measures more than 2 cm but not more than 5 cm 
T3 Cancer measures more than 5 cm in d iameter  
T4 Tumor of any size with direct extension to the chest wall and/or to the skin (u lceration or 
skin nodules 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed (eg, previously removed) 
N0 No regional lymph node metastasis 
Clin ical N1 Cancer has spread to lymph nodes under the arm on the same side of breast cancer 
Pathologic N1 Cancer is found in one to three lymph nodes 
Clin ical N2 Cancer has spread to the lymph nodes under the arm, these are attached to each other or 
to the surrounding tissue, the internal mammary lymph nodes are affected 
Pathologic N2 Cancer has spread to the lymph nodes located above or below the clav icle on the same 
side of the cancer 
Clin ical N3 Metastases in ipsilateral infraclav icular (level III axillary) lymph node(s), with or 
without level I, II axillary node involvement  
Pathologic N3 Cancer has spread to 10 or more lymph nodes under the arm 
Metastasis (M) 
M0 There is no cancer spreading 
M1 Distant detectable metastases as determined by classic clin ical and radiographic means 
and/or histologically proven > 0.2 mm 
Adapted from Sparano et al., 2016. 
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There are many staging systems, the most widely used for describing the growth and spread of 
breast cancer is the TNM staging system. The letter T refers to tumor size, N refers to number of 
lymph nodes to which the tumor has spread and the letter M refers to metastases.  Once assigned 
to the categories T, N and M, this information is combined to designate a general stage of 0, I, II, 
III or IV (NCCN, 2006) [Table 1]. 
 
Other important classification is based on the molecular subtypes. The current classification 
includes: triple negative, basal-like, Her2, luminal subtype A, luminal subtype B, normal breast 
like and “claudin-low”. They were identified by microarray-based gene expression analysis and 
unbiased hierarchical clustering. The molecular subtypes display highly significant differences in 
prediction of overall survival, as well as disease-free survival (Malhotra et al., 2010) [Figure 2].   
 
 
Figure 2. BC pathogenesis and histological and molecu lar subtypes. General considerations of each 
molecular subtype are shown. Adapted from Wong et al., 2012.  
 
The luminal molecular subtype is divided in two major categories (luminal A and luminal B), 
although there is another (luminal C). The luminal A is characterized by the highest expression of 
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hormone receptors: the ER (estrogen receptor) gene, GATA binding protein 3, X-box binding 
protein 1, trefoil factor 3, hepatocyte nuclear factor 3 and estrogen-regulated LIV-1. The 
subtype B and C showed low to moderate expression of luminal specific genes, including ER.  
Subtype C is distinguished by high expression of a set of genes like transferring receptor p90, 
nucleolar protein p40, among others whose function remains unknown, a feature that they share 
with the basal-like and Her2 subtypes (Sorlie et al. , 2001; Cancer Genome Atlas Network, 2012).  
They respond to endocrine therapy, respond to chemotherapy available (greater in luminal B than 
luminal A), and show worst prognosis and survival rates in luminal B than luminal A due to 
poorer tumor grade, larger tumor size and lymph node-positive (Schnitt, 2010).  
 
The basal like subtype, which highly overlaps with triple negative (although not all basal like 
are triple negative and viceversa), is characterized by high expression of keratins 5/17, laminin, 
fatty acid binding protein 7, basal epithelial genes and low expression of ER and Her2. A 
difference between basal like subtype and the triple negative is that the former have expression of 
certain keratins, whereas the latter typically do not show expression of these markers (Kumar et 
al., 2015; Sorlie et al. , 2001; Cancer Genome Atlas Network, 2012). Clinically, they show ER-
/PR-/Her2 - and represent 15% of invasive cancers. They do not show response to endocrine 
therapy or trastuzumab. Although hypothesized to be potentially sensitive to PARP inhibitors, 
results from ongoing phase III trials in BC are still awaited (Schnitt, 2010; Robert et al., 2017).  
  
The Her2 subtype is characterized by high expression of several genes in the ERBB2 amplicon 
at 17q22.24 including ERBB2 and GRB7 (Perou et al., 2000). Clinically, they show ER-, PR- and 
Her2+ markers, represent 15% of invasive cancers, more likely to be high grade and node 
positive. They respond to trastuzumab (Herceptin) and anthracycline-based chemotherapy 
(Schnitt, 2010; Goldhirsch et al., 2013).  
 
The normal breast like group shows higher expression of many genes known to be expressed 
by adipose tissue and other non-epithelial genes (Perou et al., 2000), nonetheless they are less 
characterized and clinically, they represent a reduced percentage of BC. The other group “claudin 
low” BC subtype, is characterized by the low to absent expression of luminal differentiation 
markers, high enrichment for epithelial-to-mesenchymal transition markers and cancer stem cell-
like features. Clinically, these latter have poor prognosis, the majority are ER-, PR-, Her2-, triple 
negative invasive ductal carcinomas with a high frequency of metaplastic and medullary 
differentiation, that have a response rate amidst basal-like and luminal BC response to standard 
preoperative chemotherapy (Prat et al., 2010).  
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2.1.2 Breast Cancer Epidemiology 
 
Breast cancer is the most frequent cancer among women with an estimated 1.67 million new 
cancer cases diagnosed in 2012, which represents 25% of all cancer cases. Incidence rates vary 
nearly four-fold across the world regions, ranging from 27 per 100,000 in Middle Africa and 
Eastern Asia to 92 in Northern America (Ferlay et al., 2015). In addition, incidence rates per 
country show an increasing trend which could be related with augmented awareness and better 
screening methods (Torre et al., 2016).  
 
BC ranks as the fifth cause of death from cancer overall (522,000 deaths). Solely in women it 
represents the 15% of all deaths due to malignant disease, followed by lung and colorectal cancer. 
The range in mortality rates between world regions is less than that for incidence because of the 
more favorable survival of breast cancer in (high-incidence) developed regions, with rates ranging 
from 6 per 100,000 in Eastern Asia to 20 per 100,000 in Western Africa (Siegel et al., 2017). 
Breast cancer also occurs in men but it is quite infrequent, representing <1% of all the cases of 
cancer in males, with an incidence estimated as <1 per 100000 men-years (Jemal et al. , 2010; Ly 
et al., 2013).  
 
Recent epidemiology studies show that, e.g. in United States the number of new cases reported 
in 2016 were 2000 and the number of deaths was 400, this elevated number of deaths are related 
with advanced state at the time of diagnosis but, in comparison with female cases, the rest of the 
cases have better prognosis (Siegel et al., 2017) [Figure 3].  
 
 
2. 1.3 Breast Cancer Risk factors 
 
There are a number of factors that increase the possibility of developing BC. Women at high 
risk can use this knowledge toward preventive measures, such as: earlier screening, prophylactic 
surgery and chemoprevention, always with the guidance of their clinician. Some of these factors 
have been associated with higher (>4.0), moderate (2.1-4.0) or a lesser risk (<2.0) (American 
Cancer Society, 2015).  
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A) 
 
 
B) 
 
Figure  3. Estimated breast cancer incidence (A) and mortality (B) worldwide. The data represent estimated 
age-standardized rates per 100,000 women. (Ferlay et al., 2015). 
 
Some of the main BC risk factors explained: 
 Gender: being female increases the risk, as this disease is quite infrequent in males, the 
latter account for a total of 1% of all the breast cancer cases (Speirs et al., 2009).  
 Age: the incidence of BC is extremely low before the age of 30, after which, the risk 
increases linearly until the age of 80 years (Singletary, 2003).  
 Hormonal treatment: oral contraceptives of frequent and prolonged use, as well as 
hormone replacement therapy for more than ten years make women more prone to this 
type of cancer (Martin et al., 2000).  
 Personal history of BC: a woman that has been diagnosed with BC, has increased risk to 
develop it again, in the same or the other breast. 
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 Reproductive factors: Menarche at an early age has been linked with a risk level of 10 to 
20% of developing BC in comparison with women with menarche at age 14, given the 
early activation of ovarian cycles. Likewise, there is an increased risk of BC if menopause 
occurs late which is related with longer lifetime exposure to progesterone/estrogen effect. 
Early age of motherhood at first pregnancy and parity have been found to decrease the 
risk of BC development. Still, the effect of pregnancy is different for different types of 
BC. For triple-negative BC, pregnancy seems to increase risk. Pregnancies exert a 
protective effect probably due to the terminal differentiation of mammary tissue, although 
this hypothesis is still under research. Breastfeeding is theorized to protect against BC 
development (McPherson et al., 2000; Azim et al., 2014).  
 Genetic inheritance and family history of BC: about 5-10% of all BC cases have a 
hereditary component, an inherited mutation in high susceptibility genes as BRCA1 and 
BRCA2, high susceptibility cancer syndrome genes (TP53, PTEN, STK11 and CDH1) 
and/or moderate and low susceptibility genes can be directly related with the appearance 
of BC, especially if there is any familial background of the disease in previous 
generations. This topic will be widely explained in the next section as the main focus of 
present thesis.  
 Race/Ethnicity: certain populations have founder mutations that make women more 
susceptible for the development of BC. An example can be seen in Ashkenazi population, 
where founder mutations in BRCA1 185delAG, 5382insC and BRCA2 6174delT have a  
higher population frequency (2%), which is also related with higher incidence of BC 
specifically in people with this lineage (Levy-Lahad et al., 1997). In addition, white 
women are slightly more likely to develop BC than are African-American women, Asian, 
Hispanic and Native American women have a lower risk of developing and dying from 
BC (Ferlay et al., 2015). 
 Benign diseases of the breast: some diseases such as fibrocystic mastopathy, lesions 
without proliferative activity (fibroadenomas, hyperplasias, cysts, ductal ectasias and 
metaplasias), as well as proliferative diseases are predisposing factors for the 
development of BC. Women who have had any of these conditions should be strictly 
followed for early detection of any malignant modification (Dupont et al., 1993).  
 Women with dense breasts on mammogram have a risk of breast cancer that is 1.2 to 2 
times that of women with average breast density (Boyd et al., 1998). 
 Diet and body mass: Higher incidence of this disease has been reported in people with an 
excessive body mass, since the adipose tissue is an important extra-gonadal source of 
bioavailable estrogens (Singletary, 2003; Hankin et al., 1978).  
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 Environmental factors: There are many factors that are strongly related to lifestyle and 
also to geographic distribution. For example, the development of BC is more frequent in 
urban populations.  Regarding lifestyle, BC risk increases if there is no physical activity 
and due to a sedentary life. Also, there are some evidences linking BC development with 
the use of products that contain high number of chemicals, like artificial dyes for the hair.  
Although the exact risk has not been calculated, a link has been established between BC 
and: alcohol consumption, tobacco use, stress, depression, use of medications such as 
reserpine or diazepam, spironolactone, exposure to electromagnetic and UV radiation, 
ionizing or contaminants as well as organochlorined pesticides, low vitamin D levels and 
unhealthy food intake (Ali et al., 2014; Moukayed et al., 2017).  
 
    2.2. Hereditary breast cancer 
 
The majority of BC cases are sporadic (>90%), the rest of the cases, approximate 5-7% are 
hereditary cases (Melchor et al., 2013). Paul Broca was the first to describe a family with high 
prevalence of carcinoma of the breast; he made a pedigree of four generations highlighting BC 
incidence in every generation, which pointed to the fact that BC indeed, could be inherited (Steel 
et al., 1991). An important proportion of hereditary cases, around 15%, are attributed to germline 
mutations in either BRCA 1/2 (breast cancer susceptibility gene 1 and 2). Other genes associated 
with cancer syndromes, as well as moderate to low susceptibility for BC explain other 20% of the 
hereditary BC cases (van der Groep et al., 2011) [Figure 4A], but there is still more than 60% of 
the cases in which the genetic cause is not known, which translates into the impossibility for the 
patients to benefit from current available genetic tests and so, measurements for prevention, 
diagnosis and prognosis are based in clinics but not supported by genetic knowledge of the 
hereditability (Rudolph et al., 2016).   
 
The genetic basis of inherited predisposition to breast cancer has been persistently investigated 
in the last decades, by using the following techniques: linkage studies (genetic loci are mapped 
using samples from many members of a large family of an interrogated phenotype to identify 
genomic segments shared among affected members and absent in healthy members to help 
localize the area of the genome related with predisposition), resequencing studies (mutational 
screening of candidate genes, selected in the basis of similarity to known genes associated with a 
specific phenotype, large numbers of cases and controls are required to identify and compare the 
total number of pathogenic mutations), Genome Wide Association Studies (GWAS, are studies in 
which hundreds of thousands of SNPs alleles of haplotypes are tested for a disease in hundreds or 
thousands of unrelated cases and controls so that association can be inferred as to the location of 
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the risk variants in the genome) (Aloraifi et al., 2015; Dawn Teare et al., 2005; Manolio, 2010). 
Major discoveries with these technologies lead to the establishment of three well defined classes 
of susceptibility alleles for BC: high-penetrance alleles (confer a relative risk of developing BC 
>4.0 fold higher than the general population risk and are very rare in population), moderate-
penetrance alleles (confer a relative risk of developing BC 2.0-4.0 fold higher than the general 
population risk and are rare in population), and low-penetrance alleles (confer a relative risk of 
developing BC <2.0 fold higher than the general population risk and more common), which will 
be described in the next section (Stratton et al., 2008) [Figure 4].  
 
 
 
 
Figure 4. (A) Proportions of familial risk of BC exp lained by inherited variants. (B) Relative risk in  
relation to minor allele frequency of high, moderate and low susceptibility genes for breast cancer (Bahcall 
2013). The main genetic technique used for the characterization of the different type of genes is marked in  
bold (Adapted from Rudolph et al., 2016 and Foulkes , 2008). 
 
 
    2.2.1 High susceptibility genes  
 
Only two genes that confer high susceptibility to develop HBOC have been described, BRCA1 
and BRCA2, which were discovered by linkage analysis (Miki et al., 1994; Wooster et al. , 1995). 
Germline pathogenic mutations in BRCA1 confers a lifetime risk of BC of 41-85% for females 
and 4% for males and in BRCA2 50-80% for females and 7% for males. For ovarian cancer, the 
lifetime risk differs between carriers of these two genes, ranging from 11 to 62% in BRCA1 
mutations carriers and from 10 to 20% in BRCA2 mutation carriers (Mavaddat et al., 2013). 
Depending on the population studied, the estimated risk tends to be more specific, e.g. in Spanish 
population, the average cumulative risk of breast cancer to age 70 years was estimated to be 52% 
A) A) B) 
ATM, PALB2, 
CHEK2  
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for BRCA1 mutation carriers and 47% for BRCA2 mutation carriers. For ovarian cancer, the 
estimates were 22% and 18%, respectively (Milne et al., 2008).  
 
The characterization of BRCA genes meant a cornerstone in diagnosis, prognosis and treatment 
for carriers of mutations in these genes. In this regard, genetic testing to identify potential 
germline pathogenic variants in BRCA1/2 should be performed to women that present any of these 
characteristics: two relatives with BC, diagnosis at or before age 35 years old, three or more 
relatives with BC regardless of age at diagnosis, a combination of both breast and ovarian cancer 
in relatives, bilateral breast cancer cases in the family, two or more relatives with ovarian cancer 
regardless of age at diagnosis, history of BC in a male relative, triple-negative BC diagnosed 
before 60y, Ashkenazi Jewish heritage with any relative presenting breast or ovarian cancer 
(Bradbury et al., 2007).   
 
Despite all the knowledge gained with BRCA1/2, mutations in these genes do not account for 
more than 20% of all the hereditary cases, which means that there should be other genes that 
confer high susceptibility that have not been identified (Apostolou et al. , 2013). Mutations in 
other genes such as TP53, PTEN, STK11 and CDH1 confer high susceptibility to breast cancer 
and are associated to cancer related syndromes: Li-Fraumeni (Gonzalez et al., 2009), Cowden 
(FitzGerald et al., 1998), Peutz-Jeughers (Hearle et al., 2006) and hereditary diffuse gastric cancer 
syndrome (Schrader et al., 2008). Lifetime risk for development of BC conferred by germline 
mutations in these genes are: 50-90%, 50-85%, 32-54% and 52%, respectively. Mutations in these 
genes also are related with the appearance of other type of tumors like: gastrointestinal, sarcomas, 
thyroid, renal, stomach, lung and testis cancer (Tan et al., 2012; van Lier et al., 2010).  
 
2.2.2 Moderate susceptibility genes 
 
Mutational screening of candidate genes, led to the discovery of genes whose inherited 
mutations confer an intermediate increase in risk of breast cancer (Beggs et al., 2009). Other 
genes that confer moderate susceptibility to HBOC are CHEK2 (Meijers-Heijboer et al. , 2002), 
NBS1 (Heikkinen et al., 2006), BRIP1 (Seal et al., 2006), PALB2 (Rahman et al., 2007), RAD51C 
(Meindl et al., 2010), RAD51D (Loveday et al., 2011) and ATM (Renwick et al., 2006). In more 
recent studies, some of these genes have been established as almost conferring a high-risk for BC 
rather than moderate risk. Such is the case of PALB2, which confers a risk that may overlap with 
that of BRCA2 mutation carriers (Antoniou et al., 2014). Other approaches, in contrast, have 
discarded some genes originally described to confer moderate susceptibility for BC and nowadays 
additional evidence shows that mutations in genes like BRIP1 (Ramus et al., 2015; Easton et al., 
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2016), RAD51C (Song et al., 2015) and RAD51D (Thompson et al. , 2013) are enriched among 
ovarian cancer and not breast cancer patients.  
 
It is worth to emphasize that the majority of these genes have been identified through 
candidate gene screening, selected upon the biological pathways where BRCA1/BRCA2 were 
initially implicated, assuming that as BRCA genes are implicated in DNA repairing/maintaining 
systems, then other functional partners encoded by genes with similar function should exist. 
Another important feature about this group of genes is the fact that they are related with Fanconi 
Anemia (FA) pathway.  
 
FA is a rare disease with an incidence of 1/350 000 births with a clear recessive pattern of 
inheritance by biallelic mutations in any of the 21 FANC genes described until today. The 
phenotype is related to abnormalities as short stature, abnormal skin pigmentation, and skeletal 
malformations of the upper and lower limbs, microcephaly and ophthalmic and genitourinary tract 
anomalies, bone marrow failure characterized by pancytopenia, thrombocytopenia and leucopenia 
(Mehta et al., 2002). It has been shown that heterozygous carriers of mutation in FA-genes (e.g. 
BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN and RAD51C/FANCO) have increased BC or 
OC susceptibility (Garcia et al. , 2008). Although the mechanisms that link FA and cancer have 
not been completely explained, the basis arises from the fact that inactivating mutations over them 
lead to chromosomal instability, accumulation of DNA damage and alteration of major DNA 
repair pathways: homologous recombination, nucleotide excision repair and mutagenic translesion 
synthesis which would be intrinsically translated to transformation and malignancy (Moldovan et 
al., 2009).  
 
2.2.3 Low susceptibility genes 
 
Multiple SNPs that can modify the risk of developing HBOC have been described in the last 
years and they have been discovered using GWAS and large scale replication studies. Numerous 
variants have been found so far, which contribute to a small percentage of disease burden. Also, 
many variants are located either in noncoding or intronic regions and their significance are 
difficult to interpret (Lynch et al., 2013). Another consideration is that, because of the 
significantly reduced penetrance and strongly non-Mendelian patterns of inheritance, there is 
often considerable uncertainty about the exact underlying genetic variant in relation with the low 
susceptibility genes (Collins et al., 2011). In comparison with high/moderate susceptibility alleles, 
the low BC susceptibility genes are mostly related with growth-promoting genes as evidence seen 
for susceptibility variants in FGFR2 and FAM84B/c-MYC (Easton et al., 2007). Though, many 
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other loci are anonymous or have functions previously unrelated to cancer development which 
complicates profound understanding of their role in inheritance (Stratton et al., 2008).  
 
Since the publication of the first GWAS studies, there have been major advances regarding 
low susceptibility alleles. In the first one, five significant loci were described; in the last decade 
other 78 have been described (Michailidou et al., 2013). These almost 100 common BC risk loci 
explain 14% of inherited genetic component, with relative risk between 1.05 and 1.26. An 
important characteristic about recent studies is the pathways being explored to find function 
relevant genes mapped by GWAS hits: DNA damage recognition and repair, apoptosis, estrogen 
receptor signaling, tumor progression, metastatic disease and epigenetic changes. In the post-
GWAS era a novel combination of strategies is needed to identify target genes and/or function 
effect of a confirmed loci, these include: fine-scale mapping the locus, bioinformatics predictions 
for functionality and in vitro/in vivo experimental verification of molecular mechanism associated 
and risk prediction modelling (Fachal et al. , 2015). Breast Cancer Association Consortium 
(BCAC) has worked very assiduously to identify new risk associated variants in large-scale 
replication study as part of the Collaborative Oncological Gene-Environtment Study (iCOGS). As 
part of this work they have associated low penetrance BC susceptibility loci with specific breast 
tumor subtypes (Broeks et al., 2011). An interesting approach that has been proposed in order to 
identify women at different level of BC risk by the combination of multiple common 
susceptibility alleles to render a genetic risk stratification effectuated in 77 BC associated SNPs in 
66000 cases and controls. This study lead to the estimation of polygenic risk scores (PRS) to 
stratify BC risk in women without family history and to refine genetic risk in women with a 
family history of BC and lead the recommendation to improve risk reduction and screening 
strategies in women with highest PRS scores. In addition, PRS data combined with other risk 
factors could also guide different management and prevention strategies (Mavaddat et al., 2015). 
Another challenge would be related to the clarification of the BC phenotype that mutations in 
particular loci confer. It is likely that in the next years, more loci that confer low susceptibility to 
BC will be found, although the clinical utility will be limited until it is known in which pathway 
and manner are these loci implicated in the disease (Freisinger et al., 2008).  
 
2.3. Next Generation Sequencing (NGS)  
2.3.1 Brief concept into NGS  
 
Before the introduction of NGS technology (a concept that stands for the parallel sequencing 
of thousands of DNA fragments at the same time), the main techniques used for identification of 
high, moderate and low susceptibility alleles had their own limitations. Linkage analysis could not 
identify the causal mutation of Mendelian disease with extreme phenotypes where the number of 
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unrelated samples available was small, which translates into weak statistical power. In addition, 
linkage analysis was not robust enough for disorders with genetic, locus and/or phenotypic 
heterogeneity, as well, as reduced penetrance and disorders caused by effect of multiple genes 
(Bush et al.,2010).  
 
Candidate gene analysis is restricted by: prior physiological, biochemical or functional known 
aspects of possible candidate genes, complex diseases that show a spectrum of phenotypes, 
incomplete penetrance, a disease that results from the effect of multiple and combined genes 
where focusing solely in one gene would not explain entirely the clinics, lack in replication of 
certain studies, among others (Zhu et al., 2007; Tabor et al. , 2002). GWAS analysis faces some 
important issues: insufficient number of cases and controls can lead to false positives, also to 
prove the biological significance and the association is daunting if coping with a complex disease, 
the use of GWAS which is mostly applied to look for low penetrance genes not for high-risk 
genes, presence of variants that can be present in linkage disequilibrium with other one that is the 
real functional cause are some of the most criticized aspects of GWAS studies (Pearson et al., 
2008). Taking all these into account, there are still a large proportion of BC familial cases with 
unidentified cause. In the last decade, the advent of high throughput technologies for massive 
sequencing has happened. The most exploited technologies into NGS are Whole Genome 
Sequencing (looks into the whole genome, including coding and non-coding regions), Whole 
Exome Sequencing (includes the whole coding regions of the genome), Amplicon-based 
sequencing (targets a small and specific region of interest for sequencing), RNA sequencing 
(evaluates RNA and gene expression) and exon capture transcriptome (baits are used to capture 
portions of the transcriptome) (Simon et al. , 2013; Metzker 2010) [Figure 5]. In the next sections, 
we will focus specifically in Whole Exome Sequencing and its application in hereditary breast 
cancer context. 
 
Figure 5. Next  Generat ion Sequencing techniques (Adapted from Simon et al., 2013).  
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2.3.2 Whole Exome Sequencing in hereditary breast cancer 
 
There have been a number of publications that use WES to study missing hereditability in 
hereditary breast cancer [Table 2]. The contribution and the effort have been remarkable, but 
principal findings have not been conclusive as expected and reasons that condition WES scope are 
exposed in the next section. Nonetheless, in the lasts years a novel putative BC susceptibility gene 
has been proposed, RECQL, meaning that WES can be successful for unraveling genetic causality 
of HBOC (Cybulski et al., 2015; Sun et al., 2015).  
 
Table 2. Whole Exome Sequencing applied to hereditary breast cancer 
 
Study Population Family Selection Strategy for Candidate 
Variant Identification 
Major Results 
Rosa-
Rosa et 
al., 2010  
and Rosa-
Rosa et al. 
, 2009 
Spain Families selected 
based in previous 
study identified by 
linkage studies 
candidate regions in 
Chromosome 3 and  
6 (10.8 and 6.5 Mb, 
respectively) for 
harboring BC 
susceptibility genes. 
Families were 
BRCAX with at 
least 2 affected 
members with BC  
Massive parallel 
sequencing. Analysis 
pipeline based on SOAP 
aligner. Hydrid selection 
on tiling microarrays used 
for enrichment of exonic 
sequences within two 
candidate regions as a 
valid second step for 
identification of putative 
HBOC genes 
Not conclusive. 8 
candidate SNPs under 
functional validation 
with missense, 3’UTR 
effect and/or interesting 
gene function. No 
truncating mutations 
identified.  
Park et al., 
2011. 
Australia and 
US 
Two greater than 
third degree 
affected relatives 
from four multiple -
case, early onset 
BC families (3). At  
least 6 cases of BC. 
Dx under 60y.  
BRCAX. Negative 
for other cancer 
related genes.   
Whole exome capture and 
massive parallel 
sequencing. Not deeply 
described 
Not conclusive. 2 
variants in the DNA 
damage repair gene 
FAN1. Not causal for 
BC. Maybe in a familial 
set and might influence 
in combination with 
other risk factors. 
Snape et 
al., 2012. 
UK  50 individuals with  
familial BrCa, 
bilateral cases (42), 
age first diagnosis 
53, 3 affected per 
family. BRCAX. 12 
selected for 
validation, no 
enrichment of 
group of 
functionally related  
genes 
Rare, protein truncating 
mutations and gene 
function.  Excluded read 
coverage>15, intronic 
variants, synonymous 
variants, select protein 
truncation, with 
frameshift indel, nonsense 
mutations and mutations 
at consensus splicing  
residues 
Not conclusive. 
Heterozygous truncating 
variants and 4 mutations 
in known predisposition 
genes  
Thompson 
et al., 
2012. 
Australia and 
New Zealand 
 15 high-risk breast 
cancer BRCAX 
families with at  
least four cases of 
Quality threshold >30, 
Read depth>10, Allele 
frequency>0.15, 
Deleterious consequences 
Not conclusive. 
Heterozygous, dominant, 
deleterious mutations in 
DNA repair genes 
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multi-generational 
BC 
nonsense SNVs, 
frameshift idels, splice 
variants and complex 
variants. Priority given in  
well-established brca-
associated DNA repair 
FANCC and BLM, 3 
truncating in FANCC and 
2 in BLM  
Park et al., 
2012 
Netherlands, 
Australia and 
Spain 
Multiple affected 
relatives from 13 
families. BRCAX 
families. Diagnosis 
before 45y 
Not deeply described Not conclusive. 2 
families with XRCC2 
mutations, one protein 
truncating and other 
probably deleterious 
missense mutation. 6 
pathogenic coding 
variants in 1308 cases.  
Hilbers et 
al., 2013 
Netherlands Six families in  
which tumours of 
multip le cases 
showed a specific 
genomic profile on  
array comparative 
genomic 
hybridizat ion 
(aCGH). Gain of 
almost whole chrs 
22.5-6 cases of 
BrCa per family. 
Onset 54y. Other 
cancers. No male 
cases.  
Removed variant with  
allele frequency>1% in  
hap map or 1000 
genomes, EVS, variant in  
homozygous state 
removed. As well, 
intergenic and non 
conserved variants in non-
coding regions. Priorized  
truncated protein (gain  
stop codon, frameshift  
and splice site variants). 
Possibly damaging. 
FunCtion in DNA 
integrity maintenance.  
Not conclusive. Linkage 
analysis revealed a 
region initially focusing 
in the linkage reg ion no 
potentially pathogenic 
variant could be 
identified. Outside of the 
linkage region multiple 
variants related to DNA 
integrity maintenance 
proteins.  
Gracia-
Aznarez 
et al., 
2013 
France, Italy, 
Netherlands, 
Australia and 
Spain 
11 indiv iduals from 
7 BRCA1/2 
negative families 
with at least 6 
affected women 
with BrCa 
diagnosed under the 
age of 60 across 
generations.   
 
 
 
 
INDEL and heterozygous 
SNPs were selected being 
common to both 
sequenced members, not 
being present in 7 HAP 
MAP controls, not being 
present in dbSNP130, 
gene function, DS and QS 
between 20 and 210. 
Variants presenting minor 
allele frequencies below 
or equal to 1% were 
reviewed, stop, frameshift  
and splicing variants were 
reanalyzed.  
Not conclusive. Known 
variant CHEK2 1100del 
C identified and a 
catalogue of 11 rare 
variants associated with 
BC related with DNA 
repair, cell proliferation 
and survival or cell cycle 
regulation. Support that 
majority of BRCAX 
BrCa families might be 
explained by the action 
of moderate and/or low 
penetrance susceptibility 
alleles 
Lynch et 
al., 2013 
US Family-focused 
approach. BRCAx 
family with 5 cases 
of BC, 4 diagnosed 
before 50 years old, 
with mendelian  
autosomal dominant 
inheritance.  
Calling score >40, 
mutated base >10 
individual sequences, non 
synonymous codifying 
changes, sift score 0.05 
Not conclusive. Two 
variants in KAT6B in 5/6 
BC affected members. 
No other variants 
detected in the entire 
coding exons in 42 
BRCAx extra cases.  
Kiiski et 
al., 2014 
Fin land 24 high risk familial 
BRCA1/2 negative 
BC patients (min 3 
breast or ovarian 
cancers in first or 
second degree 
relatives) 
Finnish population  
Mean coverage >15. 
Checked in EVS, 1000 
genomes, exome data 
from 144 fin ish noncancer 
control cancer. Genes 
participating in DNA 
repair were selected. 
Frameshift delet ions and 
22 variants of 21 DNA 
repair genes. Mutation in 
FANCM c.5101C>T 
(p.Q1701X) more 
frequent o.5% families 
BRCAX, part icular 
enrichment among 
patients with triple 
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insertion, splicing  
alteration, missense and 
nonsense SNVs. Missense 
predicted pathogenic.  
negative BC 
Wen et 
al., 2014 
US Three families with  
BRCAX familial 
BC, 17 members  
with cancer and 5 
without cancer. Plus 
22 probands for 
BRCAX familial 
BC.  
Minimum read depth 10 
and minimum base 
quality 30. Known 
variants in db SNP, 1000 
Genomes, Variants 
causing deleterious effects 
kept, with Polyphen. 
Focus in single base 
change. Removal of 
variants common in  
human population, 
remove family specific 
normal variants. Selected 
shared between affected 
members and functional 
class of the mutated 
genes. 
Not conclusive. Results 
indicate that majority of 
novel deleterious variants 
identified are family-
specific but not shared 
with other families. In 
addition to population-
approach, family-
approach can determine 
the genetic 
predisposition. Data 
cannot be considered as 
true predisposition 
without further 
phenotypic and 
functional evidences.  
Park et al., 
2014 
US, Australia 
and Canada 
89 women with BC 
from 47 families 
with at least 3 cases 
early onset BC in  
the family, with  
bilaterality. 
Ashkenazi origin  
and family history 
Exome sequencing and 
multip le parallel 
sequencing for mutational 
screening of RINT1. 
Exonic variants plus 
intronic variants that fell 
within 20 bp of a splice 
acceptor 8 bp of a splice 
donor, allele frequency 
<0.5%, explored in EVS, 
1000G 
RINT1 rare sequence 
variants associated with 
intermediate levels of BC 
risk, similar to the risk 
conferred by Lynch 
syndrome 
Sun et al., 
12015 
China 514 familial BC 
patients, BRCAX 
and with early onset 
of BC  
Variants priorized were 
heterozygous which led to 
truncating mutation or 
splice-site variants, 
looking into db SNP and 
1000G database 
RECQL mutations are 
associated with BC 
susceptibility 
Cybulsky 
et al., 
2015 
Poland and 
Canada 
195 women with  
familial BC, 
numerous early BC 
cases, with 3 or 
more affected 
relatives, familial 
story of ovarian 
cancer.  
Truncating variants 
(insertions, deletions, stop 
codons) and variants in 
consensus splice sites. 
Variants seen in more 
than two cases and genes 
with two or more variants. 
Genes selected upon its 
relation with cancer 
pathogenesis 
RECQL mutations are 
associated with BC 
susceptibility 
Noh et al., 
2015 
Korea A BRCAX family  
with three siblings, 
two of them 
affected with BC, 
one healthy. No 
cases of cancer in 
previous 
generations 
SNVs and indels 
priorized, exonic or 
splicing regions, 
compared in dbSNP and  
1000G databases, 
compared with dbNSFP 
(functional prediction and 
annotation of potential 
non synonymous SNP), 
Sift score <0.05 
Not conclusive. 7 risk 
variants in genes: XCR1, 
DLL1, TH, ACCS, 
SPPL3, CCNF, SRL. 
Genetic evidence should 
be confirmed by 
functional analysis. 
Määttä et 
al. 2017 
Fin land 13 h igh-risk 
hereditary breast 
Not deeply described Not conclusive. Variants 
in ATM, MYC, PLAU, 
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and/or ovarian 
cancer families  
RAD51, and RRM2B 
were enriched in female 
HBOC patients 
compared with controls. 
A rare nonsynonymous 
variant in RAD50 was 
detected in a male BC 
patient. In addition, a 
very rare BRCA1 variant 
was identified in a single 
high-risk family 
Jalkh et 
al., 2017 
Lebanon 45 unrelated  
patients with  
inherited BC, mean  
age of diagnosis 
44y  
Variants selected 
according to existence in 
databases (dbSNP), 
Human Genome Mutation 
Database HGMD, EVS, 
1000genomes, BIC, 
Leiden, COSMIC, BRCA 
Exchange website, <1% 
allele frequency,  
Not conclusive. 19 
pathogenic mutations in: 
ABCC12, APC, ATM, 
BRCA1, BRCA2, CDH1, 
ERCC6, MSH2, POLH, 
PRF1, SLX4, STK11, 
TP53. BRCA1 p.C44F 
detected twice in the 
cohort, suggestion a 
founder effect.  
Kim et al., 
2017 
Egypt 5 BRCAX high risk 
families.  
 Variants checked in 
dbSNP, 1000G, ESP6500. 
Also in Egyptian genome 
variation data to filter out 
polymorphis ms, 
MAF<1% 
Not conclusive. Genetic 
predisposition for 
familial BC can be 
ethnic-specific. Novel 
variants identified in 
already known 
predisposition genes like 
ATM, BRIP, CHEK2, 
RAD51C, RAD51D, 
TP53. 
Bold marks, highlight study with successful finding of a potential susceptibility gene in HBOC.  
 
2.3.3 Limitations of WES studies in hereditary breast cancer 
 
Some of the reasons of why the WES studies performed so far in hereditary breast cancer, have 
not detected another high susceptibility gene imply:  
 Model of inheritance: the studies using WES in looking for novel susceptibility gene for 
HBOC have assumed the existence of other(s) high susceptibility gene(s) that follow the 
inheritance model of BRCA1/2, which is the dominant model. Some publications have 
implemented mathematical simulations in a large numbers of families in which at least a 
percentage of the families with unknown genetic basis could be associated with a recessive 
model which has not been explored. In a three generation population-based families 
Australian study, in non-carriers of BRCA1/2 mutations, about 1/250 (95% confidence 
interval) women have a recessive risk of 86% of early breast cancer by age 50 years and near 
certainty by age 60 years (Cui et al. , 2001). Meanwhile, in another study including 2531 
Ashkenazi Jewish families, Mendelian transmission of a major recessive gene (s) was 
compatible with the data, predicting that 4% of women would carry high-risk genotype and 
85% of them developing BC at 70 years old (Kaufman et al., 2003). 
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 Incomplete design of the study: This refers, for example, to partial inclusion of the members 
of a family, due to the impossibility to gather all required samples. A small number of 
samples limit the statistical power of inference for risk assertion. An extra effort has to be put 
to the selection of families with extreme phenotypes to increase the possibility of finding 
something meaningful among the noise (Petersen et al., 2017). 
 
 Penetrance of the mutations: germline mutations are not fully penetrant, this means that the 
mutation could segregate into different members of the family but not all the carriers develop 
the disease (Ott et al., 2015).  
 
 Polygenic model: it seems that there is a percentage of hereditary BC cases where the genetic 
cause of the disease is not solely a gene, rather, it is the result of susceptibility alleles in many 
different genes in which, large numbers of susceptibility polymorphisms act multiplicatively 
on risk, modifying it. Although this hypothesis is difficult to prove in all the families in which 
there is not known mutation in major high/moderate susceptibility alleles detected, there is 
statistical data that supports high polygenic risk scores for risk prediction in hereditary BC 
families (Antoniou et al., 2003; Antoniou et al. , 2006; Pharoah et al., 2002; Muranen et al., 
2016).  
 
 Presence of variants of unknown significance (VUS): from every NGS study, there are a lot 
of variants whose implication is estimated in silico; although for many of them there is no 
functional study that demonstrates conclusive ly its role in the disease (Rainville et al. , 2014). 
Efforts through different consortia are being promoted to clarify significance of VUS in 
HBOC, as well as setting guidelines for the classification and interpretation of sequence 
variants (COMPLEXO et al., 2013; Richards et al., 2015).  
 
 Phenocopies: it refers to a member of a family that lacks specific inherited genotype, 
although, in the context of familial breast cancer, develops the disease. Presences of this type  
of events difficult the use of WES to study a hypothesized model of inheritance (Smith et al., 
2007).  
 
 Other considerations: there is the possibility of an unusual cluster of environmentally caused 
(non-familial/genetic) cases of the disease which would be taught at first glance as familial,  
but with genetic test would be unmasked. Also, careful considerations have to be taken when 
the pipeline analysis is designed so that interesting variants are not ruled out by filters since 
the beginning (Feng et al., 2011).  
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2.3.4 Clinical Relevance 
 
There have been attempts to translate current genetic knowledge in uses beyond classical 
genetic counseling of genes that have been included into screening associated to breast cancer 
risk, since the discovery of BRCA1/2. Application of WES in oncology is set toward identification 
of somatic mutations, germline mutation, novel driver mutations, mutation network reconstruction 
and identification of predisposing variants (Rabbani et al., 2014; Xuan et al., 2013).   
 
Multiple gene-sequencing is an emerging field in the eye of the scope. Nonetheless, clinical 
application is daunting, due to incorrect inferences, potential inappropriate clinical application 
and the overwhelming amount of data for which evidences of its implication as the causality of 
the disease is still missing. The management of variants of unknown significance is also a very 
delicate issue in both clinics and research (Rahman 2014). Nevertheless, the objective is set 
toward the implementation of NGS panels to identify pathogenic mutations in BRCAX families 
without a known genetic cause (Graffeo et al., 2017). This is extremely important in the set of 
management and prevention of both patients affected and carriers of the mutations. Different 
studies have already informed about the value of this technology for risk assessment in patients 
with early-onset of familial BC (Nielsen et al., 2016; Bertier et al., 2016;  Lin et al. , 2016) [Figure 
6]. 
 
Albeit the interpretation is daunting, NGS has led to the discovery of new predisposition 
genes, either family or ethnic specific. It is likely that other genes that confer high or moderate 
susceptibility appear, which a priority is in early diagnosis and prevention, to monitor mutation 
carriers, halt tumoral development through chemoprevention and applying preventive surgery to 
breast and/or ovarian tissues (Kim et al., 2017).  
 
In the case of identification of a novel variant in moderate-susceptibility gene by NGS, 
medical counsel was typically based on the extrapolation of guidelines used for management of 
individuals with high penetrance variants of cancer susceptibility genes that could translate in 
significant harm and unnecessary preventive measurements. This is why a framework for clinical 
decision-making for individuals with inherited moderate penetrance gene mutations associated 
with an increased risk of cancer has been published. In this, women carrying mutations in these 
genes could be considered for early mammographic screening and/or breast magnetic resonance 
imaging at annual starting age of 40 when mutations are present in ATM, CHEK2 (truncating 
type), NBN; whereas in PALB2, the annual starting age should be 30 years. And for mutations in 
BRIP1, RAD51C and RAD51D, the family story has to be considered if the cumulative life time 
risk (by 80 years) is >20-25%. For mutations in ATM, CHEK2, NBN and PALB2, decision-
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making over risk-reducing oophorectomy regarding prevention of ovarian cancer should be 
guided by family history of the disease, if present, because risk-reducing oophorectomy (RRSO) 
is not indicated based on the presence of moderate penetrance mutations alone. For mutations in 
BRIP1, RAD51C and RAD51D, consideration of RRSO might be warranted for individuals with 
mutations in any of these genes if the individual has a clear family history of ovarian cancer (>1 
case), especially in close relatives (Tung et al., 2016; Gradishar et al., 2017-NCCN guidelines).   
 
One of the great advantages of finding the causal variant in a BRCAX family is that it can 
guide personalized treatment for the patient. An example can be seen with the promising results 
achieved with PARP inhibitors (Farmer et al., 2005). Olaparib is the only PARP inhibitor 
approved by FDA in the treatment of patients with germline BRCA1/2 mutated advanced ovarian 
cancer pretreated with ≥3 prior lines of chemotherapy and other inhibitors like rucaparib with 
FDA breakthrough in April 2015 (Parkes et al., 2016). This selective specificity in BRCAness 
condition, depend in the high reliance of the tumoral tissue on alternative DNA repairing 
pathways, where poly(ADP-ribose) (PARP) polymerase is pivotal for survival, hence its 
inhibition favors cell death, the so-called synthetic lethality  (Herceg et al., 2001; Lord et al., 
2017). Being capable of selecting personalized medicine according to specific germline mutation 
has given crucial alternatives to patients, herein resides the importance of the NGS technologies 
and their debated implementation in clinics.  
 
In conclusion, despite technical and ethical constraints, WES has lead to the discover of many 
previously unknown mendelian causes in monogenic disorders. Its use in complex diseases is 
growing and with better strategies and refinement of bioinformatics’ analysis, WES promises to 
be more conclusive and a determinant factor toward finding missing hereditability in BC.   
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Figure 6.  Proposed clinical management of breast and ovarian tumors using NGS techniques.  NGS panels 
would be used to identify germline mutations. In the case of being pathogenic, patients are treated and 
counseled according to current HBOC recommendations. In the case of identificat ion of a variant of 
unknown significance (VUS), co-segregation or functional analysis may be undertaken to classify the VUS 
and if available, guide personalized medicine toward part icular t reatments (Adapted from Nielsen et al., 
2016). 
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3. General Objective 
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• Search for new susceptibility genes in hereditary breast cancer families (BRCAX) 
with an apparent recessive model of inheritance using WES.  
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4. Patients and Methods 
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4.1 Patients and Families of Study 
 
Families of study  
Four families with an apparent monogenic recessive model of inheritance for BC where 
selected based on: presence of two or three siblings affected with BC, early onset of BC (average 
age under 40 years for the first diagnosis of BC) and absence of familial antecedents of breast or 
ovarian cancer [Figure 7]. Deleterious mutations in BRCA1/2 had been previously ruled out by 
massive sequencing based in the Amplification kit BRCA MASTR V2.1 (Multiplicom) with the 
GS Junior 454 Sequencing Roche Machine. Blood samples from other members of the family 
were obtained for further segregation analysis. All participants signed an informed consent 
approved by the Ethics Committee of Carlos III Institute of Health. 
 
 
 
 
 
 
 
 
1) 
2) 
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Figure 7. Families with apparent recessive model of inheritance selected for study (1-4). Affected members 
with unilateral BC are represented with half blue colored circles/squares, bilateral BC are represented with 
full blue colored circles/squares; Dx, Age of diagnosis; arrow, index case; red circle, analyzed by WES. 
Other types of cancer are represented with grey dots inside circles.  
 
Cohorts of BRCAX cases and controls used in the different studies that compose this thesis are 
presented herein: 
 
BRCAX cases (OpenArray study) 
To evaluate the frequency of the selected variants found through WES, we performed a case-
control association study in 1477 BRCAX families and 589 controls. Index cases from 1477 
Spanish breast and/or ovarian cancer families recruited in the Spanish National Cancer Centre 
(CNIO) (n=577) and Hospital Clínico San Carlos (HCSC) (n=900) were selected for screening of 
the selected variants. BRCAX families fulfilled one of the following criteria: presented one BC at 
age <35 or at least two first-degree relatives diagnosed with BC at least one of them at age 50 or 
younger or fulfilled the same criteria but included at least one ovarian cancer case or at least one 
case of male BC. All the families were negative for mutations in BRCA1 and BRCA2.  
3) 
4) 
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Controls  (OpenArray study) 
DNA samples from 589 healthy women were collected from the Spanish College of Lawyers 
(n=271) and Hospital Clínico San Carlos (HCSC) (n=318) between 25 and 65 years of age and 
without personal or familial antecedents of any type of cancer. 
 
BRCAX families (ATM study) 
392 families were analyzed for a comprehensive ATM mutational study and fulfilled one of the 
following criteria: presented one BC at age <35 or at least two first-degree relatives diagnosed 
with BC at least one of them at age 50 or younger or fulfilled the same criteria but included at 
least one ovarian cancer case or at least one case of male BC. From the 392 families 172 
proceeded from CNIO and 220 from Sistemas Genómicos. All were negative for mutations in 
BRCA1 and BRCA2 (BRCAX) and the CNIO families (44%) were also negative for mutations in 
the PALB2, RAD51C and RAD51D genes. 
 
Controls (ATM study) 
350 index cases from families affected with different diseases not related to breast cancer were 
selected as a comparative group for the comprehensive analysis of the whole coding sequence of 
the ATM gene. 194 cases were affected with neurological disorders and 156 were affected with 
different cancer syndromes none of them related to breast cancer. Individuals proceeded from 
CNIO (59) and Sistemas Genómicos (291), were aged between 18 and 85 and 144 of them were 
women.  
 
BRCAx families (RECQL5 study) 
Index cases from 700 Spanish breast only cancer families recruited in the Spanish National 
Cancer Centre (CNIO, n=374) and Hospital Clínico San Carlos (HCSC, n=326) were selected for 
complete coding sequencing of the gene. BRCAX families fulfilled one of the following criteria: 
presented one BC at age <35 or at least two first-degree relatives diagnosed with BC at least one 
of them at age 50 or younger. All were negative for mutations in BRCA1 and BRCA2 (BRCAX). 
Part of these cases belonged to the cohort used for the case-control association study, selected 
upon the presence of breast only cases. 
 
Controls (RECQL5 study) 
DNA samples from 588 women were collected from the Spanish College of Lawyers (n=271) 
and Hospital Clínico San Carlos (HCSC) (n=317) between 25 and 65 years of age and without 
personal or familial antecedents of any type of cancer. Additional 166 control women (from the 
Spanish National Cancer Centre, CNIO) included in the full coding sequencing study of the gene 
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had the same characteristics as mentioned. Parts of these controls belonged to the cohort used for 
the case-control association study. 
 
Male Breast Cancer (MBC) cases and controls 
 
An initial cohort of MBC cases from Spanish population (n=50) was evaluated for the 
presence of selected variants obtained from the analysis of family 4. The characteristics for the 
selection of this preliminary cohort were: presence of one case of male breast cancer and negative 
for mutations in BRCA1/2. Importantly, this cohort is enriched in MBC cases that belong to 
BRCAX families with antecedents of the disease.  
 
A larger cohort of 1200 MBC was evaluated in collaboration with the “Complex Trait 
Genetics” laboratory, from the Institute of Cancer Research in London, UK. Because of the rarity 
of the disease, these collection of cases were not selected specifically for familial antecedents, just 
for personal story of the disease (n=1200). The mean age of diagnosis was 63.8 years, with ranges 
of age between 23 and 87 years old. Reported MBC bilaterality in only 2% of the cases.  
 
 DNA samples from 500 controls (healthy men without personal/familial antecedents of the 
disease) were used for comparison in the genotyping assay. Mean age of the cohort was 63 years 
old and age ranges between 23 and 90 years old. 
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4.2 Methods 
 
4.2.1Whole Exome Sequencing (WES) 
Genomic DNA was isolated from peripheral blood lymphocytes using the MagNA Pure LC 
Total Nucleic Acid Extraction. DNA concentration was determined using PicoGreen dsDNA 
quantification reagent (Invitrogen). As a concept, in sample preparation, genomic DNA was 
disengaged, the fragment ends were repaired by T4 DNA ligase, 3’ A-tailing was performed 
followed by ligation of paired-end adaptor to the fragments to finally amplify the prepared library 
(Rabbani et al., 2012). To enrich the library, hybridization was done with a biotinylated oligo 
library or DNA baits and captured with streptavidin beads (Exome-seq Nimblegen kit, in this 
case). Recovery of the hybridized fragments was followed by amplification. Before sequencing, 
library integrity was verified with highly sensitive methods. Samples were paired-end sequenced 
on a HiSeq2000 Illumina platform, using two lanes per sample and generating 101 base pair long 
reads with a commitment >50x.  
 
The amplification/sequencing method employed by Illumina technology was bridge 
amplification where the enriched library is tethered to a flow cell surface by ligating adapters to 
both ends of the fragments. Then, solid-phase bridge amplification was performed, resulting in the 
formation of thousand to millions of clusters from all the fragments of the library amplified. 
Cycles of sequencing were carried out by adding four fluorescent tagged reversible terminators, 
which are laser excited leading to the identification of the base being incorporated in every 
sequencing cycle, which occurred in a massive parallel form for each cluster. As nucleotides 
incorporated into the growing DNA strand, they were digitally recorded as reads (sequence) 
which would require further bioinformatics analysis to select the potential variant(s) implicated in 
the disease (Grada et al., 2013; Chong et al., 2015). 
 
4.2.2.Bioinformatic analysis and variant filtration 
Sequencing and processing of the raw data were performed in the National Center for 
Genomic Analysis (CNAG) in Barcelona, Spain.  Briefly, the output format from raw data was 
given as QC format due to the read quality control usually performed with FastQC program. 
Preprocessing was used for removal of bad quality reads, adapter reads and trimming of the reads 
under certain threshold before alignment. Mapping consisted in the comparison of the exome of 
the sample against the genome of reference, (GRCh37/hg19) using GEM mapper (Kamps et al., 
2017). Post-alignment process consisted of read duplicate removal, indel realignment and base 
quality score recalibration (Bao et al., 2014; Nielsen et al., 2011). Variant calling, annotation and 
priorization refered to the methods and bioinformatic software used to detect SNVs (single 
nucleotide variants), indels, CNVs (copy number variants), and large SVs in the sample when 
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compared with a genome of reference. Realignment and search for indels was performed using 
GATK. Variant calling was performed with Samtools19 (http://samtools.sourceforge.net). SnpEff 
(http:/snpeff.sourceforge.net) and snpSIFT were used to filter and manipulate annotated files. 
Variant filtering was performed in the Spanish National Cancer Research Centre (CNIO). 
Concisely, variants were prioritized based on sequence quality (Read Depth >10 and genotype 
Quality >25), impact on the protein (missense, stop lost/gain, frameshift, splice-site) and gMAF 
value < 0.001 for a dominant model of inheritance and < 0.05 for the recessive model of 
inheritance [Figure 8].  
 
 
 
Figure 8. General workflow including bio informat ics pipeline fo r raw data analysis. After selection of the 
families with the phenotype of interest, WES and raw data processing was performed according to their in -
house pipeline. Data analysis, variant filtering and selection per family were done as exp lained. An example 
is given for family 2, total number of variants detected by WES in four family members was 385967, 
according to the recessive model of inheritance, just homozygous variants were taken  into account and 
variants shared among healthy and affected BC sister were ru led out leaving 10961 variants. Through 
GMAF number of variants decreased to 1464. Considering quality parameters, 770 variants passed the 
threshold. Applying impact effect prio rizat ion, functional pathways and predictors, we had one variant 
selected for this family. After that, other approaches applied to assess the implication of the variant in BC 
were: validation through Sanger sequencing; effect in splicing if any; population studies (mainly, case -
control association studies) and functional studies (designed depending in the nature of the gene found).  
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4.2.3.Segregation analysis and Sanger validation 
 
To verify the status of the selected variants in each family where DNA was available, targeted 
regions for variants of interest were amplified by PCR technology (Thermo Scientific Maxima 
Hot Start Taq DNA Polymerase) using a suitable primer pair [Supplementary Table 2]. The 
products were sequenced using the Big Dye Terminator Cycle sequencing kit on an ABI 3730xl 
Sequencer (Applied Biosystems). The conditions of the PCR were: initial denaturalization 94ºC 
per 5 minutes, followed by 35 cycles of three steps (denaturing at 94ºC per 30 seconds, 
hybridization at customed temperature set by a previous PCR in gradient per 30 seconds and 
extension at 72ºC per 45 seconds), followed by a final elongation at 72ºC per 7 minutes. Sanger 
validation was used to confirm the status of the variant in the family as well as to validate the 
variants detected through WES. On average, a 80% of the variants was validated through Sanger 
sequencing.  
 
4.2.4 Case-Control Association Study 
Case control association study was performed with OpenArray Real-Time PCR technology 
(Applied Biosciences), according to manufacturer’s standard protocol. This platform is based on 
Taqman a genotyping assay that allows parallel genotyping of 64 SNPs in more than 2000 
samples at the same time and allows the detection of a studied variant in a large number of 
controls and cases to establish association with the interrogated disease (Roberts et al., 2009). 
Whether probes could not be evaluated due to technical limitations in the OpenArray or due to the 
design of the probe for this technology, normal Taqman assays were designed and performed for 
the case-control association study of specific SNPs. HapMap, sample duplicates and samples with 
status of the variant confirmed by Sanger sequencing were included in the array to serve as 
internal controls. Genotype calling and sample clustering was performed in TaqMan Genotyper 
Software v1.3 (Applied Biosciences). 
 
4.2.5. Splicing studies 
Variants predicted to trigger aberrant splicing were tested in RNA extracted from blood 
samples from affected members to verify its pathogenicity. RNA was isolated from peripheral 
blood lymphocytes from using TRIZOL reagent according to manufacturer instructions. RNA was 
quantified and samples with a ratio A260/280 ratio>1.8 were taken into account. cDNA synthesis 
was performed using 500 ng of RNA and the High Capacity cDNA reverse transcriptase kit 
(Applied Biosystems). Primers were designed to test found variants [Supplementary Table 2] and 
evaluate its impact.  
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4.2.6. Loss of heterozigosity  (LOH) analysis 
When possible, paraffin-embedded tumor from affected members of the families was obtained. 
Morphologic diagnosis was made in 4u hematoxylin and eosin (HE)-stained sections of tumor, 
after 10% formaldehyde fixative (24 hr) and paraffin embedding. Case was graded with a 
modified Bloom-Richardson score. The proportion of tumor cells was rated over 85 - 90%. DNA 
was extracted using DNA easy Blood and Tissue kit (Qiagen, Chatsworth, CA). PCR 
amplification was performed with a new set of primers for an amplicon of 200pb and Sanger 
sequencing was performed in order to compare with genomic DNA from the patient and detect 
LOH.   
 
4.2.7. Full coding sequencing of RECQL5 using the Illumina TruSeq Custom Amplicon 
platform  
Analysis of the whole coding sequence of RECQL5 gene was performed using Illumina Truseq 
Custom Amplicon designed specifically for the gene of interest adapted with 384 indexes.  
 
Briefly, 50 ng of the index case gDNA was reconstituted. Custom oligo pool, was hybridized 
by adding 5ul of a dilution of RS1with Custom Amplicon Oligo Tube (CAT) in a ratio 1:2, with 
15 ul of OHS2 (Oligo hybridization for Sequencing) per sample. After hybridizat ion, several 
washes steps were performed to ensure removal of unbounds oligos. Then, a DNA polymerase 
extended from the upstream oligos through the targeted region, followed by ligation to the 5’ end 
of the downstream oligo using a DNA ligase. Products containing the targeted regions of interest 
flanked by sequences required for amplification were formed. The conditions of the PCR were: 
37ºC for 45 minutes, 70ºC for 20 minutes and hold at 4ºC. Libraries were then amplified, adapters 
added as well as sequences required for cluster formation. The conditions of the PCR adjusted for 
less than 96 amplicons were: 95ºC for 3 minutes, 32 cycles of 98ºC for 20 seconds, 67ºC for 20 
seconds and finally, 72ºC for 40 seconds.  
 
Libraries were cleaned with sample purification beads to purify the PCR products from other 
reaction components. The correct amplification of the libraries was confirmed in this step by 
running 2 ul per sample in an agarose gel 2%. The expected PCR product size for these libraries 
was around 350 bp. At a final stage of the Truseq protocol, libraries were normalized for a 
balanced representation. After pooling the libraries (combine equal volumes of normalized 
libraries), these were diluted with HT1 according to manufacturer protocol and denatured by 
letting stand the samples at 96ºC per 2 minutes and 4ºC per 5 minutes. To verify the formation of 
the clusters, 30 ul of phiX 12.5 pM, was used as an internal control. Finally, libraries were further 
ultrasequenced in a single run in a MiSeq H2000 platform from Illumina. Five runs in total.  
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Pipeline analysis of raw data was performed using VariantStudio 2.0 Software included in the 
platform of Illumina. The settings for priorization of the variants were: heterozygous state, 
prioritizing missense, frameshift and/or stop gain/lost variants, with an alternative variant 
frequency >10% of the reads and a population frequency <1% in European population. Also, 
variants presenting low read quality and present in more than 20 heterozygous (per allele count) 
in Exome Aggregation Consortium (EXAC) (http://exac.broadinstitute.org/, last accessed March 
2017) were ruled out as putative deleterious. Clearly pathogenic germline variants were selected 
upon the lost/gain of a stop codon or effect of a frameshift mutation that generate a truncated 
product. Potential germline pathogenic variants were selected based on the combination of eight 
in silico predictors  SIFT, MUTASTER, Polyphen-2, FATHMM, SNP&Go, Mutation Assessor, 
MUTPRED and Condel, where at least 5 of them indicated pathogenicity. In addition to the 
number of predictors, Predict Protein Score (PPS, calculus by position) 
(https://www.predictprotein.org/) was taken into account to consider pathogenic/tolerated effect. 
A score higher than >50 was considered as a high pathogenic predicted effect. Variants affecting 
intron boundaries (+/-5 pb) and predicted to affect nearest splice site by 5 in silico splicing 
predictors (MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing Finder) were also taken as 
potentially deleterious. Missense variants that laid in the end of the exons were considered 
although they did not pass the filters of the predictors, as they could induce aberrant splic ing. All 
clearly/potential deleterious candidate variants for RECQL5 gene were confirmed by Sanger 
sequencing in index cases samples [Supplementary Table 3].  
 
4.2.8. In silico inference of missense variants effect in RECQL5 domains  
In silico studies were performed for putative proteins encompassing the selected mutations in 
comparison with the putative wild type (wt) RECQL5 protein. 23 variants were analyzed 
including 9 in which the helicase activity had been tested experimentally (Newman et al, 2017), 
the 10 variants putatively predicted as deleterious from our case-control study and 4 variants 
considered as negative control: 1 with high MAF (c.1439A>G; p.Asp480Gly (rs820196) quite 
frequent in our cohort and a GMAF in EXAC of 0.2 in general population) and 3 with neutral 
effect based on damage predictors). (ATP)M and (ENZIME CONC) values were taken from 
Newman et al., 2017. Putative proteins encompassing mutations in D2 domain were considered 
highly deleterious while putative proteins encompassing mutations in D1 and Zn
2+
 had 
intermediate effect. Neutral effect was considered for putative proteins with mutations annotated 
after p.435 position. 
Solvent accessibility notation (PACC) was calculated for all positions of the putative wt 
RECQL5 protein and compared to PACC of putative proteins encompassing mutations from 
Newman study. Solvent accessibility of amino acids (PACC score) was predicted using the 
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PROFAcc algorithm (Schlessinger et al., 2005) implemented in ProteinPredict (Yachdav et al., 
2014). Only one position (p.283) changed PACC score in putative proteins from Newman et al., 
2017, compared wt putative protein. PACC score for this position was calculated for all putative 
proteins encompassing the studied mutations. Secondary structures (β-strands, α-helix and loops) 
of the putative protein models were based on REPROFSec prediction. The predictions of the 
annotation (minimum REPROFSEc score of 5) of conserved secondary structures for wt RECQL5 
were based on several original prediction methods (NORSnet, DISOPRED2, PROFbval and 
Ucon) implemented in PredictProtein (Yachdav et al., 2014). Wt RECQL5 annotation was 
compared with putative proteins encompassing the studied mutations to determine loss/gain of 
secondary structures. 
Protein binding regions were found using the ISIS algorithm (Ofran et al., 2007) and SomeNA 
predictor method (Hönigschmid, 2012). Putative Protein-binding sites score (threshold >20) were 
calculated for wt RECQL5 protein. Selected positions at protein-binding domains were evaluated 
in RECQL5 mutants. Most significant score changes (threshold <15) were considered highly 
deleterious and threshold between 15>20 were considered intermediate effect. 
The clustering score was assigned regarding relative effect for each in silico study and 
normalized by the total number of in silico studies performed for each putative protein. Clustering 
was performed by score sorting and only considering the in silico studies included in the domain 
where the mutation was annotated. 
 
4.2.9. Mutational Analysis of ATM gene  
Analysis of the whole coding sequence of the ATM gene was performed using Onco-Gene 
SGKit LV2511 according to manufacturer’s protocol. Concisely, 50 ng of index case gDNA was 
tagmented, amplified and libraries were purified. Quality and quantity assessment was performed 
on an Agilent 2100 Bioanalyzer instrument. Libraries were then hybridized with capture probes 
for targeted regions. Capture system consisted in streptavidin coated magnetic beads to select 
probes hybridized. Libraries were indexed for combination in a single run for further 
ultrasequencing in a MiSeq platform from Illumina.  
 
Familial cancer-relevant genes analyzed in the kit englobe: APC, ATM, AXIN2, BARD1, BLM, 
BMPR1A, BRCA1, BRCA2, BRIP1, BUB1, CDH1, CDKN2A, CHEK2, DDB2, DKC1, ELANE, 
EPCAM, ERCC1 , ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, 
FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FLCN, GFI1, GPC3, HAX1, HOXB13, 
KIF1B, MAX, MEN1, MET, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NOP10, NSD1, 
NUDT1, OGG1, PALB2, PMS1, PMS2, POLH, PRSS1, PTEN, RAD50, RAD51C, RAD51D, 
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RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, STK11, TERT, TMEM127, TP53, 
TSC1, TSC2, VHL, WAS, WT1, XPA, XPC and XRCC2.  
 
Pipeline analysis of raw data was performed by Gene Systems (Valencia, Spain), which 
encompassed: Reads were aligned against the human reference genome version GRCh38/hg38 
using BWA aligner. Low quality reads and PCR duplicates were removed from BAM formatted 
file. Coverage and efficiency of targeted enrichment system were evaluated. Variant calling was 
performed using a combination of VarScan and GATK, along with in-house scripts to combine 
and filter variants. Identified variants were annotated using Ensembl database. The candidate 
deleterious variants for ATM gene were confirmed by Sanger sequencing in index cases samples. 
Twenty other breast and/or ovarian cancer susceptibility genes or candidate susceptibility genes 
included in the panel were subsequently analyzed in the 392 index cases. The genes are 
highlighted in bold in the list provided before, only unequivocally deleterious mutations were 
taken into account for this specific analysis.  
 
4.2.10 Immunohistochemistry 
For evidencing loss of ATM protein expression in BC tumor, paraffin embedded tissue, an 
initial automated dewaxing and rehydration step followed by heat-induced (100C for 20 min) 
antigen retrieval (15 min, Bond Enzyme Pretreatment Kit, Leica Biossytems) was performed. The 
slides were subsequently incubated with 3% hydrogen peroxide (5 min), proper primary antibody 
peroxidase (clone Y170, Abcam, Cambridge, MA, USA) diluted 1:250 (30 min), a post-primary 
blocking reagent (to prevent nonspecific polymer binding) (8min), horseradish peroxidase (HRP)-
labeled rabbit anti-mouse Ig polymer (8 min) and diaminobenzidine susbtrate (10 min). All 
reagents were components of the Bond Polymer Refine detection system (Leica Biosystems).  
 
4.2.11. Genotyping of 50 Spanish MBC cases  
Targeted regions selected upon the analysis of the MBC family through WES were amplified 
by PCR technology using a suitable primer pair [Supplementary Table 2]. The products were 
sequenced using the Big Dye Terminator Cycle sequencing kit on an ABI 3730xl Sequencer 
(Applied Biosystems) to evaluate the presence and status of the variant in a set of 50 MBC cases 
from Spanish origin.   
 
4.2.12. KBioscience Competitive Allele-Specific PCR genotyping system (KASP) Genotyping 
technology 
For the development of the assays, KASP probes were designed and validated by the company 
as KOD (KASP On Demand) probes. DNA extraction was performed with Qiagen QIAamp DNA 
Blood mini kit (cat No 51106) for the samples which were extracted from buffy coat samples and 
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Qiagen QIAamp DNA Blood maxi kit (cat No 51194) for the samples extracted from whole 
blood. DNA was quantified using PicoGreen ds Quantitation Reagent and its quality checked in a 
2% agarose gel. After that, DNA was sampled at a concentration of 10 ng in a final volume of 1 
ul, followed by the same volume of Master Mix ROX 2X Buffer and 0.040 ul of KASP KOD 
probes per samples, dispensed using an Echo Cytometer machine in an ABI PPi plate for 384 
samples. Controls with known status of the variants were included to validate the assay and 
discriminate the allelic groups, as well as adequate non template controls (NTCs). Plates were 
sealed, properly mixed and spinned down. Standard KASP thermal cycling protocol consists of 10 
cycles of touchdown PCR (annealing 61-55C, decreasing 0.6C per cycle), then 26 cycles of 
standard 2-step PCR at the lower annealing temperature (55C). The other variation of program 
was set at a touchdown of 68C-62C. The difference of the protocol used resides in the content of 
G/C and the size of the region of interest to amplify. For the lecture, three additional cycles were 
used to refine the clusters in the allelic discrimination plot. Genotyping lectures were obtained in 
a QuantStudio 6 Flex System Machine. Data analysis was performed using the Quant Studio 
Real-Time PCR Software version 1.4. 
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5. Results 
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 5.1. Exploration of the recessive model of inheritance in BRCAX female BC families 
 
Our initial hypothesis for the exploration of the families was the recessive model of 
inheritance. In order to detect potential susceptibility genes in hereditary breast cancer families 
(BRCAX) with this model of inheritance, we applied two approaches: 1) look for variants in 
homozygous state in BC affected siblings in the families, each variant coming from each parent 
and 2) look for variants as compound heterozygous (different variants that affect the same gene) 
in BC affected siblings and each variant coming from each parent. Specifically, in family 1 , we 
looked for variants in homozygous and compound heterozygous state present in the three BC 
affected members [Figure 9A]. In family 2, we looked for presence of variants in homozygous 
[Figure 9B] or compound heterozygous state [Figure 9C] in BC affected sister, heterozygous state 
or homozygous for the reference in the healthy sister (this member of the family was assumed as 
healthy since she had not developed BC at 47 years of age) and heterozygous state in the parents. 
In family 3, due to technical constraints we did not have the exome from the parents, although we 
looked for variants in homozygous and compound heterozygous in BC affected patient from 
whom we had the exome. Nonetheless, after the application of our priorization filters (described 
in Methods), we did not find any variant that adjusted to the analyzing criteria applied. As a 
consequence, no variants in a recessive model of inheritance were found for this family. Family 4 
(a hereditary male BC family) was analyzed separately and we will refer to it in a separate 
section. Of importance, exploration of genes related with roles in DNA repair, tumoral 
suppression, cell growth, cell signaling, cell survival; as well as genes implicated in hormone 
metabolism and signaling pathways were prioritized in order to increase the possibility to find a 
novel susceptibility BC gene. The list of candidate variants for family 1 and 2 are shown in Table 
3, pathways and main cellular functions are shown in Supplementary Table 1. 
 
A) 
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B)       
 
 
C) 
 
 
 
Figure 9. Example of the segregation analysis showing the recessive model of inheritance in family 1 and 
2. A) Compound heterozygous model of inheritance showing two variants in DOCK3 gene present in the 
three affected sister with BC, each variant inherited from one of the parents. B) AKR1C3 (c.230A>G; 
p.Glu77Gly ) is the only gene for which we found a variant in homozygosis in the affected sister and in 
heterozygosis the parents and healthy sister. C) Compound heterozygous model of inheritance showing 
three variants in FBF1 gene present in the affected sister with BC and absent in the healthy sister. Two are 
inherited from the mother and one from the father.   Affected members with BC are represented with half 
colored circles; Dx, Age of d iagnosis; arrow, index case; red circle, analyzed by WES.  
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Table 3.  
Candidate variants found under the recessive model of inheritance by WES in BRCAX families 
Fam Gene 
Chromo-
somal 
position 
Functional 
class 
Ref/Alt rs GMAF1  EXAC2  Variant 
   1 DOCK3 
51418611 Missense C/T rs201507848 0.0012 0,0003721 S1905L 
51127722 Missense T/C NR NR NR F218S 
 
 
2 
 
AKR1C3 5138747 Missense A/G rs11551177 0,03672 0,05018 E77G 
 
FBF1 
73916166 Missense C/T NR NR 0.00034* R603Q 
73915803 Missense G/A rs113062332 0.0074 0,02305 A680V 
73922167 Missense G/C rs201197761 NR 0,0002256 P257R 
 
TOPAZ1 
44285446 Missense A/G rs17076541 0,0058 0.003706* Q483R 
44286015 Missense C/G rs17646517 0.0080 0.01783* P673A 
44286384 Missense A/G rs17076545 0.0110 0.005698* K796E 
44373498 Missense C/G rs533942526 0.0002 0.0000922* H1692D 
GLE1 
131271171  Missense G/A rs138871311 0.0002 0.0001977 C39Y 
131271281  Missense G/A NR NR 0.0000082 A76T 
 
KLB 
39448672 Frameshift CTCTC/C NR NR 0.002272 F777del 
39450295 Missense G/A rs143809363 0.0006 0.003605 V1042I 
Bold marks, unique variant found in homozygous state according to recessive model of inheritance. The 
rest of the variants were found as compound heterozygous. NR, Not reported. 
1
GMAF based in 
1000Genomes reports. 
2
Total include European (non Finnish and Finnish), Lat ino, South Asian, African 
and East-Asian populations. .*For this variant, a note in EXAC is given: This site is covered in fewer than 
80% of the individuals in ExAC, which may indicate a low-quality site  
 
 
5.2.  Exploration of genes related with DNA maintenance and repairing systems  
 
Many genes that confer high-/moderate- susceptibility for BC are related with DNA 
maintenance and DNA repairing systems (Mavaddat et al., 2010). This is why, regardless of the 
model of inheritance, further priority was given to genes with a well-established role in DNA 
repairing pathways. We looked for the presence of variants in homozygous or heterozygous status 
affecting known genes that are related with these pathways in family BC affected members from 
family 1, 2 and 3. For this list of genes, information from in silico predictors was not taken into 
account; as well, we considered synonymous variants and checked them all. The only filter that 
we considered was the frequency of the variants in population (see methods). 
 
The list of genes explored was: UNG, SMUG1, MBD4, TDG, OGG1, MUTYH, NTHL1, MPG, 
NEIL1, NEIL2, NEIL3, APEX1, APEX2, LIG3, XRCC1, PNKP, APLF, PARP1, PARP2, PARP3, 
MGMT, ALKBH2, ALKBH3, TDP1, TDP2, MSH2, MSH3, MSH6, MLH1, PMS2, MSH4, MSH5, 
MLH3, PMS1, PMS2L3, XPC, RAD23B, CETN2, RAD23A, XPA, DDB1, DDB2, RPA1, RPA2, 
RPA3, ERCC3, ERCC2, GTF2H1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, CDK7, CCNH, 
MNAT1, ERCC5, ERCC1, ERCC4, LIG1, ERCC8, ERCC6, UVSSA, XAB2, MMS19, RAD51, 
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RAD51B, RAD51D, DMC1, XRCC2, XRCC3, RAD52, RAD54L, RAD54B, BRCA1, SHFM1, 
RAD50, MRE11A, NBN, RBBP8, MUS81, EME1, EME2, GIYD1, GIYD2, GEN1, FANCA, 
FANCB, FANCC, BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, BRIP1, FANCL, 
FANCM, PALB2, RAD51C, BTBD12, FAAP20, FAAP24, XRCC6, XRCC5, PRKDC, LIG4, 
XRCC4, DCLRE1C, NHEJ1, NUDT1, DUT, RRM2B, POLB, POLG, POLD1, POLE, PCNA, 
REV3L, MAD2L2, REV1L, POLH, POLI, POLQ, POLK, POLL, POLM, POLN, FEN1, FAN1, 
TREX1, TREX2, EXO1,  APTX, SPO11, ENDOV, UBE2A, UBE2B, RAD18, SHPRH, HLTF, 
RNF168, SPRTN, RNF8, RNF4, UBE2V2, UBE2N, H2AFX, CHAF1A, SETMAR, BLM, WRN, 
RECQL4, ATM, TTDN1, DCLRE1A, DCLRE1B, RPA4, PRPF19, RECQL, RECQL5, HELQ, 
RDM1, OBFC2B, ATR, ATRIP, MDC1, RAD1, RAD9A, HUS1, RAD17, CHEK1, CHEK2, TP53, 
TP53BP1, RIF1, TOPBP1, CLK2,l PER1, as reported in 
https://sciencepark.mdanderson.org/labs/wood/DNA_Repair_Genes.html#BER, last accessed 
December 2014. The results of this exploration are shown in Table 4 
 
Table 4. Candidate variants found in DNA repairing genes found by WES  in BRCAX families  
 
NR, Not report. 
1
GMAF based in 1000Genomes reports. 
2
Total include European (non Finish and Finnish), 
Latino, South Asian, African and East-Asian populations. 
 
In family 1, we found a variant that affected a well-established moderate HBOC gene, 
CHEK2.  
 
We found variants affecting DNA polymerases theta (family 1) and kappa (family 2), which 
are mediators of microhomology-mediated end-joining (MMEJ), an alternative non-homologous 
end-joining (NHEJ) machinery triggered in response to double-strand breaks and catalyzes 
translesion DNA synthesis, which allows DNA replication in the presence of DNA lesions, 
respectively (Ceccaldi et al., 2015; Fischhaber et al., 2002) 
 
Family Gene 
Chromo-
somal 
position 
Functional  
class 
Ref/Alt rs GMAF
1
 EXAC
2
 Variant 
 
1 
POLQ 121208275 Missense A/G NR NR NR I1168T 
CHEK2 29083961 Missense C/A NR NR 0,0002315 R562L 
POLG 89865073 Missense T/C rs41549716 0,0022 0,006277 Y831C 
 
2 
POLK 74892973 Missense A/C rs185752953 0.0006 0.001024 N819H 
RECQL5  73623704 Missense G/C rs200560792 NR 0,0001392 S958R 
RECQL5  73626708 Missense G/A  NR NR 0.00002491 T570I 
3 ATM 108173695 Frameshift  c.5441del NR NR NR L1814fsX14 
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We identified two germline variants affecting gene RECQL5 in family 2, for which relation 
with HBOC has not been explored, although other members of the family of genes have already 
been described as potential HBOC susceptibility genes (Cybulski et al. , 2015; Sun et al., 2015). 
Both variants were inherited from the mother. The variants were present in the affected sister with 
BC, but not in the healthy sister. Variants were missense: c. 1709C>T, p. T570I and c.2874C>G, 
p.S958R and would show incomplete penetrance, due to the presence in the mother (I.2) who is 
not affected with BC. Segregation analysis revealed the absence of both variants in the father (I.1) 
and in the healthy sister (II.1) [Figure 10a, 10b].  
 
c.1709C>T, p.T570I was not reported in LOVD database, meanwhile the variant c.2874C>G, 
p.S958R was reported from a panel of colon cancer genes with no phenotype associated in the 
heterozygous carrier (genre not specified) (Genomic Variant #0000148990, 
http://databases.lovd.nl/). None of these variants is reported in COSMIC. All data was last 
accessed March 2017. The variant c.2874C>G, p.S958R is localized in the end of the exon 19 and 
was predicted to affect splicing based on the predictions given by the splicing module integrated 
in Alamut® Visual 2.7. Through analysis of the cDNA of healthy and affected sister (II.1 and 
II.2), we realized that the variant leads to aberrant splicing, causing partial skipping of exon 19 
[Figure 10c] which is predicted to generate a truncated product.  This event was not present in the 
healthy sister (II.1).  
 
Theoretically the variant would provoke the loss of PIM (PCNA-Interacting Motif, residues 
964-971) and half of Set2-Rpb1-interacting (SRI) domain (residues 900-991) which is needed for 
interaction with Ser2-Ser5-phosphorylated CTD (Carboxi Terminal Domain) of PolII required for 
the elongation state of transcription (Kanagaraj et al., 2010; Kassube et al., 2013). As this was a 
potentially deleterious mutation and because of all the pathways in which RECQL5 is implicated, 
we explored its role as a novel BC susceptibility allele.  
 
In family 3, we identified a variant that affected ATM, a known moderate susceptibility allele 
for BC. Of importance, the variant is a frameshift mutation (c.5441del, L1814fsX14) that leads to 
the premature truncation of the protein. As this mutation is clearly deleterious, it was considered 
as the causal variant of the disease in family 3. Segregation analysis revealed that the mutation 
was present in index case s´ sister affected also with BC at 35 years of age, nonetheless the variant 
was not fully penetrant since the mother (I.1) carried the variant without any cancer diagnosis at 
77 years of age [Figure 11a, 11b].  
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Figure 10. a) Family 2. Affected members with BC are represented with half co lored circles . Dx, Age of 
diagnosis; arrow, index case; red dashed circle, analyzed by WES; S, result of segregation analysis; LOH, 
result of loss of heterozigosity; Other types of cancer are represented with grey dots inside circles. b) 
Family segregation analysis of RECQL5 variant (c.2874C>G; p. S958R), the other variant (c.1709C>T;  
p.T570I) has the same pattern (data not shown), performed by Sanger sequencing in indicated members of 
the family. c) Representation of aberrant splicing in II.2. Sequences of normal and aberrant splicing with 
partial skipping of exon 19 seen in cDNA from healthy and affected siblings is presented.  
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Figure 11. a) Family 3. Affected members with BC are represented with half co lored circles. Dx, Age of 
diagnosis; arrow, index case; dashed circle, analyzed by WES; S, result of segregation analysis; LOH, loss 
of heterozigosity. b) Family segregation analysis of ATM truncating mutation (c.5441delT; p. 
p.Leu1814Trpfs*14) performed by Sanger sequencing in indicated members of the family. Healthy control 
does not belong to the family and has none familial story of HBOC. c) Loss of heterozigosity. (Left) Blood 
sample from affected sister at 35y (II.2). (Right) Tumoral tissue from affected sister at 35y, loss of normal 
allele as depicted by prominent peak of altered allele.  
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 According with the pathogenicity of the mutation, tumoral DNA from paraffin-embedded 
breast tumor from one of the affected sisters (II.2) demonstrated loss of wild type allele [Figure 
11c]. In addition, IHQ analysis of the same tumor revealed very weak or absent expression of 
ATM in the tumoral cells compared with adjacent normal or immune cells, supporting the 
causality of the mutation, associated with a dominant model of inheritance [Figure 12]. Of 
interest, the mutation had not been previously reported as a germline pathogenic variant, however, 
it had been found somatically, in combination with a PTEN somatic mutation, in an advanced 
stage ovarian cancer (Pennington et al., 2014).  
 
 
 
Figure 12. IHQ analysis of the ATM protein in  a section of the breast tumor of individual (II.2). Nuclear 
ATM expression is absent in tumoral cells (Marked with black arrow) in comparison with normal 
counterparts. 
 
Noteworthy, all the other variants found while exploring genes related with DNA 
maintenance and repairing systems were heterozygous. These findings, together with the fact that 
a clearly deleterious variant in ATM explained the disease in BRCAx family 3, pointed to the fact 
that we could not rule out other models of inheritance because, at least in one family, we were 
facing a dominant model of inheritance. As a consequence, we explored this model of inheritance 
and the results are presented in the next section.  
 
5.3. Exploration of the dominant model of inheritance in BRCAX families 
 
While searching for variants located in genes related with DNA maintenance and repairing 
systems, we found seven variants which would fit a dominant model of inheritance; the same 
model of inheritance that is followed by the two major BC high susceptibility genes, BRCA1 and 
BRCA2. Given this result, we wanted to complete the panorama by exploring the rest of the genes 
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(not related with DNA repairing systems) in a dominant model of inheritance (heterozygous 
variants), in order to find novel variants and/or genes that could increase susceptibility to HBOC 
[Table 5].  
 
Table 5. Candidate alleles found under the dominant model of inheritance by WES in BRCAX 
families  
 
Fam Gene 
Chromo-
somal 
position 
Functional 
class 
Ref/Alt rs EXAC1  Variant 
 
1 
KANK1 742215 Frameshift g.742217delG NR 0.0000083 A1237fsX11 
CDH15 89257818 Frameshift g.89257821delC NR NR P439fsX38 
ACTR8 53902781 Missense G/T rs201450445 0.000033 R614S 
CERS5 50561013 Missense A/T NR NR L23Q 
KAT5 65480436 Missense C/G NR NR D97E 
MTUS1 17504536 Missense T/G NR NR N1185T 
PLEC 144991514 Missense G/A rs201069314 0.00047 R4296C 
DDX11 31238059 Missense A/G rs2536756 0.002273 R213G 
NISCH 52521676 Missense G/A NR 0.0000165 R723H 
 
 
 
2 
DEPDC1B 59938657 Missense T/C rs199716657 0.000046 M247V 
SPRED2 65561832 Missense C/T NR 0.0000082 D94N 
GPRC5B 19883558 Missense G/T NR 0.000016 L204I 
SYNE1 152476127 Missense C/T NR 0.0000165 R8010H 
HBP1 106836378 Missense A/C NR 0.000058 Q389H 
AHNAK 62293925 Missense C/A rs149615783 0.00074 G2655V 
KLF15 126070801 Missense T/C NR 0.000036* K322R 
MYBBP1A 4455198 Missense C/T rs138633396 0.0011 G334R 
HHAT 210761290 Frameshift ACT/A NR NR L366fsX86 
RANBP10 67840391 Missense C/T NR NR D17N 
CAPN2 223900358 Missense G/A rs375899944 0.00011* A6T 
CLSPN 36228012 Missense G/A rs141350492 0.00016 T272M 
PTPRG 62189151 Missense C/A rs201820508 0.00043* S561Y 
NR, No Report. 
1
Total include European (non Finish and Finnish), Latino, South Asian, African and East-
Asian populations. These list of genes do not include genes that are related with DNA repairing systems, as 
this has been already explored in the previous section.*For this variant, a note in EXAC is given: This site 
is covered in fewer than 80% of the individuals in ExAC, which may indicate a low-quality site 
 
As with the recessive model of inheritance, in the dominant model of inheritance, exploration 
of genes related with roles involved in tumoral suppression, cell growth, cell signaling, cell 
survival; as well as genes implicated in hormone metabolism and signaling pathways were 
prioritized in order to increase the possibility to find a novel susceptibility BC gene.  The 
pathways and main cellular functions where the genes are implicated together with the model of 
inheritance studied are shown in Supplementary Table 1. 
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5.4. Case-control association study of putative susceptibility variants associated with 
Hereditary Breast and Ovarian Cancer in Spanish population  
 
Case-control association study was performed to establish the frequency of the variants in 
cases and in controls, so that variants that were present with higher frequency in controls rather 
than in cases were ruled out as this would be associated with a protective effect. This served us to 
narrow the number of candidate variants and select the most interesting ones with a putative 
association with HBOC in BRCAX families from Spanish population.  
 
The initial number of candidate variants selected through WES data mining of family 1, 2 and 
3, taking into account the recessive model, the DNA repairing genes and the dominant model of 
inheritance was 43. Some of them were discarded through case-control association due to a 
frequency that did not fit with the model of inheritance studied and/or higher recurrence in 
controls against cases. These included the following: POLG (c.2492A>G; p.Y831C), FBF1 
(c.2039C>T; p.A680V), MYBBP1A (c.1000G>A; p.G334R), POLK (c.2455A>C; p.N819H), 
NISCH (c.2168G>A; p.R723H), CLSPN (c.815C>T; p.T272M) and TOPAZ1 (c.2017C>G; 
p.P673A). For other variants, the probes from the OpenArray did not showed results, so other 
types of approaches were applied in order to get the case-control association information. Such 
was the case with variants located in AKR1C3 (c.230A>G; p.E77G) and CHEK2 (c.1685G>T, p.  
R562L). For the former, even the Taqman assay did not showed results but for the latter, it was 
finally discarded due to its high frequency that do not fit with the dominant model of inheritance 
that was studied for this variant. Some other variants were discarded since the first exploration, 
because the probes designed could not efficiently discriminate among allelic clusters due to the 
position of the variants, as is the case for SPRED2 (c.280G>A; p.D94N) and DDX11 (c.637A>G; 
R213G). Due to technical limitations, some variants could not be included in the initial 
OpenArray study and will be included in further explorations as is the case for the variants located 
in KLB (c.2329_2331del; p. F777del; c.3124G>A; p. V1402I) and TOPAZ1 (c.5074C>G; 
p.H1692D). Finally, some others were eliminated since the very beginning, because the design of 
the probe did not worked either in the CEGEN facility or in the company where it was designed 
as for CAPN2 (c.16G>A; p.A6T) and PTPRG (c.1682C>T; p.S561Y) The summary of the 
variants that were finally not included in larger cohorts can be found in Supplementary Table 4.  
 
In table 6, the number of heterocigotes found for the 25 candidate variants in 1500 BRCAX 
cases and 500 controls is shown. Variants absent in cases and controls or those more prevalent in 
cases than controls were selected as candidates for further analysis. Of notice, the p-values were 
not valuable for setting selection thresholds as the variants are quite rare in the population. In a 
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similar way, it was not possible to calculate p-value in variants where no heterozygotes were 
found both in cases and controls.  
 
Table 6. Final candidate variants selected through case-control  association study in S panish 
population 
Gene Chr Variant rs P value Cases 
Total 
Cases 
Controls 
Total 
Controls 
KANK1 9 c.3709del NR 0,495 0 1484 1 604 
CDH15  16 c.1316del NR NA 0 1491 0 600 
ACTR8 3 c.1840C>A  rs201450445 NA 0 931 0 502 
CERS5 12 c.68T>A  NR NA 0 1495 0 597 
KAT5 11 c.291C>G NR NA 0 1498 0 606 
MTUS1  8 c.3554A>C NR NA 0 1461 0 600 
PLEC 8 c.12886C>T rs201069314 0,256 12 1493 2 604 
FBF1* 17 
c.1808G>A  NR 0,33 5 1464 0 582 
c.770C>G rs201197761 0,584 4 1491 0 601 
RECQL5  17 
c.2874C>G rs200560792 NA 0 1491 0 601 
c.1709C>T NR NA 0 1491 0 588 
DEPDC1B  5 c.739A>G rs199716657 1 1 1427 0 569 
GPRC5B 16 c.610C>A NR 1 2 1488 0 597 
SYNE1 6 c.24029G>A NR NA 0 1494 0 651 
HBP1 7 c.1167A>C NR 0,575 11 1474 3 603 
AHNAK  11 c.7964G>T rs149615783 0,443 6 1176 1 543 
KLF15 3 c.965A>G NR NA 0 1490 0 603 
HHAT 1 c.1096_1097del NR NA 0 1475 0 589 
RANBP10 16 c.49G>A NR NA 0 1484 0 591 
POLQ 3 c.3503T>C NR 1 1 1495 0 595 
GLE1 9 
c.116G>A  rs138871311 0,583 4 1478 0 590 
c.226G>A  NR NA 0 1494 0 602 
TOPAZ1* 3 
c.1448A>G rs17076541 0,527 10 1491 2 602 
c.2386A>G rs17076545 0,177 15 1472 2 585 
ATM  11 c.5441delT NR NA 0 1477 0 589 
Bold marks, variants with phenotypes described associated with cases. NR, not reported, NA, not 
applicable; Underlined, refers to the variants initially studied under the recessive model of inheritance, the 
rest belong to the exploration of the DNA repairing and maintenance related genes and the dominant model 
of inheritance. *Variants that remained in case-control association study in TOPAZ1 and FBF1, were 
inherited from one parent (from maternal b ranch), the other variants (2 for TOPAZ1 and one for FBF1) 
were d iscarded because of technical constraints or a frequency that does not fit the model studied. Hence, 
these variants would be studied in the dominant model of inheritance. Though, priority for further study 
would be set in the genes with higher impact effect and/or function related with cellular signaling pathways, 
DNA repair and hormone metabolism. NR, no report. 
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In table 7, we show the phenotypes associated with the variants which were reported in one or 
more cases, these are marked in the previous table in bold mark. It is interesting to emphasize 
some examples: variants in PLEC c.12886C>T and HBP1 c.1167A>C, where >70% are breast 
cancer only cases in BRCAX families.  
 
Table 7. Phenotypes associated with BRCAX index cases carrying candidate BC susceptibility 
alleles 
Gene Variant rs Cases Phenotype 
PLEC c.12886C>T rs201069314 12 8BC, 1MBC, 1OC, 2HBOC 
FBF1 c.1808G>A  NR 5 2 BC, 2OC, 1HBOC 
FBF1 c.770C>G rs201197761 4 2BC, 2OC 
DEPDC1B c.739A>G rs199716657 1 1BC 
GPRC5B c.610C>A NR 2 2 BC 
HBP1 c.1167A>C NR 11 9BC, 1HBOC, 1BiBC 
AHNAK c.7964G>T rs149615783 6 4BC, 1BiBC, 1OC 
POLQ c.3503T>C NR 1 1BiBC 
GLE1 c.116G>A  rs138871311 4 3 BC, 1 HBOC 
TOPAZ1 c.1448A>G rs17076541 10 7BC, 1OC, 2HBOC 
TOPAZ1 c.2386A>G rs17076545 15 
11BC, 1OC, 2HBOC, 
1HBiBOC 
NR, no report. BC (Breast cancer); BiBC (Bilateral breast cancer); OC(Ovarian Cancer); MBC(Male BC)  
 
 
In summary, in this first part of the thesis, we have studied three BRCAx families presenting 
an apparent recessive model of inheritance. After the exploration of the recessive model of 
inheritance, the DNA repairing genes and the dominant model of inheritance, we have found that 
two families are most probably explained by the dominant model of inheritance. Although in 
family 1, we still do not have a conclusive variant, we have a list of variants for further study as 
potential BC susceptibility alleles. In family 2 we found novel mutations in RECQL5 
(c.1709C>T, p. T570I and c.2874C>G, p.S958R) as a potential novel BC susceptibility gene, as 
well as a list of other candidate variants associated with the dominant model to further study as 
BC susceptibility which were not ruled out because the genes are implicated in quite interesting 
pathways and/or its cellular function points toward a potential tumor suppressor, which require in-
depth studies. In family 3 the BC causality was proven associated with a mutation in ATM 
(c.5441delT; p.L1814WfsX14). Also, from the case–control association study performed in 1500 
BRCAx cases and 500 controls of Spanish population, we have 25 variants selected to include 
them in higher number of cohorts to establish significant association between BC risk and the 
presence of the variants.  
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The findings in family 2 and 3, lead to the second part of the thesis, where we performed full 
coding sequencing and exon-boundaries analysis of RECQL5 and ATM, in order to establish the 
frequency and spectrum of mutation of both genes in Spanish population.  
 
5.5. Massive sequencing of RECQL5 gene in 700 BRCAX breast cancer only-cases and 
754 controls from Spanish population 
 
Due to our findings in family 2 with two variants affecting BC index case in RECQL5 and 
considering the seminal role of this gene in several cellular pathways: DNA repairing systems and 
maintenance, DNA replication, transcription and repairing (Paliwal et al., 2014; Popuri et al., 
2013; Kanagaraj et al., 2010), genome stability (Islam et al., 2012), telomere function, 
homologous recombination (Pellatt et al., 2013; Hu et al. , 2007), we decided to perform full 
coding and exon boundaries sequencing of  the gene in a cohort of 700 BRCAX BC only-cases 
and 754 controls in Spanish population, in order explore its role in BC. 
 
The full coding sequencing of RECQL5 revealed the presence of three germline pathogenic 
variants, present in unrelated BC-only BRCAX cases (Figure 14). Two of them are clearly 
deleterious mutations, as they are frameshift variants that lead to a truncated product (c.657delC, 
p. C220fsX15; c.2393dupC, p, M799fsX24), whereas the third one is a missense mutation 
(c.130G>A, p.G44S) that is located in the last nucleotide of exon 2 and predicted to affect 
splicing. Access to the DNA from other family members from BC index case harboring RECQL5 
c.130G>A, G44S was possible. Segregation analysis from dizygotic twin sister and another sister, 
affected with BC at 54 and 53 years old, revealed absence of the variant. Due to the incomplete 
segregation of the variant in other members of the family with BC, we hypothesize that this could 
be associated with a moderate risk; as well, other gene that confers susceptibility could be related 
with the disease and germline variants in RECQL5 could be modifying the risk for BC. We have 
to take into account that is was not possible to gather sample from the mother, which would be 
interesting in light of clarifying the role of RECQL5 missense variant in this family, whom could 
be also harboring the variant.  
 
At cDNA level, in the BC index case, we explored if there was aberrant splicing. Surprisingly, 
the missense variant c.130G>A, G44S was not present in heterozygosity at cDNA level [Figure 
13] although we were not able to detect which was exactly the effect of exon skipping or 
inclusion. Other SNPS along exon 9-10 (c.1439A>G) and exon 16 (c.2217C>T), revealed that at 
these positions, heterozygosity of selected SNPs was present at cDNA level. Although not fully 
characterized, we can assume that the variant affects severely the mRNA splicing process.  
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a) cDNA from BC index case harboring RECQL5 c.130G>A, G44S  
 
b) DNA from BC index case harboring RECQL5 c.130G>A, G44S  
 
Figure 13. cDNA and DNA from BC index patient harboring RECQL5 c.130G>A, G44S, loss of 
heterozigosity is seen at cDNA level [a] in contrast with DNA [b].  
 
We could not extend segregation analysis to other members of the families of BC indexes 
case, harboring (c.657delC and c.2393dupC), because access to the samples was not possible. All 
the germline clearly pathogenic variants were found in heterozygous state in index cases. The 
phenotype, age of diagnosis and familial antecedents are presented in Table 8. As well, the 
pedigrees are presented in Figure 14. In all the families there were cases of other cancers different 
than BC and OC in previous generations. In this regard, family with BC index case carrying 
RECQL5 c.2393dupC, M799fsX24, needs further exploration due to the early decease of the 
mother of BC-affected sibling and the difference on age between first and last daughter, this 
suggest that some of the siblings could be sons or daughters from a second marriage of the father, 
which is of importance in segregation analysis of other members of the family, particularly, to 
detect mutation carriers within the sisters of the BC index case. No clearly pathogenic germline 
variant was found in the 754 healthy controls explored. 
 
The prevalence of pathogenic germline variants in RECQL5 gene associated with in BRCAX 
families with BC-only cases was 0.42% (3/700).  
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Table 8. RECQL5 germline deleterious variants and phenotype associated found in 700 
Spanish BRCAX BC-only families by NGS 
 
Nucleotide 
Change
1
 
Protein 
change 
Gender 
Index Case Phenotype 
and Age of diagnosis 
Other 
cancers 
in index 
case 
ClinVar EXAC
3
 
c.2874C>G
2
 S958R F BC, 26y No NR 0.0001392 
c.130G>A  G44S F BC, 50y No NR NR 
c.657delC C220fsX15 F BiBC, 34y, 46y  No NR NR 
c.2393dupC M799fsX24 F 3N BiBC, 37y, 39y No NR NR 
1
 GenBank reference sequence NM_004259.6 with numbering starting at the A of the first ATG, following 
the HGVS guidelines, www.hgvs.org/mutnomen. 
2
Mutation found by WES was not taken in account to 
establish population percentages. F (Female), BC (Breast Cancer), OC (Ovarian Cancer), 3NBiBC (Triple 
Negative Bilateral BC), NR (No Reported). 
3
 Total values for EXAC include European (non Finish and 
Finnish), Lat ino, South Asian, African and East-Asian populations. 
 
 
Rare germline variants in RECQL5 detected in Spanish population, predicted to have a 
pathogenic effect (according to the combined information provided by 8 in silico predictors and 
PPS score) are listed in Table 9.  We found 4 potentially deleterious RECQL5 germline variants in 
cases. The pedigrees of the families are presented in Figure 15, all except one proceeded from 
external hospitals and we had no access to more information about this family. In controls, we 
found 5 rare RECQL5 germline variants.  
 
The location of all the predicted and clearly deleterious mutations in cases and controls are 
depicted along RECQL5 protein, together with all the site-directed mutagenesis in vitro assays 
that have been performed in RECQL5 to establish transcendence of missense mutations in 
different domains of the protein [Figure 16C].  
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A) Family 2099 CNIO with BC index case, harboring RECQL5 c.130G>A, G44S  
 
 
 
 
B) Family 1481, index case 5431 from San Carlos Clinic Hospital with BC index case, RECQL5 
c.2393dupC, M799fsX24  
 
 
 
 
 
Figure 14. Families harboring RECQL5 germline deleterious variants. a) Family with BC index case, 
harboring c.130G>A, p.Gly44Ser. b) Family with BC index case, harboring c.2393dupC, M799fsX24. 
Affected members with BC are represented with half co lored circles and bilateral BC with complete colored  
circle; Dx, Age of diagnosis; arrow, index case; other types of cancer are represented with grey dots inside 
circles. When information was available, the type of cancer is specified in the pedigree.  
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C)  Family 988, index case 3337 from San Carlos Clin ic Hospital with BC index case, RECQL5 c.657delC, C220fsX15  
 
 
 
 
Figure 14. Families harboring RECQL5 germline deleterious variants . C)Family with BC index case, harboring c.657delC, C220fsX15. Affected members with BC are 
represented with half colored circles and bilateral BC with complete colored circle; Dx, Age of diagn osis; arrow, index case; other types of cancer are represented with 
grey dots inside circles. When information was available, the type of cancer is specified in the pedigree.  
8
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Table 9. Putative pathogenic RECQL5 germline variants detected through mutational screening in S panish population 
 
 
 
Chromosomal 
position 
Nucleotide 
change 
Protein 
change 
rs number 
gMAF 
EXAC 
S M P F SG MA MP C PPS Final 
Phenotype and 
age of 
diagnosis 
Age 
73661150 c.233C>T P78L rs762396676 NR D D D D D D D D 91 D BC (36)  
73658791 c.539G>A R180H rs202162742 0,00017 D D D D D D D T 8 D BC (45)  
73626769 c.1648C>T R550W rs746220717 0,00002512 D D D D D D D D 78 D BC (34)  
73623552 c.2926C>T R976W rs752348322 0,00003332 D T D D D D T T 76 D BC (39)**  
73659024 c.305C>T S102L NR NR D D D D D D D D 88 D 
 
38 
73657092 c.929T>A V310D NR NR D D D D D D D T 55 D 
 
26 
73626311 c.1765C>T R589W rs780135537 0,0001422 D D D D D D D T 66 D 
 
NR 
73625270 c.2233C>T R745W rs375398949 0,0001 D T D D T T D T 63 D* 
 
45 
73625207 c.2296C>T R766C rs186857427 0,000049 D D D D D T D T 52 D 
 
30 
Bold (Cases), White (Controls) NA (Not applicable), NR(Not  reported), T (Tolerated), D (Deleterious), * When Predictors were  equal (4/4), PPS score was used to 
discriminate in silico pathogenicity. SIFT (S), MUTTASTER (M), Po lyphen-2 (P) information was obtained from Alamut Visual suite version 2.7.2, SNPs&GO (SG) 
(http://snps-and-go.biocomp.unibo.it/snps-and-go/), FATHMM (F) (http://fathmm.biocompute.org.uk/), MutationAssesor (MA) (http://mutationassessor.org/r3/), 
MutPred (MP) (http://mutpred.mutdb.org/), Condel (C) (http://bg.upf.edu/fannsdb/). PPS Score was calculated with SNAP2 algorithm (https://www.predictprotein.org/). 
A higher score assignation (>50) indicated a strong effect induced by point mutations, values (-50<score<50) indicated weak effect and low assignation (<-50) meant  
neutral/no effect.(**) for this family, the pedigree is not available.  
8
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A) Family 2821 CNIO with BC index case, RECQL5 c.233C>T; P78L    
 
 
 
 
B) Family 2694 CNIO with BC index case, RECQL5 c.539G>A; R180H 
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C) Family 2963 CNIO with BC index case, RECQL5 c.1648C>T;R550W  
 
 
 
 
 
Figure 15. Families harboring RECQL5 germline missense predicted deleterious variants . Affected 
members with BC are represented with half co lored circles and bilateral BC with complete colored circle;  
Dx, Age of diagnosis; arrow, index case; other types of cancer are represented with grey dots inside circles. 
When informat ion was available, the type of cancer is specified in the pedigree.  
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A) In cases: 
     
B) In controls: 
 
 
C) Site-directed mutagenesis in functional studies: 
 
Figure 16. Schematic representation of RECQL5 with clearly and predicted pathogenic mutations. Domains 
shown are: Helicase ATP binding site (residues 39-213), Helicase C-terminal (residues 241-354), Zn
2+
 
subdomain (residues 365-437), KIX (residues 515-620), RECQ5 (residues 625-829), RAD51 Interacting 
Region (residues 654-725), NLS (Nuclear Location Signal, residues 866-874), Set2-Rbp1 SRI (residues 
900-991), PIM (PCNA interacting region, residues 964-971). Variants originally found by WES are marked  
with black circles. Clearly deleterious variants are represented with red circles. Frameshift mutations are 
c.657delC, C220fsX15 and c.2393dupC, M799fsX24. Predicted in silico pathogenic variants are shown 
with blue circles for cases and blue diamonds for controls . Residues with in vitro studies are shown in 
green. 
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Some variants have been already reported in COSMIC: c.2926C>T, R976W was described as 
a somatic mutation in leukemia/lymphoma (COSM5706541; Kataoka et al., 2015) and variant 
c.305C>T, S102L, was found as a somatic variation in stomach cancer (COSM4271256; Kim et 
al., 2014) and melanoma (COSM4271256; Van Allen et al., 2014). As well, c.2296C>T, p.R766C 
has been reported in LOVD with no report of function affected, from a gene panel study in 
healthy controls (no more information regarding gender or age of this individual). C.539G>A, 
R180H and c.2233C>T, R745W are reported in Exome Variant Server, although no information is 
available regarding any phenotype associated or data about where the variants were detected.  
 
In silico inference of the missense variants effects in RECQL5 domains was performed in 
order to establish if there was difference among the variants found in cases and controls.  
 
To compare missense variants in cases/controls located in helicase domain, the predicted effect 
was compared against the in vitro effect of missense variants reported by Newman et al., 2017, 
who performed site directed mutagenesis of a group of three residues at different positions in the 
helicase domain: Aromatic loop so called AR-loop, Motif VI in the D2 Subdomain and Zn2+ 
binding site. Depending on the residue mutated, the missense mutation was able to exert a nule, 
intermediate or total impairment of the helicase activity. This information helped us to infer the 
effect of our predicted potentially pathogenic variants.  
 
 In a first approach [Figure 17A] the variants located along the subdomain D1 of the helicase 
(G44S, P78L, R180H) and controls (S102L) were compared against variants in the AR loop 
(W165A, H167A and D168A). Variant V310D was compared against variants in D2 subdomain 
(Q345A, R349A and R352G). A401V (negative control) was compared against variants located in 
Zn2+ domain (Y419A, F420A and D422A). D480G (frequency control), D519A (negative 
control), R550W (from a case) and R589W (from a control) were evaluated within the KIX 
domain. Variant T953S (negative control) and R976W (from a case) were evaluated within SRI 
domain.  
 
Variants acting as negative controls were included in the study for the comparison, these were 
variants that were ruled out from our original list of missense variants as more than 5 in silico 
predictors assessed a neutral/tolerated effect in the protein, these included variants (A401V, 
D519A and T953S). The frequency control refers to variant c.1439A>G; p.Asp480Gly 
(rs820196), with a MAF of 0.25 in the general population. In the present cohort studied for 
RECQL5, it presented a MAF of 0.1. Interestingly, this is the only missense variant reported in 
the gene showing a frequency higher than 1% in the general population. Of importance, in 
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RECQL gene, occurs the same. This would indicate that there is relatively low tolerance for 
missense mutations in these genes.   
 
In vitro results that were taken into account included increased (ATP)M and Enzyme 
concentration from Newman et al., 2017.  Other parameters that were calculated involved the sites 
that are modified if in theory the helicase does not function, which are residues located in p.283 
(D2 subdomain), E>-strand (p.160-161), located in subdomain D1 and have a very high impact 
in the overall function of the helicase. The positions that are predicted to have a severe effect 
within KIX domain are p.E524 and p.T568 and within SRI domain is p. K928. A score was set in 
order to measure deleterious (3) or neutral effect (1).  
 
When clustering was performed in order of decreasing deleterious score [Figure 17B], we 
realized that the RECQL5 variants found in our study in Spanish population grouped together 
with the highest deleterious score. For the case-variants located within the helicase domain 
(G44S, P78L and R180H), they resemble the effect of impairment of the helicase shown by 
variants W165A and H167A and D168A from Newman report and effect in position 283 and 160-
161, whereas control-variants located in helicase domains (S102L and V310D) show neutral 
effect for position p.160-161 which is in contrast with the effect of the case-variants. In addition, 
predicted effect of V310D is similar to that of negative control (A401V).  
 
Case-variant R550W showed the highest deleterious effect when considering KIX domain 
uniquely and taking into account comparison against negative control D519A and frequency 
control D480G. Missense variant R589W found in healthy control had no effect at position E524 
and T568, contrasting with variant R550W. As well, missense variants R745W and R766W found 
in controls located between KIX domain and SRI domain, had a decreased deleteriousness than 
R550W, with an intermediate effect in KIX position E524 and T568. A high deleterious score was 
observed for case-variant R976W in SRI domain residue K928, as opposed to negative control 
T953S.  
 
The last analysis that was performed only took into account the domain for which the variant 
was located, where we can easily realize the grouping of case-variants (G44S, R79L and R180H) 
as the most deleterious for helicase domain. As well, as case variants R550W and R976W as the 
most deleterious in comparison with the variants located in healthy controls that had a neutral 
effect within the domain where they are located, as in the entire protein [Figure 17C]. 
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Figure 17. In silico inference of potentially pathogenic missense variants in RECQL5 domains.  
9
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5.6. Deleterious mutations in the ATM gene are present in 1.78 % of breast and/or 
ovarian cancer Spanish BRCAX families 
 
 ATM is already recognized as a moderate BC susceptibility gene, although in Spanish 
population the reports about the frequency and spectrum of the mutations are scarce. There is 
solely one report performed in a very small cohort with unselected BC cases, with the caveat of 
using techniques with low sensitivity (Brunet et al., 2008). Given these, NGS panels were used 
for ATM mutational screening in a cohort of 392 HBOC Spanish BRCAX families looking for 
pathogenic variants in ATM that are related to BC.  
 
Mutational analysis of the ATM gene revealed the presence of seven pathogenic mutations in 
ATM: four frameshift, one nonsense, one missense and one splice-site mutation (Table 10). All 
the variants were found in heterozigosity in index cases. Five mutations were truncating and 
considered as deleterious. The two remaining, c. 3747-1G>C (Verhagen et al., 2012)
 
and c. 
8122G>A (Claes et al., 2013) had been previously classified as pathogenic by functional assays. 
Other rare variants, some of them potentially deleterious, were found during the screening 
[Supplementary Table 5], however only mutations unequivocally deleterious were considered for 
the purpose of this study.
 
 
The seven mutations had been previously found in AT and/or BC patients [Table 10]. In 
Spanish population, c.640delT; p. Ser214Profs*16 and c.8934_8935del; p.Glu2979Alafs*9 have 
been associated with AT cases (http://chromium.lovd.nl/LOVD2/).  
 
The prevalence of pathogenic germline variants in ATM gene was 1.78 % (7 of 392 BRCAX 
HBOC families in Spanish population). Six mutations were associated with breast cancer only 
families giving a prevalence of 1.94% (6/308) in this specific group. No mutations in the ATM 
gene were found in a comparative group consisting of 350 index cases from families affected with 
different diseases not related to breast cancer. These results are consistent with the role of ATM as 
a BC susceptibility gene.  
 
The subsequent analysis of other twenty candidate breast and/or ovarian susceptibility  genes 
revealed deleterious mutations in some of them [Supplementary Table 6]. The most frequently 
mutated genes following ATM were the BC susceptibility genes FANCM (Kiiski et al., 2014) and 
PALB2 (Antoniou et al. , 2014) which were associated with 1.5% and 1.2% of the cases 
respectively. For the rest of genes the prevalence of mutations was 0.5% at the most. 
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Table 10. ATM germline deleterious mutations and phenotype associated found in 392 Spanish BRCAX families by NGS 
 
Nucleotide 
Change
1
 
Protein change Gender 
Index Case 
Phenotype and 
Age of diagnosis 
Other cancers  
In index case 
ClinVar Familial antecedents References
3
: 
c.640delT p. Ser214Profs*16 F 49 (BC) No 
RCV000169254.1 (2 (Likely 
pathogenic*  
Ataxia-telangiectasia syndrome) 
Maternal branch: Aunt and 
cousin also affected with BC 
before 50y 
Paternal branch: Two cousins 
with BC at 52y, 54y 
Byrd et al., 1996 
c.3747-1G>C p.? F 39 (BC) No 
RCV000159717.1 (Pathogenic* 
Hereditary cancer-predisposing 
syndrome) 
Maternal branch: mother 
affected with BC and uterine 
cancer at 60/70y. 
Aunt with BC at 40y. 
Grandmother with uterine 
cancer at 70y 
Verhagen et al., 2012 
c.3754_3756delinsCA p.Tyr1252Glnfs*4 M 
NR, No 
diagnosis 
Thyroid papilar 
cancer + Renal 
Oncocytoma 
RCV000164396.1 (Pathogenic 
Hereditary cancer-predisposing 
syndrome). 
Familial BC and colon cancer CLINVAR 
c.5441delT
2
 
 
p.Leu1814Trpfs*14 F 40 (BC) No No 
Sister diagnosed with BC at 
35y. 
No other familial cancer 
antecedents  
No 
c.6100C>T p.Arg2034* F 71 (BC) 
Gastric cancer 
 
RCV000122867.2 (Pathogenic* - 
Ataxia-telangiectasia syndrome), 
RCV000115222.3 (Pathogenic** - 
Hereditary cancer-predisposing 
syndrome). 
Maternal branch: Mother 
affected with BC at 52 y, 
aunt died of BC at 68y and 
cousin diagnosed with BC at 
60y 
Paternal branch: two uncles 
died of colorectal cancer and 
gastric cancer at 49 and 31y. 
Two cousins died of 
pulmonary and prostate cancer, 
both at 68 y 
Telatar et al., 1996 
c. 8122G>A p.Asp2708Asn F 
51/60 
BilatBC+OC 
No 
RCV000132208.2 (Uncertain 
significance* - Hereditary cancer-
predisposing syndrome). 
NR Cavalieri et al., 2006 
c.8251_8254del p.Thr2751Serfs*54  F <50 (BC) No 
RCV000164777.1 (Pathogenic* - 
Hereditary cancer-predisposing 
syndrome). 
Cousin and sister affect ed with 
BC. 
Age of diagnosis not available 
CLINVAR 
c.8934_8935del p.Glu2979Alafs*9  F 32 (BC) No No 
Mother and sister with BC 
before 50y 
LOVD 
 
1
GenBank reference sequence NM_000051.3 with numbering starting at the A of the first ATG, following the HGVS guidelines, www.hgvs.org/mutnomen. 
2
Mutation 
found by WES was not taken in account to establish population percentages.
 3
 Reference lists the first database or publication informing of the mutation. F (Female), M 
(Male), BC (Breast Cancer), OC (Ovarian Cancer), NR (Not Reported). 
9
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5.7. Search for novel susceptibility genes for hereditary male breast cancer (MBC) 
 
The third part of this thesis is focused in the search of novel susceptibility genes for hereditary 
male breast cancer.  
 
The MBC family had the following characteristics: presence of three brothers affected with 
breast cancer (one of them bilateral), absence of other familial antecedents of the disease, no 
mutations in the BRCA1/BRCA2 genes. Importantly, in this family the parents were first-degree 
cousins and there were no women affected with BC in the family. In the literature, there is just 
another family reported with similar characteristics, which highlights the remarkable phenotype of 
this family (Wooster et al., 1992) which lead us to explore the X-link and recessive models of 
inheritance (Figure 7, family 4). 
 
Variant filtering and priorization were performed according to the following criteria selection: 
X-linked model of inheritance (hemizygous state of the variant in the MBC affected male and no 
presence of the altered variant in the nephews) or recessive model of inheritance (homozygous 
state in the MBC affected male, heterozygous for the variant in the nephew whose father was also 
affected with bilateral MBC and homozygous for the reference or heterozygous in the nephew 
whose father underwent prophylactic mastectomy). These criteria were taken into account with 
the information available at the time of the project as well as disposition of the DNA samples.  
 
Candidate variants following a recessive or X-linked inheritance model were identified and 
validated by Sanger sequencing with specifically designed primers, as well segregation analysis 
was performed in affected and non-affected members of the family. Initial number of variants 
after the WES was 16; nonetheless, after segregation analysis, 9 variants were ruled out because 
they did not fit in our inheritance model. In addition, when the segregation analysis was extended 
to other male members of the family, variants that did not fit the model were ruled out. The 
summary of the variants that were finally not included in larger cohorts can be found in 
Supplementary Table 7. Finally, we selected 7 candidate variants to evaluate in a cohort of 50 
hereditary male breast cancers of Spanish population [Table 11], the functions and pathways 
where the variants are implicated will be discussed further.  
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Table 11. Candidate variants for hereditary MBC found through WES  
 
 
 
 
 
Gene Ch 
Chr 
position 
Variant 
Protein 
effect 
Function
al Class 
ID 
Model of 
inheritance 
MAF in 50 
MBC 
MAF ExAc 
(European)o 
MAF ExAc 
(Total)* 
Nº Homozygotes 
ExAc (European) 
LIMD1 3 45637230 c.859G>C V287L Missense rs74851793 Recessive 0,01 0,013 0.009 3/121024 
TXNDC5 6 7883468 c.1208G>A R403Q Missense rs111331197 Recessive 0,05 0,01 0.007 5/121274 
PLCB2 15 40591100 c.749G>C R250P Missense rs199754432 Recessive 0 4,52E-05 6.57E-05 0/120176 
GATM 15 45668999 c.88G>A G30R Missense NR Recessive 0 NR NR NR 
PTPRH 19 55703094 c.2273C>A A758D Missense rs61734204 Recessive 0,0098 0,007 0.0053 None/120852 
YLPM1 14 75265235 c.3235C>T R1079W Missense rs374380781 Recessive ND 1.5E-04 1.5E-04 None/120616 
TKTL1 X 153553774 c.1401+6G>A p.? 
Splice Site 
Region 
rs183407036 X-linked 0 2.29E-04 2.28E-04 
4 hemizygotes and 
no homozygotes 
from 87657 
individuals 
NR, No report. ND, not done. Underlined, emphasize genes selected for full coding and exon-boundaries sequencing as short term perspective.*Total include European (non Finish and 
Finnish), Latino, South Asian, African and East-Asian populations. oEuropean (non-Finnish) 
9
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Of importance, from the results of the Spanish population where we genotyped 50 hereditary 
MBC cases through Sanger sequencing, we found another hereditary MBC case, who was 
homozygous for c.1208G>A p.R403Q affecting TXNDC5 gene. Regarding the clinical history, the 
patient was diagnosed at 82 years old, diagnosed with an infiltrating ductal BC with familial 
antecedents (two sisters died due to ovarian cancer at 63 and 75 years old, a sister with Paget BC 
disease and other relatives with reports of different types of cancer: Colorrectal and lung). There 
was no information available from the paraffin neither from the tumoral markers.  
 
To assess the implication of these variants in the development of MBC, an analysis was 
performed with an enlarged cohort of MBC in British population in collaboration with the 
Institute of Cancer Research (ICR) under the supervision of Dr. Nicholas Orr. Case-control 
association study included: 1200 cases of MBC and 500 controls (men without the disease and/or 
familial background of the disease). This study was performed using KASP genotyping 
technology, using the ABI 7900 instrument. From all KASP assays performed, we did not find 
other MBC cases where the variants were present in homozygous state for the recessive model of 
inheritance and in hemizygous state for the X-link model of inheritance. An example of the 
genotyping results for some of the variants is shown in Figure 18, for variants in PLCB2 
(c.749G>C; p.R250P) and GATM (c.88G>A; p.G30R) in 500 British MBC and 500 British 
healthy controls where we can differentiate clusters formed for homozygous for the reference 
group (blue), heterozygous (green) and the positive control in a separate cluster (red). Similar 
results were obtained for the rest of the variants and in 700 extra MBC from British cohort tested, 
where we detected numerous homozygous for the normal variant, few heterozygotes according to 
MAF frequency and no homozygous for the recessive model of inheritance. 
 
Considering the rarity of the disease, it is possible that an increased number of cases should be 
explored in order to increase the possibilities to find an homozygous case for the variant 
(recessive model) or hemizygous for the variant in X-linked model, but we must remember that 
the cohort of the ICR is one of the largest collection of MBC available in the world. For 
increasing the number of cases, it would be necessary to include the variants in a collaborative 
effort within different consortia.  
 
The presence of the variants was also evaluated in a set of 50 MBC exomes available in the 
database of the UK laboratory. The variant in LIMD1 (c.859G>C; p.Val287 Leu) was found in 
three patients and the variant in TXNDC5 (c.1208G>A; p.Arg403Gln) was found in one patient. 
All of them were present in heterozygous state. According to our model, heterozigosity does not 
confer susceptibility; rather its presence in cases of MBC is due to the frequency of the variants in 
the population.  
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Figure 18. Allelic discrimination plot showing results for variant in PLCB2 (c.749G>C; p.R250P) and GATM (c.88G>A; p.G30R) in 500 Brit ish MBC and 500 British 
Clusters formed are shown in blue for the homozygous for reference, in green the heterozygous (in both cases, the 3 heterozygous shown in the plots belong to members 
of the family with known status of the variant) and in red is shown the homozygous for the variant. The black squares correspond to NTC, as internal controls.
1
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6. Discussion 
 103 
 
 6.1 Exploration of the recessive model of inheritance, genes related with DNA repairing 
pathways and the dominant model of inheritance in BRCAX families using WES 
 
In this section, we will perform a general overview about the models of inheritance that were 
explored in the families and the reasons that lead to the exploration from one to another. After, we 
will discuss the most interesting findings per family.  
 
An example of recessive monogenic inheritance in cancer can be seen in bi-allelic mutations 
that lead to inactivation of MUTYH, which confer higher risk of colorectal cancer (Poulsen et al., 
2008). Regarding BC, susceptibility genes had been mostly investigated assuming that they could 
be inherited as BRCA1/2, in a dominant model. Nonetheless, some studies have found by 
mathematical simulation that other models of inheritance, as the recessive, fit better to explain a 
percentage of the BC families in which the genetic cause remains not elucidated (Kaufman et al., 
2003; Cui et al., 2001; Turnbull et al., 2010; Kuligina et al., 2013). As explained in the 
introduction, correct selection of families as well as a careful design of the study can potentiate 
the possibilities of WES to identify novel variants/genes implicated in the disease. That is why we 
decided to explore the recessive model of inheritance, in this approach, selection of BRCAX 
families with no previous familial antecedents of the disease and more than two BC siblings 
affected was prioritized. As an example, variants that affect TOPAZ1 and GLE1 as compound 
heterozygous were found in family 2 [Table 3] which will be discussed further. 
 
No other gene that confers high susceptibility to BC, different than BRCA1 and BRCA2 
(Foulkes et al. , 2008)., has been identified in the last decades, however other genes that confer 
moderate susceptibility to BC such as CHEK2, PALB2, NBN and ATM have been discovered 
(Foulkes et al., 2013). Remarkably, all of them are implicated in DNA repairing/maintenance 
pathways. Due to this circumstance, we wanted to explore all the genes with a known function 
related with DNA maintenance and repairing systems, regardless of the model of inheritance, 
exploring variants in homozygous, heterozygous and compound heterozygous state (when 
information was available) and not filtering by impact or in silico predictors. Notably, we found a 
novel pathogenic variant in the well-established BC moderate susceptibility genes ATM and quite 
interesting variants for study in genes that could be potential BC susceptibility genes such as 
POLQ and RECQL5, among others [Table 4].  
 
The finding of an ATM pathogenic variant linked to BC causality, inherited in a dominant 
model in family 3, pinpointed that we could not rule out other models of inheritance in the rest of 
the families. Consequently, we explored this model of inheritance in the rest of the genes.  
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After case-control association study, variants under the dominant model of inheritance that 
remained for further analysis were identified in KANK1, CDH15, ACTR8, CERS5, KAT5, MTUS1 
and PLEC for family 1 and HHAT, KLF15, DEPDC1B, SYNE1, GPRC5B, HBP1, AHNAK and 
RANBP10 for family 2. 
 
In the end, after exploration of different models, our study revealed new genes, which could 
contribute to breast cancer susceptibility in BRCAX families, all of them family-specific and most 
probably inherited under a dominant model. These do not imply that the recessive model of 
inheritance does not exist; rather larger number of families should be carefully analyzed to 
demonstrate its effect, taking special care in rare families with extreme phenotypes. It has to be 
noted that the phenotype linked to this type of inheritance is not ample neither easily 
recognizable, as shown by the initial survey of nearly 2000 families which yielded only 4 
candidate families. Contrast in the proportion of families bearing a recessively inherited BC 
susceptibility allele against a dominant one can be exemplified by Kugilina et al. , 2013, whom 
calculated that 1/250 BRCAX could be potentially associated with the recessive model of 
inheritance. The numbers contrast when it is compared against a gene that is inherited in a 
dominant model of inheritance; nonetheless, the recessive model could still explain a percentage 
of BRCAX families. If we consider the possible incomplete penetrance of the mutations, then this 
characteristic would make it difficult to recognize the phenotype if there are women who harbor 
the variant but do not develop the disease.  
 
Another feature that we have to take into account in the families where a dominant variant was 
found as the most probable causal but variants acting in recessive model were also identified, is 
the fact that both could add risk to the development of BC under the polygenic model, even 
though this hypothesis requires further examination.  
 
There are a number of reasons why the use of WES has been questioned as the correct tool for 
exploring Mendelian or even complex disorders as cancer, being one of them the limited or no 
coverage of non-coding regions (intronic and intergenic regions), regulatory sequences as 
promoters, enhancers and microRNAs. Nonetheless, there are an increasing number of diseases 
for which the causal variant has been found through WES. Also, although WES only explores 1% 
of the entire human genome, is within this region where major known causal variants fall (Ku et 
al., 2011). So far, available studies using WES in familial breast cancer have not been conclusive. 
In the case of the present study, we have confirmed that the use of this technology is justified for 
the exploration of missing hereditability in BRCAX families by finding novel variants in well-
established moderate susceptibility genes associated with the causality of the disease (Family 3), 
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or novel genes/variants potentially implicated with the development of the disease as RECQL5 
(Family 1 and 2).  
  
6.2 Main findings in BRCAX family 1: Best candidates putatively associated with 
increased susceptibility to hereditary breast cancer 
 
 In this family, under the recessive model of inheritance and after the case-control association 
study, no variant that fit in this model was classified for further studies. Nonetheless, during the 
exploration of DNA repairing genes, the main finding in family 1 was a variant located in gene 
POLQ:  c.3503T>C, p. I1168T not previously reported [Table 4]. POLQ is a gene implicated in 
repairing DNA double strand breaks (DSBs) by the error-prone micro homology mediated end 
joining pathway (Kent et al., 2015). It also participates in translation synthesis and DNA 
replication (Goullet de Rugy et al. , 2016). Interestingly, it has been demonstrated that codepletion 
of BRCA2 and POLQ increase sensitivity to cisplatin-resistant lung cancer cells (Dai et al., 2016), 
the characterization of both the mechanism and the effect of this synthetic lethality phenomenon 
in BC would be of interest for personalized medicine. 
 
Under the dominant model of inheritance, variants that remained for further studies are located 
in KANK1, CDH15, ACTR8, CERS5, KAT5, MTUS1 and PLEC. From these, two seem to be quite 
interesting as they are frameshift mutations that lead to a truncated product in two different genes: 
c.3709del, p.A1237fsX11 in KANK1 and c.1316del, p.P439fs-X38 in CDH15 [Table 6].  
 
KANK1 (9p24.3) encodes a product of 1352 residues and has a major role in cytoskeleton 
formation by regulating actin polymerization, inhibits actin fiber formation and cell migration and 
inhibits RhoA activity, participates in establishment and persistence of cell polarity during 
directed cell movement in wound healing (Sarkar et al., 2002; Kakinuma et al., 2009). It has been 
proposed as tumoral supressor in renal cell carcinoma, as its depletion or loss leads to cell 
movement and invasion. Expression of the gene was found reduced either by loss of 
heterozigosity and/or methylation at CpG sites in this gene in renal carcinoma samples (Sarkar et 
al., 2002; Roy et al., 2005). In addition, its depletion induces hyperactivation of RhoA, 
centrosomal amplification and genomic instability, a hallmark of cancer (Suzuki et al., 2017).  
 
CDH15 (16q.24.3) encodes a member of the cadherin-protein family, which are calcium-
dependent intercellular adhesion glycoproteins. Other members of this family have been 
implicated in BC, as CDH1 which is a gene that confer high susceptibility to this disease within 
cancer related syndromes (Pharoah et al., 2001). CDH15 is a potential tumor suppressor as LOH 
analysis performed on 62 mammary tumors induced in (BALB/c x C57BL/6) F1 mouse 
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mammary tumor virus/neu transgenic mice showed preferential LOH of the region containing this 
gene (Cool et al., 1999), an observation that was seen also in human sporadic breast cancer 
tumors (Kremmidiotis et al., 1998).  
 
KAT5 (c.291C>G, D97E), also known as TIP60, has remarkable functions, all related with 
DNA repair and BRCA1, which turns this gene into an excellent candidate. It encodes an 
acetyltransferase involved in apoptosis, cell cycle and DNA damage response. Tip60 is involved 
in homologous recombination, DSB repair and its deficiency reduces BRCA1 at DSB; 
consequently, impairing HR and conferring sensitivity to PARPi (Tang et al., 2013). It is 
considered as a novel breast cancer tumor suppressor gene required for breast cancer progression 
(Bassi et al., 2016). It can inhibit metastasis by regulating epithelial-mesenchymal transition 
(Zhang et al., 2016).  
 
A missense variant was located in MTUS1 gene (c.3554A>C, p.N1185T). This gene 
(Microtubule associated tumor suppressor) has been described in different types of cancer, where 
loss of function or reduced mRNA levels (e.g. by negative coregulation among microRNAs) are 
related with worsened prognosis and higher invasive capability of the tumors (Gu et al., 2017; 
Kara et al., 2016; Ozcan et al., 2016; Zhao et al., 2015). In familial BC, it inhibits BC cell 
proliferation, delays the progression of mitosis by prolonging metaphase, and reduces tumor 
growth (Rodrigues-Ferreira et al., 2009; Frank et al., 2007). 
 
It was interesting to find that a variant (c.12886C>T, p. R4296C) affecting PLEC gene, which 
encodes a protein of 4684 aminoacids, that has different roles, as structural protein it maintains 
cell, tissue integrity, remodelates cytoarchitecture, cell shape and also acts as scaffold protein for 
assembly, positioning, and regulation of signaling complexes (Wiche et al., 1982; Liu et al., 
1996). More interestingly, PLEC interacts with BRCA2 through an interaction that controls the 
position of the centrosome, if this interaction is dissociated it leads to centrosome disorganization, 
genomic instability and cancer development (Niwa et al., 2009). Regarding the phenotype of 
cases found in Openarray platform bearing this variant: 8/12, 66% were breast cancer-only cases. 
The presence of this variant in a high number of cases, as well as its interaction with BRCA2, 
turns this gene into a quite interesting gene for full coding sequencing in Spanish population, to 
explore the association with increased susceptibility to BC.  
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6.3 Main findings in BRCAX family 2 
6.3.1. RECQL5, another DNA helicase potentially involved in increased breast cancer 
susceptibility 
 
While studying the genes related with DNA repairing systems, we found two variants affecting 
RECQL5 (c.1709C>T, p. T570I and c.2874C>G, p.S958R). There are important features why 
RECQL5 is an excellent candidate for deep study, as: members of the RECQL helicase family of 
proteins, as BLM, WRN, and RECQL4, are related with diseases that predispose to cancer 
development, e.g. Bloom, Werner and Rothmund-Thomson syndromes (Ellis et al., 1995; Goto et 
al., 1996; Lindor et al., 2000; Bohr et al. , 2008). From all the members of the family, RECQL5 is 
the only one that has not been reported in any genetic condition. As mentioned previously, 
RECQL5 participates in a plethora of cellular activities: DNA repairing, recombination, 
replication, transcription, genome stability, homologous recombination and cell survival (Croteau 
et al., 2014). It has been shown that RECQL5 suppresses tumor formation and RECQL5 knock-
out mice have increased cancer predisposition (Hu et al. , 2007; Hu et al. , 2010). In addition, 
RECQL, another member of REC-helicases family, has been recently identified as a new putative 
BC susceptibility gene (Cybulski et al., 2015; Sun et al., 2015).  
 
Given all the characteristics that RECQL5 shares with known high/moderate BC susceptibility 
alleles, we decided to study all the coding regions and exon-intron boundaries of the gene using 
Illumina TruSeq Custom Amplicon platform in a large series BRCAX BC-only cases and controls 
(1463). From the mutational screening, we found three germline unequivocally pathogenic 
variants in cases, one missense (c.130G>A, G44S) and two frameshift (c.657delC, C220fsX15; 
c.2393dupC, M799fsX24) that led to a premature truncated protein, this would represent 0.42% of 
the cases. In controls, no clearly deleterious mutation was found. 
 
c.130G>A, G44S is a novel missense mutation that is predicted to affect nearest splicing site 
leading to the loss of several exons still to be determined, which leads to truncation of almost 95% 
of the complete product. Also, this variant introduces an extra helix in the domain and loss of 
catalytic residue N45, according to MutPred. c.657delC, C220fsX15 leads to the loss of important 
domains for helicase activity (ATP-binding site and Helicase C’ terminal) as well as all domains 
located further (Zn
2+
 subdomain, KIX, RECQ-5, RAD51 IR and SRI domains). c.2393dupC, 
M799fsX24 truncates the C’terminal extension of RECQL5, which includes PIM and SRI 
domains.  
 
Segregation analysis performed to sisters affected with BC from index case 
harboringc.130G>A, G44S revealed incomplete segregation of the variants which suggest that the 
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variant could be associated with moderate risk. Unfortunately, it was not possible to extend 
segregation analysis in other members of the families from BC index patients harboring 
c.2393dupC, M799fsX24 and c.657delC, C220fsX15.  
 
Mean age of onset at first diagnosis of BC in patients with RECQL5 deleterious mutations in 
Spanish population was 36.7 years, which is earlier than BC diagnosis for BRCA1/BRCA2 
mutation carriers (being 43.6 and 42.8, respectively) and their sporadic counterparts in Spanish 
population (Diez et al. , 2003). Average age of BC first diagnosis in patients carrying RECQL 
deleterious mutations was 45.1 years in Chinese population (Sun et al. , 2015), 48.9 years for 
French-Canadian and 54.5 years for Polish population (Cybulski et al. , 2015), the other RECQ-
helicase which has been related to increased susceptibility to BC. Nonetheless, there are two facts 
to consider regarding this data: very few cases of BC patients with RECQL5 deleterious mutations 
were taken into account for this value and the mean age of first BC diagnosis was 39.3 years in 
the Spanish BRCAX cases cohort studied (n=700). 
  
In the majority of the cases where we detected RECQL5 germline pathogenic variants, 
complete information about the IHQ of the tumor was not accessible. For c.2874C>G, S958R it 
was shown in paraffin embedded tumor, that IHQ was ER+, PR+.  For c.2393dupC, M799fsX24, 
both bilateral cases were triple negative. No more information from markers was available from 
c.130G>A, G44S and c.657delC, C220fsX15. This data would be of interest for classification, as 
a considerable percentage of BC cases with BC RECQL germline pathogenic variants were ER+, 
PR+, Her2 negative, resembling BRCA2 associated cases (Sun et al., 2015).  
 
Bearing in mind that all the RECQL5 germline pathogenic variants described in this study 
where found in heterozigosity, haploinsufficiency and/or inactivation of wild-type allele by a 
second hit could be associated with BC development, although the molecular mechanism has to 
be established to validate this hypothesis. It has been observed that knockout mice for RECQL5 
do not show loss of heterozigosity, which suggest that LOH alteration is not the primary 
underlying mechanism of cancer susceptibility (Hu et al., 2007), rather it could be related with the 
hyper recombination favored by the absence or partial function of RECQL5 if mutated which 
would increase genome instability and gross chromosomal changes that tend to be oncogenic. 
Other mechanisms could be associated taking into account the participation of the enzyme in the 
relief of replication stress generated by stalled DNA forks (Di Marco et al., 2017) and the halting 
of transcription when DNA double strand breaks are detected (Islam et al., 2010). In addition, the 
antagonic role of RECQL5 in disruption of the RAD51 presynaptic filaments (Schwendener et al., 
2010) against BRCA2 that promotes assembly of this latter could be deregulated in an oncogenic 
condition [Figure 19]. 
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Figure 19. General overview of potential mechanisms driving to tumorigenesis caused by absence/partial expression/functional impairment of RECQL5. A) In replication, absence/partial 
function of RECQL5 leads to inhibition of fork cleavage due to non disruption of RAD51 filament and no recruitment of MUS81 complex  which, after mitosis, results in genomic 
instability and cells that present aberrant micronuclei and aberrant chromosomal segregation. B) Dual mechanism of RECQL5-transcriptional repression: MRN complex recruits RECQL5 
inhibiting transcription by steric block to prevent PolII toward the site of the DBS and inhibition of elongation at stall site. C) In transcription, at elongation phase RECQL5 is not only 
relieves transcription stress, but also regulates the movement of RNApolII across genes. Without this enzyme, there is an increase of stalling, pausing and/or backtracking of RNApolII. D) 
In Homologous Recombination, antirecombinase activity of RECQL5 leads to disruption of RAD51 filament to prevent aberrant HR. Impaired or nule RECQL5 activity leads to hyper-
recombination and higher numbers of RAD51 foci (Adapted from Di Marco et al., 2017; Hu et al., 2007; Kassube et al., 2013; Schwendener et al., 2010; Saponaro et al., 2014).  
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By using a combination among in silico predictors and predict protein scores, we classified 
potentially deleterious missense germline variants in cases (c.233C>T, P78L; c.539G>A, R180H; 
c.1648C>T, R550W; 2926C>T, R976W) and controls (c.305C>T, S102L; c.929T>A, V310D; 
c.1765C>T, R589W; c.2233C>T, R745W; c.2296C>T, R766C). From these, it is important to 
mention that the majority of the predicted germline pathogenic variants are highly conserved 
residues among species centered in the RECQ-helicase, KIX or SRI domains [Figure 17].  
 
One of the variants with very high in silico predicted pathogenicity was c.1648C>T, R550W, 
present in a case with BC diagnosed at 34 years old. Site directed mutagenesis of residue R550 
has been shown to impair protein folding and abolish interaction of POLR2A (Islam et al., 2010). 
In an analogous way, variant c.1648C>T, p.R550W is predicted by MutPred to introduce 
structural changes (gain of a helix and loss of a loop) that may lead to incorrect folding of the 
protein. Also due to its location, at nucleotide 4 at the beginning of the exon 13, the variant is  
predicted to affect nearest splicing site.  
 
An in silico study was performed centered in the domains of the protein to study the effect of 
missense variants and to compare between cases and controls. Positive controls were taken into 
account considering functional studies published by Newman et al., 2017 were point mutation 
lead to null (Y419A, D168A), partial (H167A, D422A, F420A) or total decrease (R349A, 
Q345A, W165A and R352G) in the helicase activity of RECQL5 depending in the position of the 
variant inside of the helicase domain. The negative control used for computational comparison 
included missense variants with a tolerated/neutral effect found in the Spanish population and  
variant c.1439A>G; p.Asp480Gly (rs820196) quite frequent in our cohort and a GMAF in EXAC 
of 0.2 in general population. Of importance, no other missense variant have been reported in 
EXAC with GMAF higher than 1% which points to the fact that missense variants are not well 
tolerated in this gene. The results from these in silico approach showed that the missense 
pathogenic variants detected in cases exert a putative impairment in the helicase functionality , 
which is not seen in variants detected in controls for variants detected within this domain [Figure 
17]. As a perspective, functional studies are planned in order to differentiate the effect of 
missense variants at helicase level.  
 
For variants located in KIX domain, it was found that the most deleterious was present in case 
R550W, for which there are in vitro studies proving its pathogenicity (Islam et al., 2010), whereas 
variants located nearby this domain and present in controls have an effect similar to that one from 
frequency and neutral missense variants. In a comparable way, in SRI domain var iant R976W 
from case has an increased deleterious effect in comparison with controls. As KIX and SRI 
domain interact with RNA-Polymerase II, by halting transcription, and then the capability of 
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binding to this enzyme could be tested in vitro. It has been proposed that KIX and SRI domain 
have different roles at two stages of the transcription. SRI domain is more implicated in the 
elongation stage, whereas KIX domain in recognition of initiation complex of transcription 
(Aygün et al., 2009; Aygün et al., 2010). As well, they bear distinct capabilities to recognize 
hyper/hypo phosphorylated form of RNA-poll II, for which specific assays could be designed in 
order to test whether or not the different mutations affect at distinct levels of the transcription 
process, as well as the different phosphorylated forms of the enzyme. As a perspective, 
proliferation assays, apoptosis assays and interaction with RAD51 and sensitivity to a panel of 
drugs (including camptothecin derivatives) to study mechanisms of synthetic lethality which 
could be affected due to the presence of missense pathogenic variants when compared with the 
WT RECQL5 could also be performed in order to get insights about the connection between the 
predicted pathogenic variants and the development of BC.  
 
From the in silico inference of missense variants in RECQL5 domains, computational 
approach suggest that missense variants located in cases are, in fact, pathogenic germline variants, 
which would translate to an increase of the prevalence (7/700). This data, if in vitro corroborated, 
would mean that RECQL5 germline pathogenic variants would confer a moderate/high r isk in 1% 
of all BRCAX BC-only cases, a proportion similar to the explained by other moderate-high 
susceptibility BO/OC genes.  
 
Finally, alike tumors harboring BRCA1 or BRCA2 germline mutation with increased and 
selective sensitivity to PARP inhibitors (Farmer et al., 2005; Lord et al. , 2017), which is now the 
cornerstone of personalized therapy for these type of patients, it has been shown that RECQL5 
deficient cells are hypersensitive for treatment with Topoisomerase I (camptothecins, CPT) in 
colorectal cancer cell lines (Wang et al., 2011). Nonetheless, they are resistant to cisplatinum, 
mitomycin C and etoposide (Hu et al., 2009).  Thus, for carriers of RECQL5 germline pathogenic 
variants already affected with BC, this knowledge could guide the selection of specific 
chemotherapeutic regimens for RECQL5 defective BC cancers (e.g. derivatives of CPTs, 
irinotecan and topotecan). In normal conditions, accumulation of CPT-DNA-Top1 lesions, would 
lead to activation of DNA damage response, which includes RecQ5-helicase (Shamanna et al., 
2016). Nonetheless, if the RecQ5-helicase is missing, then selective elimination of this type of 
tumor would happen through a hitherto not described mechanism of synthetic lethality.  
 
Missing heritability is becoming unraveled with NGS technologies. This study supports the 
use of WES to identify new genes involved in BC susceptibility. The prevalence of at least 0.42% 
RECQL5 pathogenic germline variants associated with BC in Spanish population, justifies deeper 
attention to this gene. To calculate the exact risk, larger cohorts need to be evaluated and in vitro 
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studies are desirable to verify pathogenicity of undetermined missense variants predicted to be 
highly deleterious by numerous computational methods. Further exploration is justified to guide 
prevention, early diagnosis and future treatment alternatives in carriers of RECQL5 germline 
pathogenic variants. 
 
6.3.2. Other findings in family 2 exploring dominant and recessive model of inheritance 
 
In family 2, under the dominant model of inheritance, we found 13 candidate variants. After 
case-controls association studies, variants that remained for further insights are located in genes: 
HHAT, KLF15, DEPDC1B, GPRC5B, SYNE1, HBP1, AHNAK and RANBP10. 
 
From these, one of the most interesting variants is located in HHAT c. 1096_1097del, 
p.L366fsX86 that generates a truncated product, that losses important functional domain beyond 
residue 366. HHAT (1q32.2) encodes for Hedgehog acyltransferase, catalyzes the transfer of the 
fatty acid palmitate into Sonic Hedgehog (a pathway implicated in BC) (Konitsiotis et al. , 2015).  
Strongest evidence for selection in further studies was a report where depletion of HHAT 
decreased selectively anchorage-dependent and anchorage-independent proliferation of ER 
positive, HER2 amplified and tamoxifen-resistant cells but not triple negative breast cancer cells 
lines, which is of interest in the treatment of BC patients harboring mutations in this gene 
(Matevossian et al., 2015). 
 
Another two interesting missense variants are located in KLF15 (c.965A>G, p. K322R) and in 
DEPDC1B (c.739A>G, p. M247V).  The first one encodes (3q21.3) a protein named as Kruppel 
like factor 15, is a transcriptional regulator involved in various biological processes, including 
cellular proliferation, differentiation and death. In BC, it is a putative tumor suppressor, which 
partially stalls cancer growth through p21 up-regulation. Presence of this protein was associated 
also with clinicopathological factors predicting a better clinical outcome (Yoda et al., 2015). 
Downregulation of KLF15 by miR-262 leads to proliferation and invasion in human breast cancer 
cells (Wang et al. , 2017). Interestingly, in uterus KLF15 regulates negatively the -estradiol-
induced epithelial cell proliferation by inhibition of DNA replication licensing which is indicative 
of a role at two levels: inhibition of hormonal effect and DNA maintenance system, which make 
this gene a candidate susceptibility gene in HBOC (Ray et al., 2012). In the case of the other gene, 
DEPDC1B (5q12.1), it encodes a protein of 529 residues that is involved in cell migration, 
intracellular signal transduction, positive regulation of Wnt pathway and regulation of small 
GTPase signal transduction (Marshesi et al., 2014). In BC, it was found that tumors from BRCA1 
mutation carriers show LOH of chromosome 5 (Johannsdottir et al., 2006). Homozygous 5q 
deletions spanning 700 kbp which included DEPDC1B, had been reported twice by different 
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studies in tumors from a BRCA1 mutation carriers (Johannsdottir et al., 2006; Jönsson et al., 
2005).  
 
HBP1 (8q24.3) encodes a transcriptional repressor with a HMG box DNA-binding domain that 
binds to promoter region of target genes. Plays a role in the regulation of the cell cycle, 
senescence and in inhibition of the Wnt pathway (Sampson et al., 2001; Zhang et al., 2006). The 
molecular mechanism in Wnt signaling arises from the inhibition of transcriptional activation of 
Wnt signaling (cyclinD1 and c-MYC). For this latter, HBP1 interacts directly to c-MYC and 
negatively regulates its transcriptional activity (Escamilla-Powers et al., 2010). It can interact with 
RB1 and enhance binding to the H1
0
 promoter. Disrupts DNA interaction with TCF4 (Lemercier 
et al., 2000). A report in BC found HBP1 mutants/variants are present somatically in tumoral 
samples of invasive ductal carcinoma (IDC); interestingly, in this type of tumor (IDC) even 
without somatic mutations of HBP1, the levels of HBP1 mRNA were reduced, which was 
associated with Wnt signaling increased tumorigenic proliferation and invasiveness. This 
resembles the mechanism exerted by miR-17-5p that suppresses HBP1 and consequently 
enhances proliferation and invasiveness (Li et al., 2011). Noteworthy, low/null levels of HBP1 
mRNA correlates with bad prognosis as well as BC recurrence (Paulson et al., 2007).  Concerning 
phenotype, it was interesting to find variants with numerous cases associated with breast cancer 
only patients, as for HBP1 c.1167A>C, p.Q389H in 11 cases, from which 81% were BC-only. 
 
AHNAK (11q12.3) encodes a protein of 700KDa, which is a structural scaffold protein that 
participates in cell structure and migration, cardiac calcium channel regulation, and tumor 
metastasis (Shtivelman et al. , 1992). An interesting role in DNA maintenance complexes as 
Ahnak can interact with DNA ligase IV-XRCC4 complex in DNA non-homologous end-joining 
and stimulates DNA ligase IV-mediated double-stranded ligation (Stiff et al., 2004). In BC, it has 
been reported overexpression of Ahnak resulted in growth retardation and cell cycle arrest 
through downregulation of c-Myc and cyclin D1/D2, whereas depletion of Ahnak leads to 
significantly progressed hyperplasia of mammary glands in a mouse model and in human BC 
tissues its expression is lower in tumoral vs normal tissue(>50%). This information suggest that 
Ahnak  is a novel tumor suppressor that functions via modulation of TGFβ/Smad pathway (Lee et 
al., 2014). Ahnak has been localized in extracellular micro vesicles that allow mammary 
carcinoma cells to communicate with surrounding cells from its niche and transform them (Silva 
et al., 2016). Concerning phenotype, variant located in AHNAK (c.7964G>T, p.G2655V) was 
found in 6 cases, with 4 of them being BC only cases.  
 
Regarding the recessive model of inheritance, a quite interesting gene where potential 
pathogenic variants were found as compound heterozygous was FBF1. Two variants were 
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inherited from the mother (c.770C>G, p.P257R and c.1808G>A, p.R603Q) and one from the 
father (c.2039C>T, p.A680V). The three are present in the affected sister with BC, in exon 11, 18 
and 19, meanwhile they are WT in the healthy sister. This gene encodes a protein known as FAS 
binding factor 1 or Albatross. It has not been previously associated to BC cases, nonetheless it is 
implicated in epithelial cell polarization (in the apical junction complex (AJC) (Sujimoto et al., 
2008) and regulation of PLK1 activity at G2/M transition. Also, it is a protein that participates in 
the union of Fas antigen (TNFRSF6), a cell death mediator. FBF-1 shows sequence similarity 
with plectin which is a structural protein with a potential role in BC that we found while  studying 
other models of inheritance and will discuss further (Schmidt et al., 2000).  
 
Although we consider that the variants affecting RECQL5 could be associated with the 
causality of the disease in this family, still other genes found under the dominant and recessive 
model of inheritance are of interest for deeper molecular and statistical exploration, as they may 
be acting as modifiers of the risk and could influence at some extent the BC development in a 
family-specific way, although this hypothesis require further exploration.  
 
6.4 Main findings in BRCAX family 3: Almost 2% of Spanish breast cancer families are 
associated to germline pathogenic mutations in the ATM gene 
 
Family 3 was an example in which we were able to find the causal variant in an already known 
moderate BC susceptibility gene using WES. We found a variant located in ATM (c.5441delT; 
p.L1814WfsX14) that leads to a truncated product and provided evidence of the causality of the 
disease. Due to this finding we decided to perform complete coding sequencing of the gene in a 
large series of cases and controls to explore frequency and spectrum of ATM mutations associated 
with HBOC in Spanish cohorts due to the lack of this type of information in this population 
(Brunet et al., 2008; Graña et al., 2011).  
 
By using NGS panels, we determined a prevalence of ATM pathogenic germline variants of 
1.78 % (7 of 392 BRCAX HBOC families), which is slightly higher than that reported in other 
populations which varies between 0.69% in Japanese population (Hirotsu et al., 2015) to 1.41% in 
US population (Kurian et al., 2014) in BRCAX families. No mutations in the ATM gene were 
found in a comparative group consisting of 350 index cases from families affected with different 
diseases not related to breast cancer. Although this is not strictly a control group because patients 
were not free of disease, we think that the comparison is valid for the purpose of this study as we 
did not find any deleterious mutation, and we assume that the prevalence in the general population 
would be even lower.  
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Regarding the phenotype, the majority of mutations were found in index cases affected with 
BC (5/7) cases. Only the mutation (c.8122G>A, p.Asp2708Asn) was present in an index case with 
bilateral BC and ovarian cancer. Increased risks for bilateral BC occurrence among ATM 
heterozygous carriers have been observed (Broeks et al., 2000). Index case harboring c.6100C>T; 
p.Arg2034* mutation presented breast and gastric cancer and index case carrying 
c.3754_3756delinsCA, p.Tyr1252Glnfs*4 developed thyroid papillary cancer and renal 
oncocytoma [Table 10]. This was not surprising, as adult ATM heterozygous carriers can develop 
solid tumors which include cancers of the digestive track, lung and gallbladder, although with 
lower frequencies in comparison with BC (Taylor et al., 2015).  
 
Segregation analysis of family members from index case harboring c.3754_3756delinsCA, 
p.Tyr1252Glnfs*4, revealed two mutation carriers diagnosed with BC at 43 and 45 years, which 
strengthens the role of ATM pathogenic mutations in the development of BC. Importantly, 
average age of onset at first diagnosis of BC in patients with ATM deleterious mutations in 
Spanish population was 47.42 years, which is amid BC diagnosis for BRCA1/BRCA2 mutation 
carriers (being 43.6 and 42.8, respectively) and their sporadic counterparts in Spanish population 
(Diez et al., 2003).  
 
The prevalence found, almost 2% of ATM pathogenic variants in Spanish BC only families 
which is higher than the reported in other populations, justifies considering its incorporation in 
routine genetic tests in clinical setting for BRCAX families in Spanish population to detect ATM 
heterozygous carriers whom could benefit from specific monitoring programs.  
 
6.5 Main findings in BRCAX family 4: Novel susceptibility alleles potentially implicated 
in hereditary male breast cancer  
 
MBC accounts for a total of 1% of all the breast cancer cases (Speirs et al., 2009).  From all 
MBC, 10% are hereditary and among 60 – 70% of these cases are caused by pathogenic mutations 
in BRCA2 gene (Tournier et al., 2004). Nonetheless, little is known about other MBC 
susceptibility genes. In addition, clinical and pathological characteristics of MBC do not overlap 
female BC, mortality and survival rates have not improved significantly and its incidence is 
increasing (Rizzolo et al., 2013). Little is known about other susceptibility genes implicated in the 
development of the disease that could guide prevention and measurements for advanced cases 
(Giordano et al., 2004).  
 
By using WES, in an exceptional MBC BRCAX family with an apparent recessive or X-linked 
model of inheritance [Figure 7, family 4] , we selected candidate variants that could be related 
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with the disease [Table 11]. While exploring the presence/absence of the variants in a cohort of 
MBC Spanish cases with familial and personal background of the disease, we have found another 
MBC case who was homozygous for c.1208G>A p.R403Q affecting TXNDC5 gene which has 
been related to Androgen Receptor. A large percentage of MBC (approximately >60%) are related 
with somatic mutations occurring in hormone signaling pathways (Sas-Korczynska et al., 2015),.  
Of transcendence, germline mutations in the androgen receptor have been found associated with 
other cases of multiples MBC within the same family (Wooster et al., 1992), as well as related 
with hormone driven tumors due to dysregulation in the hormone metabolism of androgens 
(Wang et al., 2015), as prostate cancer (Baumann et al., 2012). TXNDC5 encodes a member of 
disulfide isomerase family of proteins, acting as a chaperone of endoplasmic reticulum. As a 
result, TXNDC5 interacts with many cell proteins, contributing to their proper folding and correct 
formation of disulfide bonds through its thioredoxin domains. In addition, it is a cellular adapter, 
playing an important role in cellular physiology. Deregulation of this protein has been associated 
with different pathologies like arthritis, cancer, diabetes, among others (Horna-Terrón et al., 
2014). A recent paper has described an interaction between TXNDC5 and AR, to increase its 
stability and thus, enhance its transcriptional activity (Wang et al., Oncogene 2015). Noteworthy, 
TXNDC5 SNPs could be related to the development of hepatocellular carcinoma tested in a cohort 
of Korean males (Park et al., 2013). Although the interaction between TXNDC5 and AR is not 
completely understood, in our case, having found two MBC cases that are homozygous for the 
same variant is quite interesting taking into account the rarity of the disease and the pathway 
implicated. Further insights are desired as TXNDC5 could be a MBC susceptibility gene and for 
the design of personalized medical regimens in MBC (Di Lauro et al., 2015).  
 
We have selected variants with a recessive model of inheritance affecting other quite 
interesting genes like: LIMD1, PLCB2 and YLPM1, among others, prioritized due to the functions 
and pathways where they are implicated.  
 
Missense variant affecting LIMD1 is c.859G>C, p.V287L, a gene (3p21.31) that plays multiple 
roles: assembly of numerous protein complexes and is involved in several cellular processes such 
as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell 
adhesion, cell differentiation and migration (Bai et al., 2011). It is also a negative regulator of 
Hippo signaling, a pathway that is implicated in mammary gland development and male BC (Das 
Thakur et al., 2010; Pinto et al., 2014). Interestingly, LIMD1 interacts with BRCA2 in a well 
conserved region (amino acids 2,750-3,094), by disrupting this interaction, centrosome 
localization of BRCA2 is affected yielding abnormal cell division (Hou et al. , 2016). This latter is 
of remarked importance, as BRCA2 is the only gene of susceptibility to MBC which is associated 
with a large percentage of hereditary cases.  
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Missense variant affecting PLCB2 (c.749G>A, p.R250P), a gene (15q15.1) encodes a 
Phospholipase C Beta 2, an enzyme needed for production of the second messenger molecules 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). PLCB2 is highly expressed in 
advanced female BC and is associated with poor outcome (Bertagnolo et al., 2006). May improve 
some malignant characteristics of tumor cells, like motility and invasion capability and may 
influence the modification of cell shape that characterizes cell division, motility and invasion 
(Bertagnolo et al., 2007).  
 
Missense variant affecting YLPM1 is c.3235C>T, p. R1079W, a gene (14q24.3) related to 
telomere maintenance, by reducing telomerase activity during differentiation of embryonic stem 
cells by binding to the core promoter of TERT and controlling its down-regulation (Armstrong et 
al., 2004). It is a candidate gene for mammary gland development in pigs, although further 
characterization will be needed in humans (Verardo et al., 2016). 
 
Regarding the X-linked inheritance model, we have one candidate variant affecting TKTL1 
gene (Xq28), which is a splice site variant. This gene is related with the pentose-phosphate 
pathway, with the glycolytic pathway and related with tumor metabolic reprogramming (Diaz-
Moralli et al., 2016).  It promotes cell proliferation and metastasis, is a marker of certain tumor 
tissues and induced by hypoxia (Földi et al., 2007). In BC, its expression was higher in BC and 
DCIS in comparison with normal tissues (Schmidt et al., 2010).  
 
Even though our findings in the case-control association were negative for the British cohort 
(we did not find any other variant homozygous for the recessive model and hemizygous in the X-
link model), still we have to consider that these findings do not imply that the variants can be 
ruled as potential MBC susceptibility genes; instead, larger number of MBC cases should be 
explored. 
 
In summary, these set of studies using Whole Exome Sequencing for exploring BC missing 
hereditability has guided to the exploration of different models of inheritance, and lead to the 
discovery of causal variants family specific and other variants, which overall, could be acting 
jointly to increase the risk of BC. Although there is still work to do in light of statistical power 
and functional characterization of potentially deleterious variants, WES has been proved as a 
suitable and determinant technique to find new BC susceptibility candidate genes, as well as 
variants not previously reported in well-established BC susceptibility genes.  
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7. Conclusions 
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1. Although our initial hypothesis was the recessive model of inheritance, in almost all the 
BC families studied, the model of inheritance that most probably explained the disease 
was the dominant. This highlights the difficulty of recognizing patterns of inheritance for 
this disease which is one of the reasons that has hindered the finding of new susceptibility 
genes through the years. Nonetheless, this does not imply that the recessive model is 
inexistent, as it still fits our MBC family. It is also possible that a combination of variants 
fitting the dominant and recessive model may coexist under a polygenic model of 
inheritance.  
 
2. After the exploration of the recessive model of inheritance, the DNA 
repairing/maintaining genes, the dominant model of inheritance and case-control 
association study, 25 variants were found as putative susceptibility alleles for hereditary 
breast cancer which are candidates for further studies. 
 
3. Finding of clearly pathogenic germline variants in RECQL5, which could account for at 
least 0.42% in BRCAX cases in Spanish population, pointed toward a potential 
involvement of this DNA helicase in increased breast cancer susceptibility.  
 
4. A truncating mutation in ATM gene was identified as the causal variant in a BRCAX 
family. Mutational screening of the gene revealed that nearly 2% of Spanish BC families 
are associated to germline pathogenic mutations in the ATM gene which strengthens its 
inclusion in routine genetic tests in clinical setting for BRCAX families to detect ATM 
heterozygous carriers whom could benefit from specific monitoring programs. 
 
5. We have identified variants in seven candidate susceptibility genes for hereditary male 
breast cancer. From these, the most interesting are TXNDC5 related with regulation of 
androgen receptor signaling pathway and LIMD1 which interacts with the MBC 
susceptibility gene BRCA2, which both require further in-depth analysis. 
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7. Conclusiones 
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1. Aunque nuestra hipótesis inicial fue el modelo recesivo de herencia, en casi todas las 
familias estudiadas, el modelo de herencia más probable para explicar la enfermedad 
resultó ser el modelo dominante. Esto pone de manifiesto la dificultad para reconocer 
patrones de herencia específicos en familias con cáncer de mama, siendo esta una de las 
razones que ha dificultado la identificación de nuevos genes a lo largo de los años.  Sin 
embargo, esto no implica que el modelo recesivo sea inexistente, ya que todavía se ajusta 
a nuestra familia de cáncer de mama en varón. Por otro lado, es posible que una 
combinación de variantes que ajustan con el modelo dominante y recesivo coexistan bajo 
el modelo de herencia poligénica.   
 
2. Después de explorar el modelo recesivo de herencia, los genes de reparación/ 
mantenimiento del ADN, el modelo dominante de herencia y tras el estudio de asociación 
de casos y controles, se encontraron 25 variantes candidatas de susceptibilidad a cáncer 
de mama hereditario que son candidatas a estudios en series más amplias. 
 
3. El hallazgo de mutaciones claramente deletéreas en línea germinal en RECQL5, en al 
menos un  0.42% de las familias BRCAX en población española, señalan hacia un papel 
potencial de esta DNA helicasa en la susceptibilidad al cáncer de mama. 
 
4. Se identificó una mutación truncante en el gen ATM como la variante causal en una 
familia BRCAX. El análisis mutacional de las regiones codificantes del gen reveló que 
casi el 2% de las familias españolas con cáncer de mama están asociadas a mutaciones 
deletéreas en línea germinal en el gen ATM, lo cual refuerza su inclusión en pruebas 
genéticas de rutina en el contexto clínico para familias BRCAX para detectar portadores 
heterocigotos de mutaciones que podrían beneficiarse de programas de prevención 
específicos. 
 
5. Hemos identificado variantes en siete genes candidatos de susceptibilidad a cáncer de 
mama hereditario en varón. De estos, son especialmente interesantes TXNDC5 asociado 
con la regulación de la vía de señalización el receptor de andrógenos y LIMD1 que 
interacciona con el gen de susceptibilidad para cáncer de mama en varón BRCA2, ambos 
requieren análisis moleculares y estadísticos en profundidad para establecer su relación 
con la enfermedad. 
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Supplementary Table 1:  
Principal function of the genes found through Whole Exome Sequencing   
 
Fam Gene Function* 
Model of 
inheritance 
1 DOCK3 
Dedicator Of Cytokinesis 3, family of guanine nucleotide exchange factors (GEFs), 
modifier of cell adhesion (MOCA) and presenilin-binding protein (PBP), involved in 
cytoskeletal remodeling and signal transduction. 
Recessive 
1 POLQ 
DNA Polymerase Theta, DNA DS break repair, promotes microhomology-mediated 
end-joining and promotes genomic rearrangements. 
DNA repairing 
gene 
1 CHEK2 
Checkpoint Kinase 2, required for checkpoint -mediated cell cycle arrest, activation of 
DNA repair and apoptosis in response to the presence of DNA double-strand breaks. 
DNA repairing 
gene 
1 POLG DNA Polymerase Gamma, involved in the replication of mitochondrial DNA. 
DNA repairing 
gene 
1 KANK1 
KN Motif And Ankyrin Repeat Domains 1, Cytoeskeleton formation, regulates actin 
polymerization, tumor suppressor in renal carcinoma, inhibits RhoA activity, cell 
polarity, among others.  
Dominant 
1 CDH15 
Cadherin 15, Encoding calcium-dependent intercellular adhesion glycoproteins, control 
of morphogenetic processes. 
Dominant 
1 ACTR8 
ARP8 Actin-Related Protein 8 Homolog, DNA DS Break Repair and TC-NER, 
organization of mitotic chromosomes, transcriptional regulation, DNA replication, 
DNA repair, INO80 complex. 
Dominant 
1 CERS5 
Ceramide Synthase 5, Synthesis of ceramide, a lipid molecule that is involved in a 
several cellular signaling pathways, link with apoptosis, endometrial cancer, 
upregulated in BC cell lines. 
Dominant 
1 KAT5 
Lysine Acetyltransferase 5, MYST family of histone acetyl transferases (HATs), 
chromatin remodeling, transcription and other nuclear processes by acetylating histone 
and non histone proteins, DNA repair, Signal transduction, NuA4 complex required for 
tumor suppression of cell growth, replicative senescence and apoptosis. 
Dominant 
1 MTUS1 
Microtubule Associated Tumor Suppressor 1, Cooperates with AGTR2 to inhibit  ERK2 
activation and cell proliferation. May be required for AGTR2 cell surface expression, 
inhibits breast cancer cell proliferation, delays the progression of mitosis by prolonging 
metaphase and reduces tumor growth. 
Dominant 
1 PLEC 
Plectin, Interlinking different elements of the cytoskeleton, scaffolding platforms for 
the assembly, positioning and regulation of signaling complexes, related with EFGR1 
signaling, degradation of extracellular matrix. 
Dominant 
1 DDX11 
DEAD/H-Box Helicase 11, DNA-dependent ATPase and ATP-dependent DNA 
helicase that participates in various functions in genomic stability, including DNA 
replication, DNA repair and heterochromatin organization as well as in ribosomal RNA 
synthesis. 
Dominant 
1 NISCH 
Nischarin, cytoskeletal organization and cell migration by binding to alpha-5-beta-1 
integrin. 
Dominant 
2 AKR1C3 
Aldo-Keto Reductase Family 1 Member C3, Ovarian steroidogenesis, interconverts 
active androgens, estrogens and progestins with their cognate inactive metabolites. 
Recessive 
2 FBF1 
Fas Binding Factor 1, Keratin-binding protein required for epithelial cell polarization. 
Involved in apical junction complex (AJC) assembly via its interaction with PARD3. 
Required for ciliogenesis and Fas induced apoptosis. 
Recessive 
2 GLE1 GLE1 RNA Export Mediator, Export of mature mRNA. Recessive 
2 KLB 
Klotho Beta protein, is involved in RET signaling,  involved in the transcriptional 
repression of hydroxylase 7-alpha cholesterol, participates and enhances the union of 
the fibroblast growth factor to its receptors 1 and 4. Participates in signaling pathways 
from PI3kinases and insulin receptor signaling, its functions affect the metabolism of 
the glucose, lipids and energy biogenesis. 
Recessive 
2 TOPAZ1 
Testis And Ovary Specific PAZ Domain Containing 1, germ cell specific factor, 
meiotic progression, contribute to silencing of transposable elements and maintenance 
of genome integrity 
Recessive 
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2 POLK 
DNA Polymerase Kappa, catalyzes translesion DNA synthesis, which allows DNA 
replication in the presence of DNA lesions. 
DNA repairing 
gene 
2 RECQL5 
RecQ Like Helicase 5, prevent s aberrant homologous recombination by displacing 
RAD51 from ssDNA, participates in DNA replication, transcription and repair, required 
for mitotic chromosome separation after cross-over events and cell cycle progress. 
DNA repairing 
gene 
 
SPRED2 
Sprouty Related EVH1 Domain Containing 2, regulate growth factor-induced activation 
of the MAP kinase cascade, it  also has function in stem cell factor receptor binding. 
Dominant 
2 DEPDC1B 
DEP Domain Containing 1B, Related with GPCR and signaling by Rho GTPases, 
related with BC. 
Dominant 
2 GPRC5B 
G Protein-Coupled Receptor Class C Group 5 Member B, G-protein coupled receptor 
activity and G-protein coupled receptor binding. 
Dominant 
2 HBP1 
HMG-Box Transcription Factor 1, involved in regulation of C-myc pathway, regulation 
of wnt mediated -catenin pathway, regulation of cell cycle, disrupts interaction among 
DNA and proteins. 
Dominant 
2 SYNE1 
Spectrin Repeat Containing Nuclear Envelope Protein 1, May be involved in the 
maintenance of nuclear organization and structural integrity. Connects nuclei to the 
cytoskeleton by interacting with the nuclear envelope and with F-actin in the 
cytoplasm. May be required for centrosome migration to the apical cell surface during 
early ciliogenesis. 
Dominant 
2 AHNAK 
AHNAK Nucleoprotein, blood-brain barrier formation, cell structure and migration, 
cardiac calcium channel regulation and tumor metastasis. 
Dominant 
2 KLF15 
Kruppel Like Factor 15, Transcription factor activity, sequence-specific DNA binding 
and transcriptional activator activity. 
Dominant 
2 HHAT 
Hedgehog acetyltransferase, signaling through GPCR, CDK mediated phosphorylation 
and removal CDC6, critical role in ER positive, HER2 amplified and hormone resistant 
breast cancer proliferation. 
Dominant 
2 MYBBP1A 
MYB Binding Protein 1a, encodes a nucleolar transcriptional regulator that was first 
identified by its ability to bind specifically to the Myb proto-oncogene protein, 
nucleolar stress, tumor suppression and synthesis of ribosomal DNA 
Dominant 
2 RANBP10 
RAN Binding Protein 10, Cytoplasmic Guanine nucleotide exchange factor that 
modulates non-centrosomal microtubules, novel coactivator of androgen receptor. 
Dominant 
2 CAPN2 
Calpain 2, calcium-activated neutral proteases, which is a non lysosomal, intracellular 
cysteine protease, involved in cytoskeletal remodeling and signal transduction. 
Dominant 
2 CLSPN 
Claspin, regulator of checkpoint kinase 1 and triggers a checkpoint arrest of the cell 
cycle in response to replicative stress or DNA damage. The protein is also required for 
efficient DNA replication during a normal S phase, Adapter protein which binds to 
BRCA1 and the checkpoint kinase CHEK1 and facilitates the ATR-dependent 
phosphorylation of both proteins. 
Dominant 
2 PTPRG 
Protein Tyrosine Phosphatase, Receptor Type G, molecules that regulate a variety of 
cellular processes including cell growth, differentiation, mitotic cycle and oncogenic 
transformation. 
Dominant 
3 ATM 
Ataxia Telangiectasia Mutated, important cell cycle checkpoint kinase that 
phosphorylates; thus, it  functions as a regulator of a wide variety of downstream 
proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase 
CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1, 
required for cell response to DNA damage and for genome stability . 
DNA repairing 
gene 
4 LIMD1 
LIM Domains Containing 1, Adapter or scaffold protein which participates in the 
assembly of numerous protein complexes and is involved in several cellular processes 
such as cell fate determination, cytoskeletal organization, repression of gene 
transcription, cell-cell adhesion, cell differentiation, proliferation and migration. 
Recessive 
4 TXNDC5 
Thioredoxin Domain Containing 5, encodes a protein-disulfide isomerase, reduces 
insulin disulfide bonds, participates in the modulation of androgen receptor signaling 
pathway. 
Recessive 
4 PLCB2 
Phospholipase C Beta 2, production of the second messenger molecules diacylglycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated 
phosphatidylinositol-specific phospholipase C enzymes. Important for cell signaling 
pathways mediators of survival and proliferation. 
Recessive 
4 GATM 
Glycine Amidinotransferase, mitochondrial enzyme involved in creatine biosynthesis, 
whereby it  catalyzes the transfer of a guanido group from L-arginine to glycine, 
resulting in guanidinoacetic acid, the immediate precursor of creatine, plays a vital role 
in energy, aberrant chimeric fusion alter cell migration and invasion. 
Recessive 
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4 PTPRH 
Protein Tyrosine Phosphatase, Receptor Type H, involved in cellular processes 
including cell growth, differentiation, mitotic cycle and oncogenic transformation. 
Recessive 
4 YLPM1 
YLP Motif Containing 1, Plays a role in the reduction of telomerase activity during 
differentiation of embryonic stem cells. 
Recessive 
4 TKTL1 
Transketolase Like 1, transketolase that acts as a homodimer and catalyzes the 
conversion of sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate to D-
ribose 5-phosphate and D-xylulose 5-phosphate, links the pentose phosphate pathway 
with the glycolytic pathway. 
X-linked 
*Information retrieved from http://www.genecards.org/, last accessed June 2017
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Supplementary Table 2: 
Primers designed for Sanger sequencing validation of BC candidate susceptibility alleles 
 
 
Oligo Name Tm (ºC) GC% Sequence (5'-3') 
Product 
length 
Note 
CLIP4_E11F 64 42.8 AAGATTTGCCTTGACAAGCTG 
205 
 CLIP4_E11F 64 45 ATGAAAGGGAAGGGCTTTTG 
YLPM1_E5F 64 47.6 CAGGATTGGTCAAGCAAGAAG 
230 
 YLPM1_E5F 64 60 AAGAGGTCCCCTCTCCTGAC 
TOPAZ1_Q483_E2F 64 37.5 TGTCCCAGAAACAGTAGAAAAAGA 
342 
 
TOPAZ1_Q483_E2R 66 45 GAAGCCTTTTTCCAACACCA 
TOPAZ1_K796_2EF 64 40.9 GCAAGGTAACAATAGCAAACCA 
175 
 TOPAZ1_K796_2ER 64 50 GGACACTGGTCGGAATGTTT 
GLE1_C39_2EF 64 45.8 GATGTTCAGTAAGGCATGTAGTGG 
167 
 GLE1_C39_2ER 64 55 CTCCTGCATATGGGGTAGGA 
TNN_E2_F 64 50 AAGATCGATGTGCCCAAGTC 
225 
 
TNN_E2_R 64 55 CTCCACCATCTCTTCCTCCA 
SUPT7L_E5_F 64 60 CTGAGAAGGCCACAGAGGAC 
195 
 SUPT7L_E5_R 64 52.6 TTGAAGCCTGTGGTGAAGC 
SUPT7L_E3_F 64 55 TCAGCAGCAGACAGAAGGTG 
252 
 SUPT7L_E3_R 64 40 CCTCGCATGAAAATGGAAAT 
BIRC6_E10_F 62 45 CATTTTGCTTCCACCCGATA 
241 
 
BIRC6_E10_R 62 55 TGTGTCCTGTTCCTCAGTGC 
LIMD1_E1_F 62 57.8 CTTTGGTCCACTGCCTCCT 
210 
 LIMD1_E1_R 62 45 CACATTGGGTTTGGACATCA 
PLCB2_E9_F 62 50 CATGCTAAGGCCAAACCCTA 
153 
 PLCB2_E9_R 62 55 GATGCCACTGGGCTCATACT 
GATM_E2_F 62 55 TCCATCTCCACTTCCTCCTC 
228 
 
GATM_E2_R 62 50 GGGTCCCATTCGTTGTAAGA 
HAS1_E5F 64 55 ACCATGCGTGGATGACCTAC 
230 
 HAS1_E5R 64 55 CAGGAGGCCACACATGTAGA 
PTPRH_E11F 64 55 AGGGTTGGAGACAGATGAGC 
210 
 PTPRH_E11R 62 57.8 AGCGGTCCTCCTCCTTCTT 
MXRA5_E5F 62 50 AAAGTTGCTCCGTCATCCAC 
218 
 
MXRA5_E5R 62 55 TCCACCCAAGCTGTAGGAAC 
MAMLD1_E3F 64 55 CACTGAGCTGGTGCAGGTAA 
208 
 MAMLD1_E3R 64 55 GCCTCAGTTTCCCCACTGTA 
TKTL1_E10F 64 45 AACCATGGCTCCATTTATGC 
217 
 TKTL1_E10R 62 40.9 GCAAAGAAAGGATGATGTCTCA 
TXNDC5_E10F 62 45 GCAATTTGCATGTGATCTGG 
284 
 
TXNDC5_E10R 62 50 TTTCTGAACAGCCACCACTG 
CLSPN_E5F 64 50 GTGGGGTCCATTCATTTGAG 
220 
 CLSPN_E5R 64 34.7 GAGAATTTGTTCAATCCAATCCA 
NISCH_E16F 64 57.8 CATCCTCAAGGTGCTGTGG 
237 
 NISCH_E16R 62 55 CGTACCTTGAGCACCAGACA 
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DDX11_E4F 62 55 GGTGCAGCTCAAGTATGCAG 
232 
For splicing 
variant DDX11_E7R 62 55 GGCTCTTCTTCACCTCATGC 
AKR1C3_E2F 64 50 TACCTTTGGTTGCTCCTCCA 
214  
AKR1C3_E2R 64 43.4 CACAAGCTCATCATAGACACAGT 
DOCK3_E9F 64 36 AATCTCCTTCAGTAGTGTGAAAGA 
296  
DOCK3_E9R 62 42.8 AGAACCTCACCAGAATTTCCA 
DOCK3_E53F 62 50 TCTAACATGCCCACCCTTTC 
298  
DOCK3_E53R 62 61.1 CTGGGCCTTGATGGAGTC 
POLG_E16F 64 55 TCTGCTGAGTGGTTGTAGGG 
245  
POLG_E16R 64 60 GGCCAGAGGTACAGAGGTCA 
FBF11_E19F 64 61.1 CAGCCCTCTGCCTTCCTT 
299  
FBF11_E19R 62 55 TACTCCTTGCAAGCCTGCTC 
FBF11_E18F 62 63.1 CGTGGAGTACAGCCACCTC 
206  
FBF11_E18R 62 55 TTGGGGTCAGTGTGAGATCC 
FBF11_E11F 64 60 GAGCCCCTCATACCTACAGG 
249  
FBF11_E11R 64 45 AGGTTGTGATGAAAGCCTGA 
CHEK2_E16F 64 50 CAAATGCCCCCACTTTACTG 
458  
CHEK2_E16R 64 55.5 CTGCACCACTGCACTTCA 
ATM_eE36_NF 62 30.4 TTTGACAAAGAAAACCCTTTTGA 
166 
LOH in 
tumor ATM_e36_NR 62 34.7 TTCTTACTTCACACATTGGCTTT 
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Supplementary Table 3: 
Primers designed for RECQL5 Sanger sequencing validation of candidate variants  
 
Oligo Name Tm (ºC) GC% Sequence (5'-3') Product length Note 
RECQL5_EXON3F 64 50 AAAGGCAGGAAGCACTGAGA 
216 
 RECQL5_EXON3R 64 45 ACCTTCCCCGAATCTTTTTG 
RECQL5_EXON4F 64 55 GGTCCAAGAGGACGTGTTTG 
334 
 
RECQL5_EXON4R 64 50 GCCAGGAAACCAAAGAGACA 
RECQL5_EXON9F 64 57,8 GATTCAGGCTCGGGTGAAC 
312 
 RECQL5_EXON9R 66 66,6 GGCTTCTCGGCCCCTTAC 
RECQL5_EXON17F 64 55 GATGCCTGCTCTTCCCTCTA 
292 
 RECQL5_EXON17R 64 60 CTCCCCTCCTCCAGAAGACT 
RECQL5_EXON6F 64 50 TCTCCATCTTCCCCTCCTTT 
225 
 
RECQL5_EXON6R 64 52,6 ACATGCACCTGGTCCTTTG 
RECQL5_EXON20F 64 55 GCTAACGCTCACCTCCTCAT 
280 
 RECQL5_EXON20R 64 50 GTCATCCCCAAAGCCAAGTA 
RECQL5_EXON15F2 64 63,1 CACAGCCTCCCTGCCTATC 
337 
 RECQL5_EXON15R2 64 55 GCTGGCTGGAGCAGTAACTC 
RECQL5_EXON10F 64 50 CTGGTAGGACATCAGGGACATT 
357 
 
RECQL5_EXON10R 64 45 TCTTCTATCTTGGGGTCTTTGC 
RECQL5_EXON15F 62 57,8 AGTGGTCAGTTGCCTGTGG 
315 
 RECQL5_EXON15R 62 50 AGTGAAGCCTTTCCTGGTCA 
RECQL5_INTRON19F 62 57,1 CCACCTCTCACACTTGCTGAC 
190 
 RECQL5_INTRON19R 62 50 CCATGGAAGAAGTGCCTGAT 
RECQL5_INTRON11F 62 50 AATGTTCCTGGAGGCTTGTG 
198 
 
RECQL5_INTRON11R 62 55 TGCCCGTCTCTTACCTTCAC 
RECQL5_EXON14F 62 55 CAAGAGCTCAGCAGGGAGAA  
249 
 RECQL5_EXON14R 62 66,6 CCTGAGCCCAGAGAGCTG 
RECQL5_EXON5F 64 55 AGCAGGGTGCATTACACTGG 
226 
 RECQL5_EXON5R 64 50 AAGAAGCCTCTGAGGGTGAA 
RECQL5_EXON2F 64 50 GCAAAACAGAGGGTTCTCGT 
295 
 
RECQL5_EXON2R 64 60 GAGGCAGTACGAAGGGTGAG 
RECQL5_EXON16F 64 45 CCCTGAGAAGAAGGCAAAAA 
353 
 RECQL5_EXON16R 64 55 GCCGTGTAGGTTCCAGAAGA 
RECQL5_EXON13F 64 60 GTAAGAGACGGGCAGCTCCT 
234 
 RECQL5_EXON13R 64 60 GTTGACAGGGTCCTGCAGTC 
RECQL5_EXON19F 64 60 CTTCTCCCTCTCCCTTCCAG 
169 
 
RECQL5_EXON19R 64 55 ATGAGGAGGTGAGCGTTAGC 
RECQL5_E1F 62 50 CAGCCAGCAGCCTTTAATTC 
376 For splicing variant 
RECQL5_E4R 62 50 TGCAGAGAGCTTCGAGTTCA 
RECQL5_E8F 62 57,8 GATGCCCTGGTGACCTTCT 
299 For splicing variant 
RECQL5_E10R 62 55 GCCTCATCTCTGCCTTCATC 
RECQL5_EXON3F 64 55 AGTCCGGAGTACGCTGAAGA 
351 For splicing variant 
RECQL5_EXON3R 64 50 AGCTTCATCCACCACCAAGT 
 135 
 
RECQL5_EXON17F 64 55 GATGGCCCCAGAGAAGTACA 
320 For splicing variant 
RECQL5_EXON17R 64 45 ACAACATTTGCAGCCTCCTT 
RECQL5_EXON16F2 64 55 AGCTGGTTTCCCCAAAGG 
317 For splicing variant 
RECQL5_EXON16R 64 55 GCCGTGTAGGTTCCAGAAGA 
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Supplementary Table 4:  
Candidate variants for hereditary breast cancer discarded for further studies based on Case-Control association studies 
 
  
 
Family 
 
Gene Ch 
Chromo-
somal 
position 
Variant 
Protein 
effect 
Functional 
Class 
ID 
Model of 
inheritance 
MAF ExAc 
(Total)
h
 
Nº Homozygotes ExAc 
(European) 
Eliminated due to: 
1 DOCK3 3 51127722 c.653T>C F218S Missense NR Recessive NR NR a 
1 DOCK3 3 51418611 c.5714C>T S1905L Missense rs201507848 Recessive 0.0003732 0/120582 c 
1 CHEK2 22 29083961 c.1685G>T R562L Missense NR 
DNA 
repairing 
systems 
0.0002315 NA c 
1 POLG 15 89865073 c.2492A>G Y831C Missense rs41549716 
DNA 
repairing 
systems 
0.006277 NA c 
1 DDX11 12 31238059 c.637A>G R213G Missense rs2536756 Dominant  0.002273 NA a 
1 NISCH 3 52521676 c.2168G>A R723H Missense NR Dominant 0.0000165 NA d 
2 AKR1C3 10 5138747 c.230A>G E77G Missense rs11551177 Recessive 0.05018 212/120836 a,b 
2 FBF1 17 73915803 c.2039C>T A680V Missense rs113062332 Recessive 0.02305 45/109134 c 
2 TOPAZ 3 44286015 c.2017C>G P673A Missense rs17646517 Recessive 0.01783 9/20860 c 
2 TOPAZ 3 44373498 c.5074C>G H1692D Missense rs533942526 Recessive 0.00009226 0/21678 e 
2 KLB 4 39448672 c.2329_2331del F777del Frameshift NR Recessive 0.002272 NR e 
2 KLB 4 39450295 c.3124G>A V1402I Missense rs143809363 Recessive 0.003605 5/119004 e 
2 POLK 5 74892973 c.2455A>C N819H Missense rs185752953 
DNA 
Repairing 
systems 
0.001024 NA d 
2 SPRED2 2 65561832 c.280G>A D94N Missense NR Dominant 0.000008237 NA a 
2 MYBBP1A 17 4455198 c.1000G>A G334R Missense rs138633396 Dominant 0.001129 NA c 
2 CAPN2 1 223900358 c.16G>A A6T Missense rs375899944 Dominant 0.0001054 NA g 
2 PTPRG 3 62189151 c.1682C>T S561Y Missense rs201820508 Dominant 0.00043 NA g 
2 CLSPN 1 36228012 c.815C>T T272M Missense rs141350492 Dominant 0.0001566 NA c* 
NR, No report , NA Not applicable under the model of inheritance studied  
a No results in the Openarray 
b No results in the Openarray and Taqman probe 
c High frequency both in cases and controls of the Spanish cohort (*) equal frequency in cases and controls 
d Did not fit with the model of inheritance studied and/or higher recurrence in controls against cases 
1
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e Due to technical constraints, were not included in OpenArray. They will be included in other studies 
g Since the beginning, it  was discarded from the Openarray because the design of the probe did not worked either in the CEGEN facility or in the fabric where it  was designed.   
h Total values for EXAC include European (non Finish and Finnish), Latino, South Asian, African and East-Asian populations. 
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Supplementary Table 5: 
Rare
1
 variants detected during the screening of ATM in analyzed in 392 S panish BRCAX families by NGS  
 
Nucleotide 
change
2
 
Protein 
change 
rs number ClinVar
3
 MAF 
SIFT 
Prediction 
Polyphen 
Prediction 
c.1229T>C p.Val410Ala rs56128736 
Conflicting interpretations of pathogenicity: Benign (2), Likely benign (1),  Uncertain 
significance (2) 
0,003277 deleterious benign 
c.1464G>T p.Trp488Cys rs377597949 Clinical significance: Uncertain significance 4,50E-05 tolerated benign 
c.1595G>A p.Cys532Tyr rs35963548 Clinical significance: Uncertain significance 0,0001351 deleterious benign 
c.1744T>C p.Phe582Leu rs2235006 Clinical interpretation: Benign/Likely benign, not provided 0,001004 tolerated benign 
c.1810C>T p.Pro604Ser rs2227922 
Conflicting interpretations of pathogenicity: Benign (2), Likely benign (2),  Uncertain 
significance (1) 
0,001 tolerated possibly_damaging 
c.1966A>G p.Thr656Ala Not reported Not reported 
Not 
reported 
deleterious benign 
c.2289T>A p.Phe763Leu rs34231402 Conflicting interpretations of pathogenicity: Likely benign (1),  Uncertain significance (2) 0,0004048 tolerated benign 
c.2494C>T p.Arg832Cys rs2229022 Clinical significance: Uncertain significance 0,0002414 tolerated benign 
c.2611G>C p.Glu871Gln Not reported Not reported 
Not 
reported 
tolerated benign 
c.2921+19dup p.? rs575967175 Clinical significance: Benign 
Not 
reported 
_ _ 
c.3403-15T>A p.? rs79701258 Clinical significance: Benign 0,002607 _ _ 
c.4060C>A p.Pro1354Thr rs145119475 Clinical significance: Uncertain significance 0,0003757 tolerated benign 
c.4388T>G p.Phe1463Cys rs138327406 
Conflicting interpretations of pathogenicity: Benign (2), Likely benign (1),  Uncertain 
significance (2) 
0,002276 deleterious probably damaging 
c.4523A>G p.Tyr1508Cys Not reported Not reported 
Not 
reported 
tolerated benign 
c.5071A>C p.Ser1691Arg rs1800059 Clinical significance: Benign/Likely benign, not provided 0,003132 tolerated benign 
c.5497-15G>C p.? rs3092828 Benign 0,004346 _ _ 
c.5558A>T p.Asp1853Val rs1801673 Clinical significance: Benign/Likely benign, not provided 0,006934 deleterious benign 
c.5611A>C p.Thr1871Pro Not reported Not reported 
Not 
reported 
tolerated benign 
c.6067G>A p.Gly2023Arg rs11212587 
Conflicting interpretations of pathogenicity: Benign (1), Likely benign (2),  Uncertain 
significance (1) 
0,002324 deleterious probably_damaging 
c.7187C>G p.Thr2396Ser rs370559102 Clinical significance: Uncertain significance 0,0002555 tolerated benign 
c.7788+8G>T p.? rs112775908 Clinical significance: Benign/Likely benign 0,002599 _ _ 
c.79G>A p.Val27Ile rs754770960 Clinical significance: Uncertain significance 1,50E-05 tolerated benign 
1
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c.8113G>A p.Val2705Ile rs587779870 Clinical significance: Uncertain significance 1,50E-05 tolerated benign 
c.8584+19T>C p.? rs772128061 Not reported 1,50E-05 _ _ 
c.931A>G p.Ile311Val Not reported Clinical significance: Uncertain significance 
Not 
reported 
tolerated benign 
c.984_986del p.Ser328del Not reported Clinical significance: Uncertain significance 
Not 
reported 
tolerated benign 
c.998C>T p.Ser333Phe rs28904919 Clinical significance: Benign/Likely benign, not provided 0,001398 deleterious possibly_damaging 
1
 Variants were considered as rare and included in this table when MAF (Minor Allele Frequency) reported in ExAc (http://exac.broadinstitute.org) for European (non-finish) population was lower than 0.01 
2
 GenBank reference sequence NM_000051.3 with numbering starting at the A of the first  ATG, following the HGVS guidelines, www.hgvs.org/mutnomen 
3
 Summary of classification as appearing in ClinVar database. None of the variants in this table were classfied in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) with three asterisks and were therefore considered as 
Unknown Significance Variants. 
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Supplementary Table 6:  
Candidate deleterious mutations found in other 20 susceptibility genes or candidate susceptibility genes analyzed in 392 Spanish BRCAX families by NGS  
 
 
Gene
2
 Nucleotide change Protein change GenBank refseq rs number ClinVar
3
 MAF
4
 
Nº of carriers in 392 
BRCAX families 
BARD1 c.334C>T p.Arg112* NM_000465.3 rs758972589 Clinical significance:Pathogenic** 0 1 
CHEK2 c.507del p.Asp169Glufs*5 NM_001005735.1 Not reported Not reported Not reported 1 
CHEK2 c.1229del p.Thr410Metfs*15 NM_001005735.1 rs555607708 Clinical significance:Pathogenic** 0,002341 1 
FANCE c.1239dupT p.Pro414Serfs*54 NM_021922.2 Not reported Not reported Not reported 1 
FANCI c.3626_3627delGT p.Cys1209Leufs*10 NM_001113378.1 rs770318990 Clinical significance:Pathogenic* 0,00E+00 1 
FANCL5 c.1096_1099dup p.Cys367Leufs*3 NM_001114636.1 Not reported Not reported Not reported 1 
FANCM c.855del p.Val286Leufs*30 NM_020937.2 Not reported Not reported Not reported 2 
FANCM6 c.1511_1515del p.Arg504Asnfs*29 NM_020937.2 Not reported Not reported Not reported 1 
FANCM c.1972C>T p.Arg658* NM_020937.2 rs368728266 Not reported Not reported 2 
FANCM
7
 c.5791C>T p.Arg1931* NM_020937.2 rs144567652 Not reported 0,0009456 1 
PALB2 c.172_175del p.Gln60Argfs*7 NM_024675.3 rs180177143 
Conflicting interpretations of pathogenicity: Likely 
pathogenic(1);Pathogenic(4);Uncertain significance(1) 
Not reported 1 
PALB2 c.757_758del p.Leu253Ilefs*3 NM_024675.3 rs180177092 Clinical significance:Pathogenic** 1,50E-05 1 
PALB2 c.1188C>A p.Cys396* NM_024675.3 Not reported Not reported Not reported 1 
PALB2 c.2257C>T p.Arg753* NM_024675.3 rs180177110 Clinical significance:Pathogenic** 4,50E-05 1 
PALB2 c.1653T>A p.Tyr551* NM_024675.3 rs118203997 Clinical significance:Pathogenic** Not reported 1 
RAD50 c.2517dup p.Asp840Argfs*5 NM_005732.3 Not reported Clinical significance:Pathogenic* Not reported 1 
RAD51C c.709C>T p.Arg237* NM_058216.1 rs770637624 Clinical significance:Pathogenic** 1,50E-05 1 
RAD51D c.94_95del p.Val32Phefs*38 NM_002878.3 Not reported Clinical significance:Pathogenic* Not reported 1 
SLX4 c.4739+1G>T p.? NM_032444.2 rs759186986 Not reported 1,50E-05 1 
SLX4 c.5154-1G>T p.? NM_032444.2 Not reported Not reported Not reported 1 
XRCC2 c.96del p.Phe32Leufs*30 NM_005431.1 rs730882048 
Conflicting interpretations of pathogenicity: 
Pathogenic(1);Uncertain significance(1) 
1,36E-04 1 
1
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1
 Only mutations giving rise to a premature stop codon or affecting consensus splicing sites (+/-1 and +/- 2) and/or reported in ClinVar as pathogenic with three asterisks*** were considered 
2
 The genes included in the analysis are detailed in the methods section 
3
 Summary of classification as appearing in ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) 
4 
MAF (Minor Allele Frequency) reported in ExAc (http://exac.broadinstitute.org) for European (non-finish) population 
5
 The patient carrying this mutation also carried the mutation c.855del in FANCM 
6
 The patient carrying this mutation also carried the mutation c.4739+1G>T in SLX4 
7
 This mutation was found in homozigosity 
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Supplementary Table 7:  
Candidate variants for hereditary male breast cancer discarded from initial studies  
 
 
 
 
Gene Ch 
Chromo-
somal 
position 
Variant 
Protein 
effect 
Functional 
Class 
ID 
Model of 
inheritance 
MAF ExAc 
(Total)
a
 
Nº Homozygotes ExAc 
(European) 
Eliminated due to: 
TNN 1 175046826 c.272G>A R91H Missense rs41266078 Recessive 0,02902 65/121020 c 
BIRC6 2 32641040 c.2681C>T T894M Missense rs34996177 Recessive 0.02384 54/121272 d 
SUPT7L 2 27883899 c.371A>C N124T Missense rs147739348 Recessive 0,001506 2/120148 
d
 
SUPT7L 2 27878328 c.886G>A A296T Missense rs201935160 Recessive 0,0004817 0/120398 d 
GPR113 2 26534250 c.2346A>G I782M Missense rs114354727 Recessive 0,03048 90/121242 e 
MGAM 7 141765575 c.4714A>T M1572L Missense rs4507684 Recessive 0,03956 621/116030 e 
HAS1 19 52217128 c.1289C>T A430V Missense rs34682338 Recessive 0.008392 6/108680 
d
 
MXRA5 X 3240238 c.3488G>A R1163H Missense rs139106444 X-linked 0,005675 164//82817 b d 
MAMLD1 X 149631097 c.156A>G P52P Silent rs16996606 X-linked 0,005213 90/83249  b d 
a Total values for EXAC include European (non Finish and Finnish), Latino, South Asian, African and East -Asian populations. 
b Refers to the number of hemyzogotes   
c False positive 
d Did not fit the model of inheritance when the segregation analysis were extended to other members of the family 
e Presented a high frequency in EXAC population and/or there were technical constraints to consider the variant for further analysis 
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